

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

**BMJ** Open

# **BMJ Open**

#### An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-066898
Article Type:	Protocol
Date Submitted by the Author:	25-Jul-2022
Complete List of Authors:	Kelly, John; Harvard Medical School, Psychiatry; Massachusetts General Hospital, Psychiatry Levy, Samuel; Massachusetts General Hospital, Psychiatry Hoeppner, Bettina B; Harvard Medical School
Keywords:	Substance misuse < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH



**BMJ** Open

An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

John F. Kelly<sup>1,2</sup>, Samuel Levy<sup>1</sup>, Bettina Hoeppner<sup>1,2</sup>

1. Massachusetts General Hospital, Psychiatry Department, Boston, Massachusetts; 2. Harvard Medical School, Department of Psychiatry, Boston, Massachusetts

Corresponding Author: John F. Kelly, PhD, MPH 151 Merrimac St, 6<sup>th</sup> Floor Boston, MA 02114 Email: jkelly11@mgh.harvard.edu Tel: 617-643-1980

Word Count: 3925

# ABSTRACT

# Introduction

Alcohol use disorder (AUD) remains one of the most pervasive of all psychiatric illnesses conferring a massive health and economic burden. In addition to professional treatments to address AUD, mutual-help organizations (MHOs) such as Alcoholics Anonymous (AA) and newer entities like SMART Recovery play increasingly important salutary roles in many societies. While much is known about the positive effects of AA, very little is known about SMART Recovery. Hence, this study seeks to estimate real-world patterns of utilization and derived benefit from SMART Recovery as well as explore for whom (moderators) and how (mechanisms) SMART may confer recovery benefits.

# Methods and analysis

Naturalistic, longitudinal, cohort study (N=368) of individuals with AUD initiating a new recovery attempt who self-select into one of four groups at study entry: 1. SMART Recovery; 2. AA; 3. SMART+AA; 4. Neither SMART nor AA; (stratified by DSM 5 severity markers), with assessments conducted at intake, and 3-, 6-, 9-, 12-, 18-, and 24-months. Primary outcomes are: Frequency of SMART and AA meetings attendance; Percent Days Abstinent (PDA) and percent days heavy drinking (PDHD). Secondary outcomes include: psychiatric distress; quality of life and functioning. Moderator variables include sex/gender; race/ethnicity; spirituality. Mediational variables include: social networks; coping skills; self-efficacy; impulsivity. Multivariable regression with propensity score matching will test for patterns of attendance and effects of MHO participation over time on outcomes and test for mechanisms and moderators.

# Ethics and dissemination

This study is approved by the Mass General Brigham Institutional Review Board. Results will be published in peer-reviewed journals and presented at relevant conferences.

# Registration

This is a non-randomized, naturalistic, longitudinal, cohort study, and thus was not registered in advance. Results stemming from the study, therefore, should be considered exploratory. The study was funded by the US National Institute of Alcohol Abuse and Alcoholism (NIAAA; 5R01AA026288).

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study will be one of the first rigorous, real-world, evaluations of the addiction recovery mutual-help organization, SMART Recovery, providing objective estimates of patterns of utilization and recovery benefits, and will explore the moderators and mechanisms of behavior change to determine who benefits from SMART Recovery participation and why.
- Individuals (N=368) with primary alcohol use disorder who self-select into either SMART Recovery, Alcoholics Anonymous (AA), both SMART and AA, or neither, will be compared over time on addiction recovery processes and outcomes.
- Participant characteristics, changes processes, and outcomes will be measured prospectively at study intake, and again at 3-, 6-, 9-, 12-, 18-, and 24-months later.
- Primary outcomes will be: number of SMART and AA meetings attended per week at each follow-up; percent days abstinent (PDA); percent days heavy drinking (PDHD); alcohol use disorder remission status; alcohol/drug related consequences. Secondary outcomes include quality of life and functioning psychiatric distress, self-esteem, happiness.
- Due to COVID-19, the majority of study visits are being conducted remotely, meaning that substance use outcomes will be provided exclusively by participant self-report without biochemical verification.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text

# INTRODUCTION

Alcohol and other drug use disorders confer a prodigious burden of disease, disability, and premature mortality in most middle- and high-income countries globally. To help alleviate this burden, most countries provide an array of professionally delivered addiction treatment services. Yet, despite these efforts, such services are often unable to meet both acute care and long-term relapse prevention needs of the millions or tens of millions affected annually. In response, most countries also possess an array of informal community-based peer recovery support services which can provide ongoing assistance for individuals suffering from these disorders [1]. The oldest and largest of these are the 12-step mutual-help organizations (MHOs), such as Alcoholics Anonymous (AA). Rigorous research evidence has now demonstrated that when AA is subjected to the same scientific standards as other addiction focused interventions it does as well on most outcomes measures, is better at sustaining abstinence and remission over time, and is highly cost effective [1].

A limitation of the current standard of care, however, borne out of a limitation in available empirical data, is the fact that referral oftentimes focuses solely on spiritually-oriented 12-step organizations, such as AA, which is the only empirically-supported MHO continuing care referral option. Not everyone chooses AA as a pathway to recovery for various reasons, and alternative MHO options - although much newer and smaller - are growing and may contain many of the same positive therapeutic elements and dynamics possessed by AA [2, 3]. These therapeutic pathways include adaptive social network changes, increases in social abstinence self-efficacy, and reducing negative affect. Indeed, some preliminary evidence suggests such organizations may confer similar benefits for those who self-select into them [4].

The largest and possibly most well-known of these newer alternative MHOs is Self-Management and Recovery Training (SMART) Recovery. There are approximately 1,200 SMART groups nationwide and another 1,000 internationally. SMART also has a strong online support presence including online meetings, forums, and chat rooms. Unlike AA, SMART is founded upon cognitive-behavioral principles and practices and is led by trained facilitators. It focuses on enhancing and maintaining motivation to abstain or (more recently) reduce use to non-problematic levels, coping with urges, problem solving, and lifestyle balance [5]. It also advocates for appropriate use of professional psychosocial and pharmacological treatments. A compelling aspect of SMART as an MHO is, because it is itself based on empirically-derived CBT principles, it provides a philosophically compatible recovery resource that is aligned with cognitive-behavioral treatment principles, which make up a large majority of national and international evidence-based treatments [6]. Consequently, SMART is appealing to many individuals with SUD [5], yet due to the lack of empirical evidence supporting its effectiveness, clinicians remain less likely to discuss or refer patients to SMART [7, 8]. This has hindered its growth and prevented many the opportunity to learn about and try SMART.

Compared to the dozens of high-quality studies examining 12-step MHOs [9-12], there have been just a handful of studies on SMART. We conducted a systematic review of this research [13] and found that only 12 studies exist (4 of which are unpublished dissertations) that have focused on SMART Recovery and used any kind of formal measurement. Most of these (8 out of the 12) are cross-sectional with mixed results and suffer from considerable biases as they possess substantial methodological limitations making it difficult to draw firm conclusions [14-16]. For instance, these studies have rarely assessed mental health status or its severity, despite the high rates of comorbidity between AUD and mental health. Two recent high-quality studies

#### **BMJ** Open

examining SMART Recovery, however, have been conducted, one in a criminal justice context, the other examining its effect on heavy alcohol use in an RCT.

The criminal justice study was a large quasi-experimental study of criminal offenders in Australia [17]. It compared a group of individuals participating in SMART Recovery and/or a criminal justice intervention (called "Getting SMART") designed to link offenders with SMART meetings following prison release, to a group of control participants who did not interact with any SMART materials or attended meetings, but who were matched on various other relevant characteristics through the use of propensity scores. The study found that participation in Getting SMART by itself, and Getting SMART + SMART Recovery meeting attendance, was associated with a reduced overall rate of reconviction with rates of reconviction reduced by 19 and 22%, respectively. For violent reconvictions, rates were reduced by 30% for Getting SMART participation and 42% for Getting SMART + SMART Recovery. While an important and promising set of results in their own right, unfortunately, the authors did not examine or report any alcohol/drug use outcomes [17].

There has been only one small, randomized trial evaluating SMART Recovery, which randomized people to (a) "Overcoming Addictions" (OA) - a SMART Recovery web application, (b) SMART Recovery meeting attendance, or (c) OA + SMART Recovery meeting attendance combined. The study found participants from all groups benefitted equally with respect to alcohol outcomes [18]. This finding underlines the promise of SMART Recovery to provide recovery support. Unfortunately, however, this trial did not include a control group, who did not have any exposure to SMART materials. Given, however, that all groups participated in SMART, it is not clear if observed benefits were simply naturally occurring improvements in alcohol outcomes, or really a function of SMART participation. Another limitation is that it only enrolled subjects with heavy drinking problems and excluded participants with more severe forms of AUD, who more typically enroll in formal treatment and are thus in need of referral options for continuing care.

A more recent study examined participation among individuals with alcohol use disorder recruited from various online and community venues with varying lengths of sobriety who self-selected into one of four different types of MHOs: Alcoholics Anonymous, LifeRing Secular Organization, SMART Recovery, and Women for Sobriety[4]. This study found that SMART Recovery participants had as good alcohol outcomes at 6- and 12-month follow-ups as those attending other MHOs. Again, however, the study did not include a control group with no MHO involvement.

These results provide some preliminary information about real-world benefits related to SMART Recovery participation. There is very little, if any, information regarding how involved they become or the mechanisms of behavior change through which SMART may help individuals attain AUD remission and recovery (e.g., via social changes, coping skills, recovery motivation, abstinence self-efficacy; reduced impulsivity). SMART has the potential to be a secular MHO alternative to 12-step MHOs for those preferring the secular and cognitivebehavioral foundation of SMART, yet in order to increase clinical confidence and referrals, more systematic research is needed. This study will be one of the first rigorous, real-world, evaluations of SMART providing objective estimates of recovery benefit (e.g., abstinence, AUD remission, quality of life, psychosocial functioning), and will explore the mechanisms (e.g., social network changes, self-efficacy, decreased impulsivity) and moderators (e.g., sex, race/ethnicity, addiction severity, psychiatric co-morbidity) of behavior change to determine how SMART Recovery may help its affiliates achieve and maintain remission from addiction and who seems to benefit most. To this end this study has the following specific aims: 1. Characterize and describe professional and non-professional recovery support service participation choices, migrations, and pathways using group trajectory analyses over a two-year period for individuals (N=368) starting a new AUD recovery attempt. More specifically in this regard, we will investigate the real-world effectiveness of SMART Recovery by comparing outcomes of AUD individuals making a new recovery attempt (N=368) pursuing either a SMART Recovery pathway (online or face-to-face; N=184) or a non-SMART recovery pathway (N=184). Because, according to SMART Recovery's annual survey data, roughly half of SMART participants also attend AA, we will use a stratified design to enroll persons with AUD making naturally occurring continuing care choices vis-à-vis participation in MHOs in a balanced fashion and follow them prospectively across a 24-month period. This stratified design will allow us to compare the outcomes of persons choosing to participate in SMART Recovery vs. not (balanced by AUD severity), while accounting for simultaneous choices regarding AA or neither AA or SMART MHO participation. 2: Explore moderators and mechanisms of behavior change. Exploration of factors that may help uncover who (i.e., moderators) and why (i.e., mechanisms) SMART affiliates benefit from participation will be investigated. Moderators will include sex and gender, addiction severity, psychiatric distress; and mechanisms will include social network changes, recovery motivation, cognitive-behavioral coping, abstinence self-efficacy, and impulsivity.

#### **METHODS AND ANALYSIS**

#### Study overview

This study is a naturalistic, prospective, longitudinal cohort study of 368 individuals making a new recovery attempt from AUD with seven assessments over a 24-month follow-up period. Following the baseline assessment, research staff will conduct additional follow-up assessments at 3, 6, 9, 12, 18, and 24 months after study enrollment. Assessments include both self-reports by participants using online surveys, and staff-administered assessments, conducted via phone and/or Zoom. Baseline visits were conducted from February 2019 to February 2022. Follow-up visits are ongoing and will continue until approximately February 2024. The study was fully reviewed and approved by the Institutional Review Board at Mass General Brigham, Boston, MA USA.

#### Sample size determination

The primary outcome variables are percent days abstinence (PDA) and percent days heavy drinking (PDHD; NIAAA-defined). Secondary outcomes include quality of life and psychosocial functioning. To estimate a plausible effect size to be expected in PDA as a function of mutual help organization (MHO) utilization, we examined the PDA outcomes in Project MATCH [19] for persons utilizing AA vs. not. Effects were surprisingly consistent across time, with patients with any AA utilization reporting a higher average number of PDA than patients with no AA involvement (d=0.45, 0.39, 0.38, 0.42, and 0.39 at 3-, 6-, 9-, 12- and 15-month follow-up respectively). Thus, conservatively, we are powering this study to detect an effect size of d=0.35, leading to a combined sample size of n=260 (equally balanced, due to stratification, in terms of AA utilization and addiction severity). With a conservatively estimated retention rate of 75%, we would need to enroll n=347 to retain n=260. Given our stratified design (i.e., 2 [SMART vs. not] x 2 [12-step vs. not] x 3 [mild vs. moderate vs. severe AUD] design = 12

#### **BMJ** Open

stratification cells), we proposed to enroll a final sample size of n=348 (i.e., n=29 per cell). In addition, 20 further participants were enrolled to increase representation of individuals attending SMART Recovery and to account for participants who withdrew, were terminated from the study, were found ineligible, or were otherwise no longer participating (e.g., death unrelated to the study).

Using this design, we will be equally well powered to test the main effect of 12-step participation. In terms of conducting pair-wise comparisons between the four possible combinations of using SMART Recovery and/or 12-Step, this sample size would enable us to detect pairwise differences of medium effect size (d=0.50). Improvements over our conservatively estimated retention rate would increase power (e.g., could detect d=0.46 with 85% retention).

#### Recruitment

Participants were recruited through SMART Recovery meetings, inpatient and outpatient treatment programs, and a variety of commercial recruitment sources during the recruitment period (January 2019 to January 2022).

Flyers and postcards for the study were distributed around buildings of Massachusetts General Hospital, particular around inpatient and outpatient SUD clinics. SMART facilitators were asked to advertise the study at SMART meetings and were provided with recruitment postcards and flyers. The study was also advertised on the SMART San Diego website. Additional recruitment methods included ResearchMatch, PeRC, TrialFacts, Rally for Recruitment, the Metro Newspaper, radio advertisements, MBTA advertisement, Facebook, Craigslist, and Reddit. For radio, MBTA, Facebook, and Craigslist advertisements, this study was advertised along with another ongoing R01 study of individuals making a new recovery attempt from AUD with similar eligibility criteria. Monthly meetings were also held with regional SMART Recovery MHO group facilitators to provide them with updates and inquire if there was anything we could provide to help facilitate study recruitment from online SMART resources or SMART meetings.

Interested individuals called the study-specific phone line, emailed the study-specific email address, or filled out an online screening form. Individuals were then able to participate in a brief 10–15-minute phone screen, during which eligibility criteria were confirmed. If the individual was eligible to participate, the baseline visit was scheduled and contact information for two locator contacts who can assist research staff in locating participants was collected.

#### Eligibility

Participants were required to be 18 years or older, living in the New England or San Diego metropolitan area, and willing to travel to Boston, Massachusetts, to complete study visits (for New England residents) or to complete study visits remotely (due to COVID-19 and for the San Diego participants). The geographical catchment area eligibility criteria were expanded to include people from the San Diego area in December 2020 to increase the number of SMART participants in the study. Since all visits were conducted remotely beginning in March 2020 due to the COVID-19 pandemic, participants from the New England area would also be considered eligible even if they could not travel to the Boston office for assessments in the foreseeable future.

Participants could be using other drugs but had to report alcohol as their primary substance of concern; they were also required to have a self-perceived alcohol problem, to meet

current criteria for DSM 5 alcohol use disorder (AUD) using semi-structured interview; to have consumed alcohol in the past 90 days and report currently engaged in a new recovery attempt defined as "a serious effort to abstain from drinking or to drink without problems in the past 90 days or planning to make one in the next 14 days."

Additionally, participants were required to provide locator contact information for two close friends/family members in case we were unable to contact the participant directly; provide their social security number for reimbursement or be willing to not receive reimbursement; provide a urine sample and breathalyzer (for in-person visits) or remote saliva test (for remote visits) for biochemical verification; and provide a stable home address and contact information. These initial bioassay requirements were not required following the start of COVID-19 lock-downs which began in March 2020.

#### Methods

All assessments were initially conducted (prior to COVID) with a study research coordinator in person at our downtown Boston offices at the MGH Recovery Research Institute. Each assessment consisted of staff-administered and self-administered surveys, which were completed via REDCap (a secure, web-based application designed to support data capture for research studies), a computerized task to assess impulsivity (Go/No-Go task), and biochemical verification tests of abstinence (breathalyzer, urine) for all participants at all time points. For in person visits, the baseline and follow-up assessments lasted for approximately 3 hours. At the end of the first visit and every follow-up visit, the next follow-up was scheduled.

Due to the COVID-19 pandemic, all assessments were transitioned to be conducted remotely beginning in March 2020. During remote visits, the computerized task and urine and breath biochemical verifications of abstinence were not completed. A web-based version of the computerized task was tested, but the effects of internet speed on results made data unreliable. In lieu of the urine and breathalyzer tests, saliva tests were implemented for remote visits from March 2021 to May 2021 but were discontinued due to documented inconsistent results. Relative to in-person assessments, remote assessments were shorter with assessments lasting approximately 1.5 hours (for baseline) or 45 minutes (for follow-ups) on the phone and approximately 1 hour for participants to complete surveys individually.

All participants (in-person and remote) agreed to provide their phone numbers and email information and that of two locator contacts so that they may be contacted for follow-up assessment reminders. Research staff contacted and confirmed the contact information of the locator contacts as needed if research staff loses touch with the participant. Participants indicated their preferred method of contact (phone call, email, or text message) for receiving automated reminders throughout the project period. In keeping with a validated research follow-up protocol for maximizing retention in clinical addiction research, after the baseline assessment, research staff proactively reached out to participants for reminders and to check if there were any changes to their contact information. Check-ins occurred 1 month, 14 days, 7 days, and 24 hours before the next scheduled visit. These messages are automated and sent with Twilio, which is an approved REDCap module by Mass General Brigham.

Participants are compensated \$45 for completing the baseline visit and \$55, \$60, \$65, \$70, \$75, and \$85 for completing the 3-, 6-, 9-, 12-, 18-, and 24-month follow-up visits, respectively. Payment for each timepoint is broken up into payment for the staff-administered surveys, self-administered surveys, and travel reimbursement. During remote visits due to

COVID-19, all participants were still paid the travel reimbursement to maintain the same payment structure used for in-person assessments.

#### Measures

Staff-administered measures assess the following: substance use history, AUD and SUD status and severity, tobacco use, treatment utilization for physical health problems and alcohol/drug use problems, anti-craving and anti-relapse medications (alcohol and opioids), mental and emotional health diagnoses, hospitalizations, treatment history, and psychiatric medication use, social networks, 12-step/MHO attendance history, online resource utilization, SMART involvement, 12-step MHO involvement (MM-HAS), recovery/abstinence time, recovery support services and formal treatment program utilization, substance use change over the past year (YES), impulsivity (Go/No-go cognitive task), and biochemical verification of substance use (breathalyzer, urine drug screen).

Self-administered measures assess the following: demographics, criminal justice involvement, religiosity and spirituality (RBBS, religious and spiritual intensity, DSES), stress and psychiatric distress (PSS-4, K6), coping (CSS), self-efficacy (A-DSES-20, single item selfefficacy), alcohol/other drug craving (PADCS-5), commitment to sobriety (CSS-5), substance use consequences (SIP-2R), recovery status (questions about recovery, drinking goal), recovery capital (BARC-10), behavioral addictions, medical marijuana use, medication attitudes, impulsive behavior (SUPPS-S), quality of life and psychosocial functioning (TPS, Q-LES-Q, EQ5D3L, EUROHIS-QOL, self-esteem, happiness, and satisfaction with life), and physical health (PSQI, pain VAS, IPAQ, meals).

All measures were administered at each timepoint except for the Year End Summary (YES), SUD DART, and Questions about Recovery, which were administered at baseline, 12-months, and 24-months. Detailed descriptions of measures are available in Supplement 1.

#### **COVID-19** impact

The COVID-19 pandemic significantly affected the conduct of study assessments as all assessments were transitioned to fully remote visits beginning in March 2020. As previously noted, this shift to remote assessments meant that we were unable to conduct the Go/No-go cognitive measure, breathalyzer, or urine screen. Due to these changes, all substance use outcomes are self-reported. Self-administered saliva tests were used briefly as a replacement, but inconsistent results (e.g., false negatives, partial results, no results) made data collected from these tests unreliable and this strategy was stopped.

Additionally, recruitment was halted as the study team transitioned to remote assessments and many previous recruitment methods were no longer viable (e.g., recruitment from outpatient clinics, advertisements on Boston area trains). It was particularly challenging to recruit individuals attending SMART as meetings were halted, then moved to virtual-only. To address these challenges, we expanded the recruitment area to San Diego, where there is a large SMART Recovery MHO participation community. We also maintained contact with SMART facilitators throughout the recruitment period to encourage them to share the study with meeting attendees and solicit feedback on how to best improve recruitment of SMART participants.

To capture potential changes in recovery resource utilization due to the COVID-19 pandemic, we added a staff-administered measure related to use of online recovery resources and social network site use. In addition, a supplemental study focusing on the impact of COVID-19 was conducted, consisting of both quantitative measures and a qualitative interview with a sub-

group (n=80) of study participants selected at random from the SMART, AA, SMART+AA, and neither cohorts (n=20 from each group).

# Patient and public involvement

No patient or public involvement.

#### Data analysis plan

<u>Aim 1 Effectiveness</u>. We will use multiple linear regression analyses to determine whether our primary stratification factor of interest (predictor: SMART vs. no SMART) is associated with alcohol outcomes (primary dependent variables: PDA; PDHD) at 24-month (primary end-point), and 3-, 6-, 9-, 12- and 18-month (secondary) follow-ups, while controlling for other confounding variables using propensity score matching methods that we have used successfully in prior work. We will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity. We will also test longitudinal models to investigate the dynamic relationship of these various recovery pathways over time (e.g., using hierarchical linear modeling as we have done previously [20]).

<u>Aim 2a. Mechanisms and Moderators</u>. We will use mediational modeling, using the product-ofcoefficients approach [21, 22] to test how SMART Recovery confers benefit (or fails to do so). The independent variable will be stratification group (i.e., SMART vs. no SMART), and the outcome variables will be PDA (primary), PDHD, AUD remission, quality of life, and measures of psychosocial functioning. The mediators will be our theorized mechanisms of change (e.g., social network changes, recovery motivation, coping, self-efficacy, impulsivity), which we will quantify as change since baseline in these constructs as measured via REDCap administered scales prior to the outcome (e.g., change in craving observed from baseline to 3-month would be used to predict 6-month ultimate outcomes). We will use multiple mediation to determine the relative impact of each mechanism, and moderated multiple mediation to identify differences in mechanisms across (moderator) subgroups (e.g., males vs. females, severe AUD addiction severity vs. moderate/mild), similar to our prior approach in delineating mechanisms of behavior change in AA [23-25].

Aim 2b. Dose-response relationship of SMART Recovery. Using only data from participants in the stratified SMART group, we will use linear regression (primary outcome: PDA) to test if the level of SMART involvement, as measured by the SMART Involvement Scale, is related to PDA at 24-month (primary endpoint) and other follow-up points over time. We will use basic model building practices to determine if such an effect persists after accounting for demographics, other important contextual variables, moderators, and baseline levels of the theorized mechanisms of change. In follow-up analyses, we will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity.

<u>Multiple Testing</u>. We will use the false recovery rate adjustment [26] to control for multiple testing.

#### **BMJ** Open

<u>Missing Data.</u> Some data will inevitably be missing. We will explore patterns of missingness to determine if missingness is occurring at random (MAR) (i.e., unrelated to the value of the missing observation) or likely to be missing not at random (MNAR). For each analysis, we will use a variety of recommended strategies to address the issue of missing data (e.g., multiple imputation, maximum likelihood estimation)[27]. Consistency in findings across missing data methods will enhance our confidence in the findings. Note that study participation will be completely separate from SMART participation; thus, participants should feel comfortable remaining in the study regardless of whether they continue in SMART or not. Assuming some attrition, we plan to conduct analyses examining predictors of attrition and control for these.

for peet teries only

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de

Enseignement Superieur

(ABES)

ata mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

#### ETHICS AND DISSEMINATION

All study procedures are approved by the Institutional Review Board of Mass General Brigham (approval number: 2017P002029). Written consent was received from all participants following an explanation of the study, including confidentiality and freedom of choice to participate. Results will be published in relevant peer-reviewed scientific journals and presented at conferences.

to beet teries only

# **AUTHORS' CONTRIBUTIONS**

JK developed the idea and conceptualized the study design and led the writing of the manuscript. SL contributed to conducting the study and writing the manuscript. BH contributed to study design and development and statistical analysis as well as reviewing and editing final versions of the manuscript.

#### **FUNDING STATEMENT**

This study is supported by NIAAA grant number 5R01AA026288 (Kelly, John F), the Massachusetts General Hospital Recovery Research Institute, and NIAAA grant number K24AA022136 (Kelly, John F).

# **COMPETING INTERESTS STATEMENT** ERES

None declared.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de

Enseignement Superieur

(ABES

Protected by copyright, including for uses related to text

#### REFERENCES

1. Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. *Cochrane Database Syst Rev.* 2020;3(3):Cd012880.

2. Kelly JF. Is Alcoholics Anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research. *Addiction*. 2017;112(6):929-36.

3. Kelly JF, Magill M, Stout RL. How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. *Addiction Research & Theory*. 2009;17(3):236-59.

4. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD. *J Subst Abuse Treat*. 2018;88:18-26.

5. Horvath AT, Yeterian JD. SMART Recovery: Self-empowering, science-based recovery support. *Journal of Groups in Addiction and Recovery*. 2013.

6. Roman PM, Johnson JA. National Treatment Center Study Summary Report: Private Treatment Centers. Athens, GA: Institute for Behavioral Research, University of Georgia; 2004.

7. Fenster J. Characteristics of clinicians likely to refer clients to 12-Step programs versus a diversity of post-treatment options. *Drug Alcohol Depend*. 2006;83(3):238-46.

8. Kelly JF, Stout R, Zywiak W, Schneider R. A 3-year study of addiction mutual-help group participation following intensive outpatient treatment. *Alcoholism: Clinical and Experimental Research* 2006;30(8):1381-92.

9. Emrick CD, Tonigan JS, Montgomery H, Little L. Alcoholics Anonymous: What is currently known? *Research on Alcoholics Anonymous: Opportunities and Alternatives* 1993:41-76.

10. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. *J Addict Dis*. 2009;28(2):145-57.

11. Kelly JF. Mutual-help for substance use disorders: History, effectiveness, knowledge gaps & research opportunities. *Clinical Psychology Review*. 2003;23(5):639-63.

12. Kelly JF, Yeterian JD. Empirical awakening: the new science on mutual help and implications for cost containment under health care reform. *Subst Abus*. 2012;33(2):85-91.

13. Beck AK, Forbes E, Baker AL, Kelly PJ, Deane FP, Shakeshaft A, et al. Systematic review of SMART Recovery: Outcomes, process variables, and implications for research. *Psychol Addict Behav.* 2017;31(1):1-20.

14. Atkins RG, Jr., Hawdon JE. Religiosity and participation in mutual-aid support groups for addiction. *J Subst Abuse Treat*. 2007;33(3):321-31.

15. Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: twelve-step and selfmanagement and recovery training. *The American journal of drug and alcohol abuse*. 2003;29(2):359-83.

16. MacGregor S, Herring R. The alcohol concern SMART Recovery pilot project final evaluation report. Middlesex University Drug and Alcohol Research Group; 2010.

17. Blatch C, O'Sullivan K, Delaney JJ, Doorn Gv, Sweller T. Evaluation of an Australian domestic abuse program for offending males. *Journal of Aggression, Conflict and Peace Research.* 2016;8(1):4-20.

18. Hester RK, Lenberg KL, Campbell W, Delaney HD. Overcoming Addictions, a Webbased application, and SMART Recovery, an online and in-person mutual help group for

4

5

6

7

8 9

#### **BMJ** Open

58 59

60

problem drinkers, part 1: three-month outcomes of a randomized controlled trial. J Med Internet Res. 2013;15(7):e134.

Project MATCH Research Group. Matching Alcoholism Treatments to Client 19. Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58(1):7-29.

20. Kelly JF, Stout RL, Magill M, Tonigan JS, Pagano ME. Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change. Alcohol Clin Exp Res. 2011;35(3):454-63.

Sobell ME. Asymptotic confidence intervals for indirect effects in structural equations 21. models. In: Leinhart S, editor. Sociological Methodology. San Francisco, CA: Jossey-Bass; 1982. p. 290-312.

22. Sobell ME. Some new results on indirect effects and their standard errors in covariance structure models. In: Tuma N, editor. Sociological Methodology. Washington, DC: American Sociological Association; 1986. p. 159-86.

Hoeppner BB, Hoeppner SS, Kelly JF. Do young people benefit from AA as much, and 23. in the same ways, as adult aged 30+? A moderated multiple mediation analysis. Drug Alcohol Depend. 2014;143:181-8.

Kelly JF, Hoeppner B, Stout RL, Pagano M. Determining the relative importance of the 24. mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis. Addiction. 2012;107(2):289-99.

Kelly JF, Hoeppner BB. Does Alcoholics Anonymous work differently for men and 25. women? A moderated multiple-mediation analysis in a large clinical sample. Drug Alcohol Depend. 2013;130(1-3):186-93.

Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and 26. Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-300.

Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychol Methods*. 27. 2002;7(2):147-77.

# Table 1 (staff-administered measures)

Measure	Description
Substance Use History	Participants answered a series of questions about 15 substances/classes of substances (hereafter simply referred to as substances) from the Global Appraisal of Individual Needs (GAIN-I; (Dennis et al., 2002)): 1) Alcohol, 2) Marijuana, 3) Heroin, 4) Methadone, 5) Buprenorphine and its formulations (e.g., suboxone), 6) Other opioids (e.g., pharmaceutical opioids), 7) Cocaine, 8) Amphetamines (including MDMA), 9) Methamphetamine, 10) Benzodiazepines, 11) Barbiturates, 12) Hallucinogens, 13) Synthetic drugs (e.g., synthetic cannabinoid like "K2" and synthetic cathinones such as "bath salts"), 14) Inhalants, and 15) Steroids, as well as "Other" (specified by participant). At baseline, participants reported which of these substances they used 10 or more times in their life. Then for each substance endorsed, they provided information on the following from the Form-90 (Miller & Delboca, 1994): a) Age of first use; b) If they had ever used the substance regularly (i.e., at least once per week) (yes/no) and if so, the age of first regular use; c) Whether they had used the substance in the past three months (yes/no), and if so how many days out of the past 90 they used the substances in any capacity in the past 3 months, if they had used these substances in any capacity in the past 3 months, if they had used the substance. Participants then chose their primary substance ("drug of choice") and secondary substance from the substances they had used (lifetime use for baseline assessment, past 3 month use for follow-ups). Finally, participants were asked for how many of the past 90 days their use of alcohol/drugs interfered with their functioning, and how many out of the past 90 days they got drunk at all or high for most of the day.
Alcohol Use Disorder DART	Participants were asked this validated semi-structured interview to capture AUD status (AUD severity and withdrawal symptoms). Participants were first asked if they had consumed alcohol in the past 3 months. If the participant answered 'yes', the DART would pertain to the past 3 months. If the participant answered 'no', they would be asked if they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered into the past 12 months. If the participant answered 'no', they would be asked if they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered 'no' to both the questions, they would only be asked if they experienced strong urges or cravings to drink.
Substance Use Disorder DART	Participants were asked about the recreational drugs/medications they used in the past 12 months. They then ranked the substances in the order that they caused problems for them. The DART was administered for the top 3 substances that caused the most problems for participants.
NIH PhenX Toolkit	Participants reported on lifetime use of cigarettes, e-cigarettes, or another tobacco/nicotine product (specified by participant). For those who smoked cigarettes, they reported on the following: 1) Age of first regular use; 2) Of how many of the past 30 days they smoked cigarettes 3) Average number of cigarettes smoked per day in the past 30 days 4) Whether or not they had ever made a serious attempt to quit smoking. This was asked pertaining to 'lifetime' for the baseline visit and for the past 90 days in the follow-up visits. If participants had made a serious quit attempt either in their life (baseline) or in the past 90 days (follow-up), they reported how old they were when they most recently quit smoking, the number of quit attempts in the past 90 days, the longest length of time they had quit smoking for, as well as on psychosocial smoking cessation resources. If not currently still smoking cessation resources used in their most recent quit attempt. Finally, regarding smoking cessation, all participants answered a single item with four multiple choice options to gauge attitudes toward inclusion of smoking cessation in AOD treatment (e.g., "Services that help people stop smokingshould be automatically included in addiction treatment.").

BMJ Open

	(National Cancer Institute, 2009; National Institutes of Health & U.S. Food and Drug Administration, 2013; Prorok et al., 2000).
Treatment for Injuries or Physical Health Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for health problems. At baseline, participants reported for both lifetime and past 3 months. At follow-up visits, participants were asked to report only on treatments in the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Treatment for Alcohol and Drug Use Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for alcohol or drug use problems. At baseline, participants reported for both lifetime and past 3 months. At follow-up visits, participants were asked to report only on treatments in the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Anti-craving and Anti- relapse Medications (Alcohol and Opioids)	At baseline, participants reported whether they had ever been prescribed a medication to prevent them from drinking alcohol or using opioids. At follow-up visits, participants were asked if they had been newly prescribed any medication to prevent them from drinking alcohol or using opioids in the past 3 months. If participants responded yes to either item, participants reported lifetime (baseline), past 3 months (follow-up) and current (baseline and follow-up) use of specific medications from the Form-90, including both generic and brand names (Miller & Delboca, 1994). Participants were also asked to rate what proportion of the time they used each medication as medically indicated.
Mental and Emotional Health: Diagnoses, Hospitalizations, Treatment History	Participants reported whether they had ever been told that they had a mental health condition by a doctor, nurse, or counselor, including agoraphobia, anorexia nervosa, bipolar disorder, bulimia nervosa, delusional disorder, dysthymic disorder, generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, personality disorder, post-traumatic stress disorder, schizoaffective disorder, schizophrenia, social anxiety disorder, specific phobia, substance use disorder, and other. For each diagnosis endorsed, participants indicated whether this had been a problem for them in the past 12 months. Participants reported treatment in an emergency room and admissions to a hospital for at least one night for mental, emotional, behavioral, or psychological problems. Participants reported for both lifetime and past 3 months. Participants also reported the number of times they had seen a mental health doctor in an office or outpatient clinic (including telehealth) in the past 3 months, on how many of the past 90 days they had been bothered by mental, emotional, behavioral, or psychological problems and on how many of the past 90 days these problems had kept them from meeting their responsibilities or made them feel like they could not go on (Dennis et al., 2002; Miller & Delboca, 1994).
Mental and Emotional Health: Psychiatric Medication Use	Participants were asked if they had ever been prescribed medication by a physician or medical practitioner to help them with a mental health condition (lifetime use). If they said yes, they were asked which medication they had ever been prescribed with the options antidepressants, anti-anxiety medication, anti-psychotics, mood stabilizers, stimulants, painkillers, medications for sleep and other (to be specified). Participants were then asked i they were still taking the medicines they indicated. If participants were still taking the medication as medically indicated. At follow-up visits, participants were asked if they were still using any medication to help with a mental health condition, and if yes, what type of medication. For each medication endorsed, participants reported what proportion of the time they used the medication as medically indicated (Dennis et al., 2002; Miller & Delboca, 1994).
Social Support Questionnaire (SSQ)	Participants were asked to list the initials of up to 5 family members, up to 5 friends, and up to 3 other important people in their life who they felt close to. For each person, they listed their initials, relationship, alcohol use pattern, drug use pattern, days per month they had

Page	18	of	26

	contact with this person over the past 3 months (including contact via phone/text), how much they value their relationship on a scale of 1 ( <i>not at all</i> ) to 10 ( <i>a great deal</i> ) and how helpful they are in their recovery efforts on a scale of 1 ( <i>not at all helpful</i> ) to 10 ( <i>a great deal</i> ) (Zywiak et al., 2009).
12-step/MHO Attendance History	At baseline, participants were asked about lifetime attendance to help with their AOD problem at 12 different MHOs, with an "other" option specified by participant (Kelly et al., 2011): 1) Alcoholics Anonymous (AA); 2) Narcotics Anonymous (NA); 3) Marijuana Anonymous (MA); 4) Cocaine Anonymous (CA); 5) Crystal Methamphetamine Anonymous (CMA); 6) SMART Recovery; 7) LifeRing Secular Recovery; 8) Moderation Management; 9) Celebrate Recovery; 10) Women for Sobriety; and 11) Secular Organization for Sobriety (S.O.S.).; 12) Dual Diagnosis Anonymous (DDA); and 13) Other. Other options were examined for possible inclusion in existing categories, and recategorized as appropriate. At follow-ups, participants reported attendance for the past 3- months. For each MHO attended, participants reported a) Whether they attended regularly (at least once per week), b) Number of meetings in the past 3 months, and c) Whether they had ever attended a meeting online.
Online Resources and Social Network Sites	For each MHO that a participant had attended online (as noted in "12-step/MHO Attendance History"), participants reported how many meetings they had attended online in the past 3 months, how they accessed these meetings (video, audio only, telephone, etc.), and how helpful they felt the online meetings were on a scale of 1 to 10. Participants also reported whether they used any online or mobile technologies to support their AOD problem resolution or recovery in their lifetime (baseline) and in the past 3 months. Potential online and mobile technologies included recovery-focused social network sites (e.g., InTheRooms.com), general social network sites (e.g., Facebook), and mobile smartphone applications. For each online or mobile technology endorsed, participants indicated how many of the past 90 days they had used the technology for recovery and how helpful they found it on a scale of 1 to 10. Participants were also given the opportunity to provide any other information or comments on their use of online or mobile recovery resources.
SMART Involvement	Questions about SMART involvement were asked for participants who had attended SMART Recovery. Participants were asked how long they have been attending SMART Recovery, how they heard about SMART Recovery, whether they consider themselves to be a current member of SMART Recovery ( <i>yes/no</i> ), how many times they have attended SMART recovery in their lifetime ( <i>numerical value</i> ) and if another member of SMART Recovery served as a personal mentor or guide to them in the past 3 months ( <i>yes/no</i> ). The participants were asked questions about their participation in SMART meetings in the past 3 months to gauge the frequency of the use of SMART meetings, tools, website, and web- application 'Overcoming Addictions.' Participants were also asked four questions about their level of engagement in SMART meetings.
Recovery/Abstinence time	Participants were asked to report in years and months how long they had been either 1) Sober (not using any alcohol/drugs) or 2) Drinking/using drugs without problems.
Multidimensional Mutual-Help Activity Scale (MM-HAS)	Questions from the MM-HAS were asked for participants who had attended meetings of any of the following MHOs: Alcoholics Anonymous, Narcotics Anonymous, Marijuana Anonymous, Cocaine Anonymous, Crystal Methamphetamine Anonymous, and Dual Diagnosis Anonymous. For each organization, participants were asked if they currently considered themselves to be a part of the MHO, their activities as part of the MHO in the past 3 months (sponsor, contact with sponsor outside a meeting, contact with other members outside a meeting, read 12 step literature outside of a meeting, shared or talked during meetings, helped with setting up/running a meeting), and the number of steps out of the 12 step program that they completed while participating in the MHO in the past 3 months. Participants were then asked to rate the helpfulness, enjoyability, and safety of the

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	MHO from a scale of 1 ( <i>not at all helpful, do not enjoy at all,</i> or <i>not at all safe</i> ) to 10 ( <i>extremely helpful, enjoy a great deal,</i> or <i>completely safe</i> ) (Kelly et al., 2013; Kelly et a 2011).
Recovery support services and formal treatment programs (RSSTX)	The questionnaire assessed history of participation in nine psychosocial treatment and recovery support services: 1) Sober living environment; 2) Recovery high school; 3) College recovery program/community 4) Recovery community center (RCC); 5) Faithbased recovery services (e.g., a recovery group provided by a church, synagogue, mosq etc.); 6) State or local recovery community organization (RCO); 7) Outpatient addiction treatment; 8) Alcohol/drug detoxification services; 9) Inpatient or residential treatment. they responded yes to any treatment service (7, 8 or 9), they reported the number of tim they used the service (i.e., number of treatment episodes) in their lifetime (baseline) and past 3 months (baseline and follow-up). (Dennis et al., 2002; Miller & Delboca, 1994).
Year End Summary (YES)	At baseline, 12-month follow-up, and 24-month follow up, participants were asked if the felt like they were better off now than they were 12 months ago in terms of their alcoho and drug problems (worse off, same, better off). Participants were then asked to elabora on the reason for that answer. Participants were asked if their substance use had change stayed the same in the past 12 months (changed for the better, changed for the worse, st the same). If participants reported 'stayed the same', they were asked what factors they thought were most responsible for their substance use staying the same.
Timeline Follow Back (TLFB)	Participants provided specific dates for alcohol use, substance use, MHO attendance, inpatient and outpatient addiction treatment, inpatient and outpatient mental health treatment, and incarceration for the past 3 months (baseline, 3-, 6-, 9-, and 12-month follow-ups) or 6 months (18- and 24-month follow-ups) (Miller & Delboca, 1994). For alcohol use, participants were asked to report the number of standard drinks consumed each drinking day. For MHO attendance and outpatient treatment for addiction and mer health, participants were asked to report whether services were in-person or online. Dur in-person study visits, a printed calendar was used to facilitate the TLFB. For remote vi study staff prompted participants with potentially memorable dates within the timefram (e.g., holidays).
Go/No-Go Cognitive Measure*	The Inquisit Go/No-Go Cognitive Measure is a computerized task used to assess impulsivity. The Inquisit script implemented the Go/No-Go Task as described in Fillmon al. (2006). Participants were asked to press the spacebar when they see a green rectangle (go) but refrain from pressing the spacebar when they see a blue rectangle $(no-go)$ . The and green rectangles could be vertical or horizontal. The vertical rectangle had a high probability (4:1) of being green $(go)$ and the horizontal rectangle had a high probability of being blue $(no-go)$ . Participants were given information about the orientation of the rectangle shortly before the color of the rectangle was revealed. Participant response tim and error rates were recorded. For remote visits, a web-based version of the Go/No-Go was tested, but due to the effect of internet speed on results, this measure was not includ
Breathalyzer*	Breathalyzer tests were used to establish a baseline level of substance use for participant the first assessment and to ensure that data was not collected from participants who wer impaired due to alcohol use. Breathalyzer tests were performed at baseline and all follow time points prior to starting each assessment. If a participant's BAC was above .02, stuc staff did not conduct the study visit; instead, study staff either waited with the participant until their BAC dropped to .02 or lower or attempted to re-schedule the participant's vis a participant's BAC was above the legal limit (.08), and the participant had driven to the assessment, study staff asked to hold the participant's car keys while waiting for their B to drop below the legal limit. If the participant insisted on holding their car keys and/or driving, or if the participant did not stay with study staff until their BAC dropped below study staff called security as a safety precaution. Study staff also offered to arrange and for a cab to transport the participant home. If a participant had driven to the appointmer

	and decided to take a cab home, the participant could return to pick up their car keys during business hours when their BAC was below .08. For remote visits, study staff were unable to perform breathalyzer tests and instead asked participants to verify that they had not used alcohol or other drugs prior to the assessment via self-report.
Urine Drug Screen*	Urine drug screens were used to establish baseline substance use at baseline and to verify self-reported estimates of alcohol and other drug use. For remote visits, study staff were unable to perform urine drug screens.
Saliva Test	Self-administered saliva tests were implemented in March 2021 as an alternative method of biochemical verification during remote visits. Participants were contacted prior to their assessment to confirm willingness to participate in the saliva test, what address the test would be mailed to, and whether the visit would be conducted over Zoom or on the phone. During the assessment, participants were able to self-administer the saliva test with study staff guidance. If participants completed the assessment over Zoom, participants showed the test results to the research coordinator who screenshotted the test and uploaded it to REDCap. If the participant completed the assessment over the phone, they uploaded images of the test to REDCap or, if unable to upload images, self-reported the results. Due to inconsistencies in saliva test results (no results, partial results, and false negatives), saliva test use was discontinued in May 2021.
* = not administered d	uring remote visits

# Table 2 (self-administered measures)

Measure	Description
Demographics Background	Participants reported the following: gender, race, ethnicity (whether participants were Hispanic/Latino), where they were living for the majority of the past 3 months (with fam or other relatives, with group of friend(s) or non-family members, alone in own dwelling homeless, hospital rehabilitation facility or nursing home, jail, prison or other corrections facility, other), current marital status (single, married, living with someone as if married, relationship, engaged to be married, legally separated, divorced, widowed), sexual orientation, left or right handed, highest level of schooling completed, highest level of schooling completed by either parent, whether they held a job in the past 3 months, (if ye nature of employment (odd jobs, part time, full time), (if no) reason for unemployment, major source of financial support, total annual household income, type of health insurance and financial well-being of their family. Numerical values were collected for the followin in the past 3 months: unplanned absences from work/school, times disciplined on the job school, times your job/school has been in jeopardy, times you were suspended or fired fr work/school (Dennis et al., 2002; Miller & Delboca, 1994).
Criminal Justice Involvement	<ul> <li>work/school (Dennis et al., 2002; Miller &amp; Delboca, 1994).</li> <li>The questionnaire used adapted items about criminal justice involvement from the Form (Miller &amp; Delboca, 1994). Participants reported on their current legal status (none, on probation only, on parole only, on probation and parole, awaiting charge, trial or sentence outstanding warrant, case pending, other). At baseline, participants reported whether the had ever been arrested (yes/no). If yes, they reported how many times overall, how many times for DUI/DWI in their lifetime, and how many times for other reasons in their lifeti At follow-up visits, participants reported how many times overall, how many times for DUI/DWI in the past 3 months (yes/no). If yes, they reported how many times for other reasons in the past 3 month at baseline, participants reported whether they had ever stayed in jail or prison overnigh longer (yes/no). If yes, they reported how many times in their lifetime and how many times the past 3 months. At follow-up visits, participants only reported the number of times the past 3 months.</li> </ul>

Religious Background and Behaviors (RBBS)	At baseline, the questionnaire assessed if the participant considered themselves to be par a religious group (No/none, Baptist, Buddhist, Catholic, Evangelical, Hindu, Jewish, Lutheran, Methodist, Mormon, Muslim, Presbyterian, Other Protestant, Shinto, Native American Church, Traditional Native American, Christian, Some other group). For all timepoints participants were asked which of the following describes them at this time: atheist, agnostic, unsure, spiritual, religious. Participants were asked how often they participated in religious activities in the past 3 months on a 7-point Likert scale ( <i>never</i> , <i>rarely, once a month, twice a month, once a week, twice a week, almost daily, more than</i> <i>once a day</i> ) and, at baseline, how often they participated in certain religious activities in their lifetime on a 3 point-Likert scale ( <i>never, yes, in the past but not now, yes, and I stil</i> (Connors et al., 1996).
Religious and Spiritual Intensity	The questionnaire included four items assessing participants' religiosity and spirituality. Participants reported the extent to which they considered themselves religious/spiritual of Likert scale from <i>not religious/spiritual at all</i> (1) to <i>very religious/spiritual</i> (4). Participareported the extent to which their religious/spiritual practices and beliefs help them with resolving an alcohol/drug problem on a scale from <i>do not help at all</i> (1) to <i>make all the difference</i> (5) (Idler et al., 2003).
Twelve Promises Scale (TPS)	This questionnaire assessed participants' current psychosocial state and attitudes toward drinking and using drugs. Participants rated how true each item was for them at the curre time on a scale of <i>never true</i> (1) to <i>true most of the time</i> (5) (Kelly & Greene, 2013).
Perceived Stress Scale (PSS-4)	This questionnaire assessed participants' level of stress over the last month. Participants rated each item on a scale from <i>never</i> (1) to <i>very often</i> (5) (Warttig et al., 2013).
Kessler 6 (K6)	This six-item scale assessed psychiatric symptoms (also referred to as psychological distress). On a scale from <i>all of the time</i> (1) to <i>none of the time</i> (5), participants are asked how often they felt: nervous, hopeless, restless or fidgety, so depressed that nothing could cheer you up, that everything was an effort, and worthless (Kessler et al., 2003).
Coping Strategies Scale (CSS)	Participants were asked to select how often they used a variety of coping strategies or thoughts in the past 3 months to help them not use alcohol or drugs. Participants rated ea item on a scale from <i>never</i> (1) to <i>frequently</i> (4) (Litt et al., 2003; Prochaska et al., 1988).
Alcohol and Drug Abstinence Self Efficacy (A-DSES-20)	Participants were asked about their feelings of confidence to not drink or use drugs in various situations in the past week. Participants rated their level of confidence for each scenario on a scale of <i>not at all confident</i> (1) to <i>extremely</i> (5) (Diclemente et al., 1994).
Penn Alcohol and Drug Craving (PADCS-5)	This questionnaire assessed the frequency and strength of cravings to use alcohol and oth drugs during the past week. Participants reported how often they thought about drinking/using drugs, how strong the craving was at its most severe, how much time they have spent thinking about drinking/using drugs, how difficult it would have been to resist drinking/using drugs, and then rated their overall alcohol/drug craving with options rang from <i>never thought about drinking/using drugs nearly all of the time and had the urge to drink/use drugs nearly all of the time</i> (Flannery et al., 1999).
Commitment to Sobriety Scale (CSS-5)	In this questionnaire, participants were asked 5 questions about their commitment to not using alcohol/drugs. Participants rated the extent to which they agreed with these statem on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6) (Kelly & Greene, 2014).
Drinking Goal	In this questionnaire, participants chose one goal that was the most true to them currentl from the 5 options: 1) Total abstinence; never use again; 2) Total abstinence; but realize slip is possible; 3) Occasional use when urges strongly felt; 4) Temporary abstinence; or Controlled use.

Short Inventory of Problems (SIP-2R)	This questionnaire assessed how often participants had experienced various problems during the past 3 months because of their drinking/drug. Participants indicated how often they had experienced each problem on a scale of <i>never</i> to <i>daily or almost daily</i> . Participants were also asked to indicate whether they had had an accident while drinking or intoxicated in the past 3 months (Miller et al., 1995).
Questions about Recovery	This questionnaire assessed recovery identity, definition, and what participants believe are the factors helping them resolve their problem with alcohol/drugs at baseline, 12-month follow-up, and 24-month follow-up. Participants selected a statement that best applied to them from whether they consider themselves to be <i>in recovery</i> , <i>seeking recovery</i> or <i>not in or seeking recovery</i> . If participants chose that they were 'in recovery', they were asked to provide the date they use to mark the beginning of their recovery. Participants were asked to provide their definition of recovery in one sentence (free response) and to select one of three statements that best fit their definition of recovery: 1) Abstinence from all drugs/alcohol; 2) Abstinence from only those drugs/alcohol with which they had a problem; or 3) Non-problematic/moderate use of drugs/alcohol, including those with which they had a problem. Participants were then asked to list the top 3 things that have helped or are helping them to resolve their problem with alcohol/drugs.
Brief Assessment of Recovery Capital (BARC-10)	The BARC-10 (Vilsaint et al., 2017) is a 10-item, abridged version of the Addiction Recovery Capital Scale (Groshkova et al., 2013). The BARC-10 measures personal (e.g., "I take full responsibility for my actions"), social (e.g., "I get lots of support from friends"), physical (e.g., "I have enough energy to complete the tasks I set for myself"), and environmental resources (e.g., "My living space has helped to drive my recovery journey") used to initiate and sustain recovery. Participants rated their agreement with each statement on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6).
Behavioral Addictions	The questionnaire used items adapted from Laudet et al. (2015) to assess whether individuals ever had a problem with one or more other behaviors apart from AOD use in their lifetime (baseline) and currently, including 1) Eating disorder; 2) Sex/love addiction; 3 Gambling; 4) Video gaming addiction; 5) Compulsive shopping; 6) Internet addiction (for issues not assessed by other choices); 7) Compulsive exercise; 8) Internet pornography addiction; 9) Self-harm/injury and 10) Other (specified). "Other" options were examined for possible inclusion in existing categories, and recategorized as appropriate. Participants were asked if any reported behavioral addictions had been a problem for them in the past 3 month and if so, how many days out of 90. If reporting more than one, participants indicated which behavior had been the most problematic.
Medical Marijuana Use	Participants were asked if they had ever been recommended to use marijuana for medical reasons. If yes was indicated, participants were asked how many days out of the past 90 marijuana was used for medical reasons and to list up to three medical reasons for using marijuana.
Medication Attitudes	This questionnaire assessed participant attitudes toward medication for an alcohol problem, opioid problem, any kind of alcohol/drug problem, and emotional problem. Participants rated their agreement with the use of medication for these problems on a scale of <i>strongly disagree</i> (1) to <i>strongly agree</i> (6).
Impulsive behavior (SUPPS-S)	This questionnaire assessed impulsivity. Participants rated their agreement with 20 items describing situations or feelings related to impulsivity on a scale of <i>agree strongly</i> (1) to <i>disagree strongly</i> (4) (Coskunpinar et al., 2013).
Quality of Life (Q-LES-Q)	This measure of quality of life was used to assess satisfaction related to physical health, mood, relationships, activities, and economic status. Participants rated their satisfaction with

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Quality of Life (EQ5D3L)	This measure of quality of life was used to assess physical and mental health states. Participants rated their current mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Participants also rated their current overall physical and mental health states using a visual analogue scale with options between 0 ( <i>worst</i> ) and 100 ( <i>best</i> ) (Devlin & Brooks, 2017).
Quality of Life (EUROHIS-QOL)	This measure of quality of life is a widely used eight-item measure of quality of life, adapted from the World Health Organization Quality of Life – Brief Version (WHOQOL-BREF) (Schmidt et al., 2006). Participants rated each item on a 5-point Likert scale from 1 ( <i>very poor, very dissatisfied,</i> or <i>not at all</i> ) to 5 ( <i>very good, very satisfied,</i> or <i>completely</i> ) (da Rocha et al., 2012).
Pittsburgh Sleep Quality Index (PSQI)	This questionnaire assessed quality of sleep. Participants reported how many hours of sleep they got on average per night over the past month. Participants then rated their quality of sleep on a scale from <i>very good</i> (1) to <i>very bad</i> (4) (Buysse et al., 1989).
Pain Visual Analogue Scale (VAS)	This measure assessed physical pain. Participants rated the current severity of their pain using a visual analogue scale with options between 0 ( <i>no pain</i> ) to 100 ( <i>very severe pain</i> ) (Wewers & Lowe, 1990).
International Physical Activity Questionnaire (IPAQ)	This questionnaire asks participants about their level of physical activity over the past seven days. Participants indicate how many days in the past 7 days they have done: vigorous physical activity, moderate physical activity, and walking. Participants then indicate how much time per day they usually spent on each activity in hours and minutes. Participants are also asked how many hours they usually spent sitting on weekdays over the past 7 days (Hagstromer et al., 2006).
Meals	Participants reported how many meals on average they have eaten per day during the past 3 months.
Self-esteem, Happiness, and Satisfaction with Life	Three single-item measures were used to assess self-esteem (Robins et al., 2001), happiness, and satisfaction with life (Diener et al., 1985). For self-esteem, participants indicated their agreement with the statement "I have high self-esteem" on a scale from 1 ( <i>not very true of</i> me) to 10 ( <i>very true of</i> me). For happiness, participants rated how happy they were with their life in general on a scale of 1 ( <i>completely unhappy</i> ) to 10 ( <i>completely happy</i> ). For satisfaction with life, participants indicated their agreement with the statement "I am satisfied with my life" on a scale of <i>strongly disagree</i> (1) to <i>strongly agree</i> (7).
Abstinence Self- Efficacy Single Item	Participants rated how confident they were that they could remain abstinent or drink/use drugs without problem in the next 3 months on a scale from <i>not at all confident</i> (1) to <i>very confident</i> (10).
Daily Spiritual Experiences Scale (DSES)	This questionnaire assesses spiritual and/or religious experiences. The questionnaire includes items with the word "God" used but includes instructions for participants that if "God" is not a comfortable word that they should substitute it for one that calls to mind the divine and holy for them. Participants read 15 items describing spiritual and/or religious experiences that a person may have and rate how often they have this experience from <i>many times a day</i> (1) to <i>never or almost never</i> (6). The last item asks participants how close they feel to God from <i>not close</i> (1) to <i>as close as possible</i> (4) (Underwood & Teresi, 2002)

# References

1 2

3

4

5 6

7

8

9

10

11

12

13 14

15

16

- Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res, 28(2), 193-213. https://doi.org/10.1016/0165-1781(89)90047-4
- Connors, G. J., Tonigan, J. S., & Miller, W. R. (1996). A Measure of Religious Background and Behavior for Use in Behavior Change Research. Psychology of Addictive Behaviors, 10(2), 90-96.
- Coskunpinar, A., Dir, A. L., & Cyders, M. A. (2013). Multidimensionality in impulsivity and alcohol use: a meta-analysis using the UPPS model of impulsivity. Alcohol Clin Exp Res, 37(9), 1441-1450. https://doi.org/10.1111/acer.12131
- da Rocha, N. S., Power, M. J., Bushnell, D. M., & Fleck, M. P. (2012). The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health, 15(3), 449-457. https://doi.org/10.1016/j.jval.2011.11.035
- Dennis, M. L., Titus, J., White, M., Unsicker, J., & Hodkgins, D. (2002). Global Appraisal of Individual Needs (GAIN): Administration Guide for the GAIN and Related Measures. In. Bloomington, IL: Chestnut Health Systems.
- 18 Devlin, N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future [Review]. Applied 19 Health Economics and Health Policy, 15(2), 127-137. https://doi.org/10.1007/s40258-017-0310-5 20
- Diclemente, C. C., Carbonari, J. P., Montgomery, R. P. G., & Hughes, S. O. (1994). The Alcohol Abstinence 21 22 Self-Efficacy Scale [Article]. Journal of Studies on Alcohol, 55(2), 141-148. 23 https://doi.org/10.15288/jsa.1994.55.141 24
- Diener, E., Emmons, R. A., Larsen, R. J., & Griffin, S. (1985). The Satisfaction With Life Scale [Article]. 25 Journal of Personality Assessment, 49(1), 71-75. https://doi.org/10.1207/s15327752jpa4901\_13
- 26 Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction 27 Questionnaire - A New Measure [Article]. *Psychopharmacology Bulletin*, 29(2), 321-326. < Go to 28 29 ISI>://WOS:A1993MC72000028
- 30 Fillmore, M. T., Rush, C. R., & Hays, L. (2006). Acute effects of cocaine in two models of inhibitory control: 31 implications of non-linear dose effects [Article]. Addiction, 101(9), 1323-1332. 32 https://doi.org/10.1111/j.1360-0443.2006.01522.x 33
- Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999). Psychometric properties of the Penn Alcohol 34 Craving Scale [Article]. Alcoholism-Clinical and Experimental Research, 23(8), 1289-1295. 35 https://doi.org/10.1111/j.1530-0277.1999.tb04349.x 36
- 37 Groshkova, T., Best, D., & White, W. (2013). The Assessment of Recovery Capital: Properties and 38 psychometrics of a measure of addiction recovery strengths [Article]. Drug and Alcohol Review, 32(2), 39 187-194. https://doi.org/10.1111/j.1465-3362.2012.00489.x 40
- Hagstromer, M., Oja, P., & Sjostrom, M. (2006). The International Physical Activity Questionnaire (IPAQ): a 41 study of concurrent and construct validity [Article]. Public Health Nutrition, 9(6), 755-762. 42 https://doi.org/10.1079/phn2005898 43
- Idler, E. L., Musick, M. A., Ellison, C. G., George, L. K., Krause, N., Ory, M. G., Pargament, K. I., Powell, L. 44 45 H., Underwood, L. G., & Williams, D. R. (2003). Measuring multiple dimensions of religion and 46 spirituality or health research - Conceptual background and findings from the 1998 General Social 47 Survey [Article; Proceedings Paper]. Research on Aging, 25(4), 327-365. 48 https://doi.org/10.1177/0164027503025004001 49
- Kelly, J. F., & Greene, M. C. (2013). The Twelve Promises of Alcoholics Anonymous: Psychometric measure 50 validation and mediational testing as a 12-step specific mechanism of behavior change [Article]. Drug 51 52 and Alcohol Dependence, 133(2), 633-640. https://doi.org/10.1016/j.drugalcdep.2013.08.006
- 53 Kelly, J. F., & Greene, M. C. (2014). Beyond motivation: Initial validation of the commitment to sobriety scale 54 [Article]. Journal of Substance Abuse Treatment, 46(2), 257-263. 55 https://doi.org/10.1016/j.jsat.2013.06.010 56
- Kelly, J. F., Stout, R. L., & Slaymaker, V. (2013). Emerging adults' treatment outcomes in relation to 12-step 57 mutual-help attendance and active involvement [Article]. Drug and Alcohol Dependence, 129(1-2), 151-58 157. <u>https://doi.org/10.1016/j.drugalcdep.2012.10.005</u> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 59 60

Page 25 of 26

# BMJ Open

•	
1	Kelly, J. F., Urbanoski, K. A., Hoeppner, B. B., & Slaymaker, V. (2011). Facilitating comprehensive
1	assessment of 12-step experiences: A Multidimensional Measure of Mutual-Help Activity. Alcoholism
2	<i>Treatment Quarterly</i> , 29(3), 181-203. <go isi="" to="">://MEDLINE:22081741</go>
4	Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.
5	L. T., Manderscheid, R. W., Walters, E. E., & Zaslavsky, A. M. (2003). Screening for serious mental
6	illness in the general population [Article]. Archives of General Psychiatry, 60(2), 184-189.
7	https://doi.org/10.1001/archpsvc.60.2.184
8	Laudet, A. B., Harris, K., Kimball, T., Winters, K. C., & Moberg, D. P. (2015). Characteristics of Students
9	Participating in Collegiate Recovery Programs: A National Survey [Article]. Journal of Substance
10	Abuse Treatment, 51, 38-46, https://doi.org/10.1016/j.jsat.2014.11.004
11	Litt, M. D., Kadden, R. M., Cooney, N. L., & Kabela, E. (2003). Coping skills and treatment outcomes in
13	cognitive-behavioral and interactional group therapy for alcoholism [Article]. Journal of Consulting and
14	<i>Clinical Psychology</i> , 71(1), 118-128, https://doi.org/10.1037/0022-006x.71.1.118
15	Miller, W. R., & Delboca, F. K. (1994). Measurement of Drinking Behavior Using the Form-90 Family of
16	Instruments [Article]. Journal of Studies on Alcohol, 112-118.
17	https://doi.org/10.15288/isas.1994.s12.112
18	Miller, W. R., Tonigan, J. S., & Longabaugh, R. (1995). The Drinker Inventory of Consequences (DrInC): An
20	instrument for assessing adverse consequences of alcohol abuse. Test manual. In M. E. Mattson & L. A.
21	Marshall (Eds.), Project MATCH Monograph Series (Vol. 4), National Institute on Alcohol Abuse and
22	Alcoholism
23	National Cancer Institute. (2009). Tobacco Use Supplement to the Current Population Survey: Reports and
24	<i>publications using the TUS-CPS</i> , http://riskfactor.cancer.gov/studies/tus-cps/publications.html
25	National Institutes of Health, & U.S. Food and Drug Administration. (2013). Population Assessment of
20 27	Tobacco and Health (PATH) Study: Final Adult Baseline (Wave 1) Ouestionnaire. In. Bethesda, MD:
27	National Institutes of Health.
29	Prochaska, J. O., Velicer, W. F., Diclemente, C. C., & Faya, J. (1988). Measuring Processes of Change -
30	Applications to the Cessation of Smoking [Article]. Journal of Consulting and Clinical Psychology.
31	56(4), 520-528, https://doi.org/10.1037/0022-006x.56.4.520
32	Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., Crawford, E. D., Fogel, R., Gelmann, E.
33 24	P., Gilbert, F., Hasson, M. A., Hayes, R. B., Johnson, C. C., Mandel, J. S., Oberman, A., O'Brien, B.,
35	Oken, M. M., Rafla, S., Reding, D., Rutt, W., Team, P. P. (2000). Design of the Prostate, Lung,
36	Colorectal and Ovarian (PLCO) Cancer Screening Trial [Review]. Controlled Clinical Trials, 21(6),
37	273S-309S. https://doi.org/10.1016/s0197-2456(00)00098-2
38	Robins, R. W., Hendin, H. M., & Trzesniewski, K. H. (2001). Measuring global self-esteem: Construct
39	validation of a single-item measure and the Rosenberg self-esteem scale [Article]. Personality and
40 41	Social Psychology Bulletin, 27(2), 151-161. https://doi.org/10.1177/0146167201272002
42	Schmidt, S., Muhlan, H., & Power, M. (2006). The EUROHIS-QOL 8-item index: psychometric results of a
43	cross-cultural field study [Article]. European Journal of Public Health, 16(4), 420-428.
44	https://doi.org/10.1093/eurpub/cki155
45	Underwood, L. G., & Teresi, J. A. (2002). The daily spiritual experience scale: Development, theoretical
46	description, reliability, exploratory factor analysis, and preliminary construct validity using health-
4/ 10	related data [Article]. Annals of Behavioral Medicine, 24(1), 22-33.
40 49	https://doi.org/10.1207/s15324796abm2401_04
50	Vilsaint, C. L., Kelly, J. F., Bergman, B. G., Groshkova, T., Best, D., & White, W. (2017). Development and
51	validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder
52	[Article]. Drug and Alcohol Dependence, 177, 71-76. https://doi.org/10.1016/j.drugalcdep.2017.03.022
53	Warttig, S. L., Forshaw, M. J., South, J., & White, A. K. (2013). New, normative, English-sample data for the
54	Short Form Perceived Stress Scale (PSS-4) [Article]. Journal of Health Psychology, 18(12), 1617-1628.
55 56	https://doi.org/10.1177/1359105313508346
57	Wewers, M. E., & Lowe, N. K. (1990). A Critical Review of Visual Analog Scales in the Measurement of
58	Clinical Phenomena [Review]. Research in Nursing & Health, 13(4), 227-236.
59	https://doi.org/10.1002/nur.4770130405
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 2 4 5 6 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 14 5 6 7 8 9 10 11 2 3 2 4 5 6 6 7 8 9 10 11 2 3 3 4 5 6 6 7 8 9 0 11 2 3 3 4 5 6 6 7 8 9 0 11 2 2 3 2 4 5 6 6 7 8 9 0 11 2 2 3 4 5 6 7 7 8 9 0 11 2 2 3 4 5 6 7 7 8 9 0 31 3 2 3 3 4 5 6 6 7 7 8 9 0 1 1 2 9 0 1 2 2 3 2 4 5 6 7 8 9 0 1 2 2 3 3 4 5 6 6 7 7 8 9 0 1 2 2 3 3 4 5 6 6 7 7 8 9 0 1 2 2 3 3 4 5 6 6 7 8 9 0 1 2 3 3 4 5 6 6 7 7 8 9 0 1 2 3 3 4 5 6 6 7 7 8 9 0 1 2 3 3 4 5 6 6 7 7 8 9 0 1 2 3 3 4 5 6 6 7 7 8 9 0 1 2 3 3 4 5 6 7 7 8 9 0 1 2 3 3 4 5 6 7 7 8 9 0 1 2 3 3 3 4 5 6 7 7 8 9 0 1 2 3 3 4 5 6 7 7 8 9 0 0 1 2 3 3 3 4 5 6 7 7 8 9 4 0 7 8 9 9 0 1 2 9 1 2 9 1 2 2 3 2 3 3 2 3 3 2 3 3 3 3 2 3 3 3 3	Zywiak, W. H., Neighbors, C. J., Martin, R. A., Johnson, J. E., Eaton, C. A., & Rohsenow, D. J. (2009). The Important People Drug and Alcohol interview: Psychometric properties, predictive validity, and implications for treatment [Article]. <i>Journal of Substance Abuse Treatment, 36</i> (3), 321-330. https://doi.org/10.1016/j.jsat.2008.08.001
<ol> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> <li>51</li> <li>52</li> <li>53</li> <li>54</li> <li>55</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> <li>60</li> </ol>	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

# **BMJ Open**

#### An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-066898.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Dec-2022
Complete List of Authors:	Kelly, John; Harvard Medical School, Psychiatry; Massachusetts General Hospital, Psychiatry Levy, Samuel; Massachusetts General Hospital, Psychiatry Hoeppner, Bettina B; Harvard Medical School
<b>Primary Subject Heading</b> :	Addiction
Secondary Subject Heading:	Health services research, Evidence based practice
Keywords:	Substance misuse < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH



**BMJ** Open

An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

John F. Kelly<sup>1,2</sup>, Samuel Levy<sup>1</sup>, Bettina Hoeppner<sup>1,2</sup>

1. Massachusetts General Hospital, Psychiatry Department, Boston, Massachusetts; 2. Harvard Medical School, Department of Psychiatry, Boston, Massachusetts

Corresponding Author: John F. Kelly, PhD, MPH 151 Merrimac St, 6<sup>th</sup> Floor Boston, MA 02114 Email: jkelly11@mgh.harvard.edu Tel: 617-643-1980

Word Count: 3925

# ABSTRACT

#### Introduction

Alcohol use disorder (AUD) remains one of the most pervasive of all psychiatric illnesses conferring a massive health and economic burden. In addition to professional treatments to address AUD, mutual-help organizations (MHOs) such as Alcoholics Anonymous (AA) and newer entities like Self-Management and Recovery Training (SMART Recovery) play increasingly important roles in many societies. While much is known about the positive effects of AA, very little is known about SMART. Hence, this study seeks to estimate real-world patterns of utilization and benefit from SMART Recovery as well as explore for whom (moderators) and how (mechanisms) SMART confers recovery benefits.

### Methods and analysis

Naturalistic, longitudinal, cohort study (N=368) of individuals with AUD recruited between February 2019-February 2022, initiating a new recovery attempt who self-select into one of four groups at study entry: 1. SMART Recovery; 2. AA; 3. SMART+AA; 4. Neither SMART nor AA; (stratified by DSM 5 severity markers), with assessments conducted at intake, and 3-, 6-, 9-, 12-, 18-, and 24-months. Primary outcomes are: Frequency of SMART and AA meetings attendance; Percent Days Abstinent (PDA) and percent days heavy drinking (PDHD). Secondary outcomes include: psychiatric distress; quality of life and functioning. Moderator variables include sex/gender; race/ethnicity; spirituality. Mediational variables include: social networks; coping skills; self-efficacy; impulsivity. Multivariable regression with propensity score matching will test for patterns of attendance and effects of participation over time on outcomes and test for mechanisms and moderators.

#### Ethics and dissemination

This study is approved by the Mass General Brigham Institutional Review Board. Results will be published in peer-reviewed journals and presented conferences.

# **Registration and Funding**

This is a non-randomized, naturalistic, longitudinal, cohort study, and thus was not registered in advance. Results, therefore, should be considered exploratory. The study was funded by the US National Institute of Alcohol Abuse and Alcoholism (NIAAA; 5R01AA026288; K24AA022136).

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- Individuals (N=368) with primary alcohol use disorder who self-select into either SMART Recovery, Alcoholics Anonymous (AA), both SMART and AA, or neither, will be compared over time on addiction recovery processes and outcomes.
- Participant characteristics, changes processes, and outcomes will be measured prospectively using validated measures at study intake, and again at 3-, 6-, 9-, 12-, 18-, and 24-months later.
- Primary outcomes will be: number of SMART and AA meetings attended per week at each follow-up; percent days abstinent (PDA); percent days heavy drinking (PDHD); alcohol use disorder remission status; alcohol/drug related consequences. Secondary outcomes include quality of life and functioning psychiatric distress, self-esteem, happiness.
- The study has a cohort based, naturalistic, non-randomised, design; research staff are not blinded to participants' self-selected recovery pathway and the use of self-report measures, despite psychometric validation, can yield social desirability and recall biases.
- Descriptive and longitudinal inferential modeling analyses will be conducted (accounting for missing data) to describe and estimate effects related to different pathway choices.
- .

# INTRODUCTION

Alcohol and other drug use disorders confer a prodigious burden of disease, disability, and premature mortality in most middle- and high-income countries globally. To help alleviate this burden, most countries provide an array of professionally delivered addiction treatment services. Yet, despite these efforts, such services are often unable to meet both acute care and long-term relapse prevention needs of the millions or tens of millions affected annually. In response, most countries also possess an array of informal community-based peer recovery support services which can provide ongoing assistance for individuals suffering from these disorders [1]. The oldest and largest of these are the 12-step mutual-help organizations (MHOs), such as Alcoholics Anonymous (AA). Rigorous research evidence has now demonstrated that when AA is subjected to the same scientific standards as other addiction focused interventions it does as well on most outcomes measures, is better at sustaining abstinence and remission over time, and is highly cost effective [1].

A limitation of the current standard of care, however, borne out of a limitation in available empirical data, is the fact that referral oftentimes focuses solely on spiritually-oriented 12-step organizations, such as AA, which is the only empirically-supported MHO continuing care referral option. Not everyone chooses AA as a pathway to recovery for various reasons, and alternative MHO options - although much newer and smaller - are growing and may contain many of the same positive therapeutic elements and dynamics possessed by AA [2, 3]. These therapeutic pathways include adaptive social network changes, increases in social abstinence self-efficacy, and reducing negative affect. Indeed, some preliminary evidence suggests such organizations may confer similar benefits for those who self-select into them [4].

The largest and possibly most well-known of these newer alternative MHOs is Self-Management and Recovery Training (SMART) Recovery. There are approximately 1,200 SMART groups nationwide and another 1,000 internationally. SMART also has a strong online support presence including online meetings, forums, and chat rooms. Unlike AA, SMART is founded upon cognitive-behavioral principles and practices and is led by trained facilitators. It focuses on enhancing and maintaining motivation to abstain or (more recently) reduce use to non-problematic levels, coping with urges, problem solving, and lifestyle balance [5]. It also advocates for appropriate use of professional psychosocial and pharmacological treatments. A compelling aspect of SMART as an MHO is, because it is itself based on empirically-derived CBT principles, it provides a philosophically compatible recovery resource that is aligned with cognitive-behavioral treatment principles, which make up a large majority of national and international evidence-based treatments [6]. Consequently, SMART is appealing to many individuals with SUD [5], yet due to the lack of empirical evidence supporting its effectiveness, clinicians remain less likely to discuss or refer patients to SMART [7, 8]. This has hindered its growth and prevented many the opportunity to learn about and try SMART.

Compared to the dozens of high-quality studies examining 12-step MHOs [9-12], there have been just a handful of studies on SMART. We conducted a systematic review of this research [13] and found that only 12 studies exist (4 of which are unpublished dissertations) that have focused on SMART Recovery and used any kind of formal measurement. Most of these (8 out of the 12) are cross-sectional with mixed results and suffer from considerable biases as they possess substantial methodological limitations making it difficult to draw firm conclusions [14-16]. For instance, these studies have rarely assessed mental health status or its severity, despite the high rates of comorbidity between AUD and mental health. Two recent high-quality studies

#### **BMJ** Open

examining SMART Recovery, however, have been conducted, one in a criminal justice context, the other examining its effect on heavy alcohol use in an RCT.

The criminal justice study was a large quasi-experimental study of criminal offenders in Australia [17]. It compared a group of individuals participating in SMART Recovery and/or a criminal justice intervention (called "Getting SMART") designed to link offenders with SMART meetings following prison release, to a group of control participants who did not interact with any SMART materials or attended meetings, but who were matched on various other relevant characteristics through the use of propensity scores. The study found that participation in Getting SMART by itself, and Getting SMART + SMART Recovery meeting attendance, was associated with a reduced overall rate of reconviction with rates of reconviction reduced by 19 and 22%, respectively. For violent reconvictions, rates were reduced by 30% for Getting SMART participation and 42% for Getting SMART + SMART Recovery. While an important and promising set of results in their own right, unfortunately, the authors did not examine or report any alcohol/drug use outcomes [17].

There has been only one small, randomized trial evaluating SMART Recovery, which randomized people to (a) "Overcoming Addictions" (OA) - a SMART Recovery web application, (b) SMART Recovery meeting attendance, or (c) OA + SMART Recovery meeting attendance combined. The study found participants from all groups benefitted equally with respect to alcohol outcomes [18]. This finding underlines the promise of SMART Recovery to provide recovery support. Unfortunately, however, this trial did not include a control group, who did not have any exposure to SMART materials. Given, however, that all groups participated in SMART, it is not clear if observed benefits were simply naturally occurring improvements in alcohol outcomes, or really a function of SMART participation. Another limitation is that it only enrolled subjects with heavy drinking problems and excluded participants with more severe forms of AUD, who more typically enroll in formal treatment and are thus in need of referral options for continuing care.

A more recent study examined participation among individuals with alcohol use disorder recruited from various online and community venues with varying lengths of sobriety who self-selected into one of four different types of MHOs: Alcoholics Anonymous, LifeRing Secular Organization, SMART Recovery, and Women for Sobriety[4]. This study found that SMART Recovery participants had as good alcohol outcomes at 6- and 12-month follow-ups as those attending other MHOs. Again, however, the study did not include a control group with no MHO involvement.

These results provide some preliminary information about real-world benefits related to SMART Recovery participation. There is very little, if any, information regarding how involved they become or the mechanisms of behavior change through which SMART may help individuals attain AUD remission and recovery (e.g., via social changes, coping skills, recovery motivation, abstinence self-efficacy; reduced impulsivity). SMART has the potential to be a secular MHO alternative to 12-step MHOs for those preferring the secular and cognitivebehavioral foundation of SMART, yet in order to increase clinical confidence and referrals, more systematic research is needed. This study will be one of the first rigorous, real-world, evaluations of SMART providing objective estimates of recovery benefit (e.g., abstinence, AUD remission, quality of life, psychosocial functioning), and will explore the mechanisms (e.g., social network changes, self-efficacy, decreased impulsivity) and moderators (e.g., sex, race/ethnicity, addiction severity, psychiatric co-morbidity) of behavior change to determine how SMART Recovery may help its affiliates achieve and maintain remission from addiction and who seems to benefit most. To this end this study has the following specific aims: 1. Characterize and describe professional and non-professional recovery support service participation choices, migrations, and pathways using group trajectory analyses over a two-year period for individuals (N=368) starting a new AUD recovery attempt. More specifically in this regard, we will investigate the real-world effectiveness of SMART Recovery by comparing outcomes of AUD individuals making a new recovery attempt (N=368) pursuing either a SMART Recovery pathway (online or face-to-face; N=184) or a non-SMART recovery pathway (N=184). Because, according to SMART Recovery's annual survey data, roughly half of SMART participants also attend AA, we will use a stratified design to enroll persons with AUD making naturally occurring continuing care choices vis-à-vis participation in MHOs in a balanced fashion and follow them prospectively across a 24-month period. Of note, self-selection of treatment/recovery pathway options has been shown to potentially enhance outcomes. This will be explored in this study as well. This stratified design will allow us to compare the outcomes of persons choosing to participate in SMART Recovery vs. not (balanced by AUD severity), while accounting for simultaneous choices regarding AA or neither AA or SMART MHO participation. 2: Explore moderators and mechanisms of behavior change. Exploration of factors that may help uncover who (i.e., moderators) and why (i.e., mechanisms) SMART affiliates benefit from participation will be investigated. Moderators will include sex and gender, addiction severity, psychiatric distress; and mechanisms will include social network changes, recovery motivation, cognitive-behavioral coping, abstinence self-efficacy, and impulsivity.

#### **METHODS AND ANALYSIS**

#### Study overview

This study is a naturalistic, prospective, longitudinal cohort study of 368 individuals making a new recovery attempt from AUD with seven assessments over a 24-month follow-up period. Following the baseline assessment, research staff will conduct additional follow-up assessments at 3, 6, 9, 12, 18, and 24 months after study enrollment. Assessments include both self-reports by participants using online surveys, and staff-administered assessments, conducted via phone and/or Zoom. Baseline visits were conducted from February 2019 to February 2022. Follow-up visits are ongoing and will continue until approximately February 2024. The study was fully reviewed and approved by the Institutional Review Board at Mass General Brigham, Boston, MA USA.

#### Sample size determination

The primary outcome variables are percent days abstinence (PDA) and percent days heavy drinking (PDHD; NIAAA-defined). Secondary outcomes include quality of life and psychosocial functioning. To estimate a plausible effect size to be expected in PDA as a function of mutual help organization (MHO) utilization, we examined the PDA outcomes in Project MATCH [19] for persons utilizing AA vs. not. Effects were surprisingly consistent across time, with patients with any AA utilization reporting a higher average number of PDA than patients with no AA involvement (d=0.45, 0.39, 0.38, 0.42, and 0.39 at 3-, 6-, 9-, 12- and 15-month follow-up respectively). Thus, conservatively, we are powering this study to detect an effect size of d=0.35, leading to a combined sample size of n=260 (equally balanced, due to stratification, in terms of AA utilization and addiction severity). With a conservatively estimated retention rate of

#### **BMJ** Open

75%, we would need to enroll n=347 to retain n=260. Given our stratified design (i.e., 2 [SMART vs. not] x 2 [12-step vs. not] x 3 [mild vs. moderate vs. severe AUD] design = 12 stratification cells), we proposed to enroll a final sample size of n=348 (i.e., n=29 per cell). In addition, 20 further participants were enrolled to increase representation of individuals attending SMART Recovery and to account for participants who withdrew, were terminated from the study, were found ineligible, or were otherwise no longer participating (e.g., death unrelated to the study).

Using this design, we will be equally well powered to test the main effect of 12-step participation. In terms of conducting pair-wise comparisons between the four possible combinations of using SMART Recovery and/or 12-Step, this sample size would enable us to detect pairwise differences of medium effect size (d=0.50). Improvements over our conservatively estimated retention rate would increase power (e.g., could detect d=0.46 with 85% retention).

#### Recruitment

Participants were recruited through SMART Recovery meetings, inpatient and outpatient treatment programs, and a variety of commercial recruitment sources during the recruitment period (January 2019 to January 2022).

Flyers and postcards for the study were distributed around buildings of Massachusetts General Hospital, particular around inpatient and outpatient SUD clinics. SMART facilitators were asked to advertise the study at SMART meetings and were provided with recruitment postcards and flyers. The study was also advertised on the SMART San Diego website. Additional recruitment methods included ResearchMatch, PeRC, TrialFacts, Rally for Recruitment, the Metro Newspaper, radio advertisements, MBTA advertisement, Facebook, Craigslist, and Reddit. For radio, MBTA, Facebook, and Craigslist advertisements, this study was advertised along with another ongoing R01 study of individuals making a new recovery attempt from AUD with similar eligibility criteria. Monthly meetings were also held with regional SMART Recovery MHO group facilitators to provide them with updates and inquire if there was anything we could provide to help facilitate study recruitment from online SMART resources or SMART meetings.

Interested individuals called the study-specific phone line, emailed the study-specific email address, or filled out an online screening form. Individuals were then able to participate in a brief 10–15-minute phone screen, during which eligibility criteria were confirmed. If the individual was eligible to participate, the baseline visit was scheduled and contact information for two locator contacts who can assist research staff in locating participants was collected.

**Consent Process:** Participants completed the consent process with a trained study staff member and were encouraged to ask questions about any aspect of the study. Through this process, participants were informed about the nature and extent of the study duration and procedures including the types of assessments administered, the risks and benefits of participation, as well as the financial renumeration schedule and protocol, and given telephone and email contact information in order to contact study staff at any time during the course of the study (see Consent Form in Supplementary Materials section for more details).

#### Eligibility

Participants were required to be 18 years or older, living in the New England or San Diego metropolitan area, and willing to travel to Boston, Massachusetts, to complete study visits (for
New England residents) or to complete study visits remotely (due to COVID-19 and for the San Diego participants). The geographical catchment area eligibility criteria were expanded to include people from the San Diego area in December 2020 to increase the number of SMART participants in the study. Since all visits were conducted remotely beginning in March 2020 due to the COVID-19 pandemic, participants from the New England area would also be considered eligible even if they could not travel to the Boston office for assessments in the foreseeable future.

Participants could be using other drugs but had to report alcohol as their primary substance of concern; they were also required to have a self-perceived alcohol problem, to meet current criteria for DSM 5 alcohol use disorder (AUD) using semi-structured interview; to have consumed alcohol in the past 90 days and report currently engaged in a new recovery attempt defined as "a serious effort to abstain from drinking or to drink without problems in the past 90 days or planning to make one in the next 14 days."

Additionally, participants were required to provide locator contact information for two close friends/family members in case we were unable to contact the participant directly; provide their social security number for reimbursement or be willing to not receive reimbursement; provide a urine sample and breathalyzer (for in-person visits) or remote saliva test (for remote visits) for biochemical verification; and provide a stable home address and contact information. These initial bioassay requirements were not required following the start of COVID-19 lock-downs which began in March 2020.

### Methods

All assessments were initially conducted (prior to COVID) with a study research coordinator in person at our downtown Boston offices at the MGH Recovery Research Institute. Each assessment consisted of staff-administered and self-administered surveys, which were completed via REDCap (a secure, web-based application designed to support data capture for research studies), a computerized task to assess impulsivity (Go/No-Go task), and biochemical verification tests of abstinence (breathalyzer, urine) for all participants at all time points. For in person visits, the baseline and follow-up assessments lasted for approximately 3 hours. At the end of the first visit and every follow-up visit, the next follow-up was scheduled.

Due to the COVID-19 pandemic, all assessments were transitioned to be conducted remotely beginning in March 2020. During remote visits, the computerized task and urine and breath biochemical verifications of abstinence were not completed. A web-based version of the computerized task was tested, but the effects of internet speed on results made data unreliable. In lieu of the urine and breathalyzer tests, saliva tests were implemented for remote visits from March 2021 to May 2021 but were discontinued due to documented inconsistent results. Relative to in-person assessments, remote assessments were shorter with assessments lasting approximately 1.5 hours (for baseline) or 45 minutes (for follow-ups) on the phone and approximately 1 hour for participants to complete surveys individually.

All participants (in-person and remote) agreed to provide their phone numbers and email information and that of two locator contacts so that they may be contacted for follow-up assessment reminders. Research staff contacted and confirmed the contact information of the locator contacts as needed if research staff loses touch with the participant. Participants indicated their preferred method of contact (phone call, email, or text message) for receiving automated reminders throughout the project period. In keeping with a validated research follow-up protocol for maximizing retention in clinical addiction research, after the baseline assessment, research

#### **BMJ** Open

staff proactively reached out to participants for reminders and to check if there were any changes to their contact information. Check-ins occurred 1 month, 14 days, 7 days, and 24 hours before the next scheduled visit. These messages are automated and sent with Twilio, which is an approved REDCap module by Mass General Brigham.

Participants are compensated \$45 for completing the baseline visit and \$55, \$60, \$65, \$70, \$75, and \$85 for completing the 3-, 6-, 9-, 12-, 18-, and 24-month follow-up visits, respectively. Payment for each timepoint is broken up into payment for the staff-administered surveys, self-administered surveys, and travel reimbursement. During remote visits due to COVID-19, all participants were still paid the travel reimbursement to maintain the same payment structure used for in-person assessments.

## Measures

Staff-administered measures assess the following: substance use history including capture of primary outcomes (percent days of heavy drinking; percent days abstinent from alcohol/other drugs), AUD and SUD status and severity (including remission status), tobacco use, treatment utilization for physical health problems and alcohol/drug use problems, anti-craving and anti-relapse medications (alcohol and opioids), mental and emotional health diagnoses, hospitalizations, treatment history, and psychiatric medication use, social networks, 12-step/MHO attendance history, online resource utilization, SMART involvement, 12-step MHO involvement (MM-HAS), recovery/abstinence time, recovery support services and formal treatment program utilization, substance use change over the past year (YES), impulsivity (Go/No-go cognitive task), and biochemical verification of substance use (breathalyzer, urine drug screen).

Self-administered measures assess the following: demographics, criminal justice involvement, religiosity and spirituality (RBBS, religious and spiritual intensity, DSES), stress and psychiatric distress (PSS-4, K6), coping (CSS), self-efficacy (A-DSES-20, single item selfefficacy), alcohol/other drug craving (PADCS-5), commitment to sobriety (CSS-5), substance use consequences (SIP-2R), recovery status (questions about recovery, drinking goal), recovery capital (BARC-10), behavioral addictions, medical marijuana use, medication attitudes, impulsive behavior (SUPPS-S), quality of life and psychosocial functioning (TPS, Q-LES-Q, EQ5D3L, EUROHIS-QOL, self-esteem, happiness, and satisfaction with life), and physical health (PSQI, pain VAS, IPAQ, meals).

All measures were administered at each timepoint except for the Year End Summary (YES), SUD DART, and Questions about Recovery, which were administered at baseline, 12-months, and 24-months. Detailed descriptions of measures are available in Supplement 1.

## **COVID-19** impact

The COVID-19 pandemic significantly affected the conduct of study assessments as all assessments were transitioned to fully remote visits beginning in March 2020. As previously noted, this shift to remote assessments meant that we were unable to conduct the Go/No-go cognitive measure, breathalyzer, or urine screen. Due to these changes, all substance use outcomes are self-reported. Self-administered saliva tests were used briefly as a replacement, but inconsistent results (e.g., false negatives, partial results, no results) made data collected from these tests unreliable and this strategy was stopped.

Additionally, recruitment was halted as the study team transitioned to remote assessments and many previous recruitment methods were no longer viable (e.g., recruitment from outpatient

#### **BMJ** Open

clinics, advertisements on Boston area trains). It was particularly challenging to recruit individuals attending SMART as meetings were halted, then moved to virtual-only. To address these challenges, we expanded the recruitment area to San Diego, where there is a large SMART Recovery MHO participation community. We also maintained contact with SMART facilitators throughout the recruitment period to encourage them to share the study with meeting attendees and solicit feedback on how to best improve recruitment of SMART participants.

To capture potential changes in recovery resource utilization due to the COVID-19 pandemic, we added a staff-administered measure related to use of online recovery resources and social network site use. In addition, a supplemental study focusing on the impact of COVID-19 was conducted, consisting of both quantitative measures and a qualitative interview with a sub-group (n=80) of study participants selected at random from the SMART, AA, SMART+AA, and neither cohorts (n=20 from each group).

## Limitations

The study employs a cohort based, naturalistic, non-randomised, design and research staff are not blinded to participants' self-selected recovery pathways. The use of self-report measures, despite having good psychometric properties and adequate validation, can still yield social desirability and memory recall biases.

## Patient and public involvement

No patient or public involvement.

## Data analysis plan

<u>Aim 1 Effectiveness</u>. We will use multiple linear regression analyses to determine whether our primary stratification factor of interest (predictor: SMART vs. no SMART) is associated with alcohol outcomes (primary dependent variables: PDA; PDHD) at 24-month (primary end-point), and 3-, 6-, 9-, 12- and 18-month (secondary) follow-ups, while controlling for other confounding variables (e.g., baseline variation in levels of the outcome variables) and by using propensity score matching methods that we have used successfully in prior work. We will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity. We will also test longitudinal models to investigate the dynamic relationship of these various recovery pathways over time (e.g., using hierarchical linear modeling as we have done previously [20]) controlling for baseline variation in the outcome variables.

<u>Aim 2a. Mechanisms and Moderators</u>. We will use mediational modeling, using the product-ofcoefficients approach [21, 22] to test how SMART Recovery confers benefit (or fails to do so). The independent variable will be stratification group (i.e., SMART vs. no SMART), and the outcome variables will be PDA (primary), PDHD, AUD remission, quality of life, and measures of psychosocial functioning. The mediators will be our theorized mechanisms of change (e.g., social network changes, recovery motivation, coping, self-efficacy, impulsivity), which we will quantify as change since baseline in these constructs as measured via REDCap administered scales prior to the outcome (e.g., change in craving observed from baseline to 3-month would be used to predict 6-month ultimate outcomes). We will use multiple mediation to determine the relative impact of each mechanism, and moderated multiple mediation to identify differences in

#### BMJ Open

mechanisms across (moderator) subgroups (e.g., males vs. females, severe AUD addiction severity vs. moderate/mild), similar to our prior approach in delineating mechanisms of behavior change in AA [23-25].

<u>Aim 2b. Dose-response relationship of SMART Recovery</u>. Using only data from participants in the stratified SMART group, we will use linear regression (primary outcome: PDA) to test if the level of SMART involvement, as measured by the SMART Involvement Scale, is related to PDA at 24-month (primary endpoint) and other follow-up points over time. We will use basic model building practices to determine if such an effect persists after accounting for demographics, other important contextual variables, moderators, and baseline levels of the theorized mechanisms of change. In follow-up analyses, we will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity.

<u>Multiple Testing</u>. We will use the false recovery rate adjustment [26] to control for multiple testing.

<u>Missing Data.</u> Some data will inevitably be missing. We will explore patterns of missingness to determine if missingness is occurring at random (MAR) (i.e., unrelated to the value of the missing observation) or likely to be missing not at random (MNAR). For each analysis, we will use a variety of recommended strategies to address the issue of missing data (e.g., multiple imputation, maximum likelihood estimation)[27]. Consistency in findings across missing data methods will enhance our confidence in the findings. Note that study participation will be completely separate from SMART participation; thus, participants should feel comfortable remaining in the study regardless of whether they continue in SMART or not. Assuming some attrition, we plan to conduct analyses examining predictors of attrition and control for these.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de

Enseignement Superieur

(ABES)

ata mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

## ETHICS AND DISSEMINATION

All study procedures are approved by the Institutional Review Board of Mass General Brigham (approval number: 2017P002029). Written consent was received from all participants following an explanation of the study, including confidentiality and freedom of choice to participate. Results will be published in relevant peer-reviewed scientific journals and presented at conferences.

to beet terien only

# **AUTHORS' CONTRIBUTIONS**

JK developed the idea and conceptualized the study design and led the writing of the manuscript. SL contributed to conducting the study and writing the manuscript. BH contributed to study design and development and statistical analysis as well as reviewing and editing final versions of the manuscript.

## **FUNDING STATEMENT**

This study is supported by NIAAA grant number 5R01AA026288 (Kelly, John F), the Massachusetts General Hospital Recovery Research Institute, and NIAAA grant number K24AA022136 (Kelly, John F).

# **COMPETING INTERESTS STATEMENT**

None declared.

## REFERENCES

1. Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. *Cochrane Database Syst Rev.* 2020;3(3):Cd012880.

2. Kelly JF. Is Alcoholics Anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research. *Addiction*. 2017;112(6):929-36.

3. Kelly JF, Magill M, Stout RL. How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. *Addiction Research & Theory*. 2009;17(3):236-59.

4. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD. *J Subst Abuse Treat*. 2018;88:18-26.

5. Horvath AT, Yeterian JD. SMART Recovery: Self-empowering, science-based recovery support. *Journal of Groups in Addiction and Recovery*. 2013.

6. Roman PM, Johnson JA. National Treatment Center Study Summary Report: Private Treatment Centers. Athens, GA: Institute for Behavioral Research, University of Georgia; 2004.

7. Fenster J. Characteristics of clinicians likely to refer clients to 12-Step programs versus a diversity of post-treatment options. *Drug Alcohol Depend*. 2006;83(3):238-46.

8. Kelly JF, Stout R, Zywiak W, Schneider R. A 3-year study of addiction mutual-help group participation following intensive outpatient treatment. *Alcoholism: Clinical and Experimental Research* 2006;30(8):1381-92.

9. Emrick CD, Tonigan JS, Montgomery H, Little L. Alcoholics Anonymous: What is currently known? *Research on Alcoholics Anonymous: Opportunities and Alternatives* 1993:41-76.

10. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. *J Addict Dis*. 2009;28(2):145-57.

11. Kelly JF. Mutual-help for substance use disorders: History, effectiveness, knowledge gaps & research opportunities. *Clinical Psychology Review*. 2003;23(5):639-63.

12. Kelly JF, Yeterian JD. Empirical awakening: the new science on mutual help and implications for cost containment under health care reform. *Subst Abus*. 2012;33(2):85-91.

13. Beck AK, Forbes E, Baker AL, Kelly PJ, Deane FP, Shakeshaft A, et al. Systematic review of SMART Recovery: Outcomes, process variables, and implications for research. *Psychol Addict Behav.* 2017;31(1):1-20.

14. Atkins RG, Jr., Hawdon JE. Religiosity and participation in mutual-aid support groups for addiction. *J Subst Abuse Treat*. 2007;33(3):321-31.

15. Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: twelve-step and selfmanagement and recovery training. *The American journal of drug and alcohol abuse*. 2003;29(2):359-83.

16. MacGregor S, Herring R. The alcohol concern SMART Recovery pilot project final evaluation report. Middlesex University Drug and Alcohol Research Group; 2010.

17. Blatch C, O'Sullivan K, Delaney JJ, Doorn Gv, Sweller T. Evaluation of an Australian domestic abuse program for offending males. *Journal of Aggression, Conflict and Peace Research.* 2016;8(1):4-20.

18. Hester RK, Lenberg KL, Campbell W, Delaney HD. Overcoming Addictions, a Webbased application, and SMART Recovery, an online and in-person mutual help group for

#### **BMJ** Open

problem drinkers, part 1: three-month outcomes of a randomized controlled trial. *J Med Internet Res.* 2013;15(7):e134.

 Project MATCH Research Group. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. *J Stud Alcohol*. 1997;58(1):7-29.

20. Kelly JF, Stout RL, Magill M, Tonigan JS, Pagano ME. Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change. *Alcohol Clin Exp Res.* 2011;35(3):454-63.

21. Sobell ME. Asymptotic confidence intervals for indirect effects in structural equations models. In: Leinhart S, editor. Sociological Methodology. San Francisco, CA: Jossey-Bass; 1982. p. 290–312.

22. Sobell ME. Some new results on indirect effects and their standard errors in covariance structure models. In: Tuma N, editor. Sociological Methodology. Washington, DC: American Sociological Association; 1986. p. 159–86.

23. Hoeppner BB, Hoeppner SS, Kelly JF. Do young people benefit from AA as much, and in the same ways, as adult aged 30+? A moderated multiple mediation analysis. *Drug Alcohol Depend*. 2014;143:181-8.

24. Kelly JF, Hoeppner B, Stout RL, Pagano M. Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis. *Addiction*. 2012;107(2):289-99.

25. Kelly JF, Hoeppner BB. Does Alcoholics Anonymous work differently for men and women? A moderated multiple-mediation analysis in a large clinical sample. *Drug Alcohol Depend*. 2013;130(1-3):186-93.

26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995;57(1):289-300.

27. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychol Methods*. 2002;7(2):147-77.

## Table 1 (staff-administered measures)

Measure	Description
Substance Use History	Participants answered a series of questions about 15 substances/classes of substances (hereafter simply referred to as substances) from the Global Appraisal of Individual Needs (GAIN-I; (Dennis et al., 2002)): 1) Alcohol, 2) Marijuana, 3) Heroin, 4) Methadone, 5) Buprenorphine and its formulations (e.g., suboxone), 6) Other opioids (e.g., pharmaceutical opioids), 7) Cocaine, 8) Amphetamines (including MDMA), 9) Methamphetamine, 10) Benzodiazepines, 11) Barbiturates, 12) Hallucinogens, 13) Synthetic drugs (e.g., synthetic cannabinoid like "K2" and synthetic cathinones such as "bath salts"), 14) Inhalants, and 15) Steroids, as well as "Other" (specified by participant). At baseline, participants reported which of these substances they used 10 or more times in their life. Then for each substance endorsed, they provided information on the following from the Form-90 (Miller & Delboca, 1994): a) Age of first use; b) If they had ever used the substance regularly (i.e., at least once per week) (yes/no) and if so, the age of first regular use; c) Whether they had used the substance in the past three months (yes/no), and if so how many days out of the past 90 they used the substances in any capacity in the past 3 months, if they had used these substances in any capacity in the past 3 months, if they had used the substance. Participants then chose their primary substance ("drug of choice") and secondary substance for mole substances they had used (lifetime use for baseline assessment, past 3 month use for follow-ups). Finally, participants were asked for how many of the past 90 days their use of alcohol/drugs interfered with their functioning, and how many out of the past 90 days they got drunk at all or high for most of the day.
Alcohol Use Disorder DART	Participants were asked this validated semi-structured interview to capture AUD status (AUD severity and withdrawal symptoms). Participants were first asked if they had consumed alcohol in the past 3 months. If the participant answered 'yes', the DART would pertain to the past 3 months. If the participant answered 'no', they would be asked if they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered 'no', they would be asked if they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered 'no' to both the questions, they would only be asked if they experienced strong urges or cravings to drink.
Substance Use Disorder DART	Participants were asked about the recreational drugs/medications they used in the past 12 months. They then ranked the substances in the order that they caused problems for them. The DART was administered for the top 3 substances that caused the most problems for participants.
NIH PhenX Toolkit	Participants reported on lifetime use of cigarettes, e-cigarettes, or another tobacco/nicotine product (specified by participant). For those who smoked cigarettes, they reported on the following: 1) Age of first regular use; 2) Of how many of the past 30 days they smoked cigarettes 3) Average number of cigarettes smoked per day in the past 30 days 4) Whether or not they had ever made a serious attempt to quit smoking. This was asked pertaining to 'lifetime' for the baseline visit and for the past 90 days in the follow-up visits. If participants had made a serious quit attempt either in their life (baseline) or in the past 90 days (follow-up), they reported how old they were when they most recently quit smoking, the number of quit attempts in the past 90 days, the longest length of time they had quit smoking for, as well as on psychosocial smoking cessation resources. If not currently still smoking cessation resources used in their most recent quit attempt. Finally, regarding smoking cessation, all participants answered a single item with four multiple choice options to gauge attitudes toward inclusion of smoking cessation in AOD treatment (e.g., "Services that help people stop smokingshould be automatically included in addiction treatment.").

BMJ Open

	(National Cancer Institute, 2009; National Institutes of Health & U.S. Food and Drug Administration, 2013; Prorok et al., 2000).
Treatment for Injuries or Physical Health Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for health problems. At baseline, participants reported for both lifetime and past 3 months. At follow-up visits, participants were asked to report only on treatments in the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Treatment for Alcohol and Drug Use Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for alcohol or drug use problems. At baseline, participants reported for both lifetime and past 3 months. At follow-up visits, participants were asked to report only on treatments in the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Anti-craving and Anti- relapse Medications (Alcohol and Opioids)	At baseline, participants reported whether they had ever been prescribed a medication to prevent them from drinking alcohol or using opioids. At follow-up visits, participants were asked if they had been newly prescribed any medication to prevent them from drinking alcohol or using opioids in the past 3 months. If participants responded yes to either item, participants reported lifetime (baseline), past 3 months (follow-up) and current (baseline and follow-up) use of specific medications from the Form-90, including both generic and brand names (Miller & Delboca, 1994). Participants were also asked to rate what proportion of the time they used each medication as medically indicated.
Mental and Emotional Health: Diagnoses, Hospitalizations, Treatment History	Participants reported whether they had ever been told that they had a mental health condition by a doctor, nurse, or counselor, including agoraphobia, anorexia nervosa, bipolar disorder, bulimia nervosa, delusional disorder, dysthymic disorder, generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, personality disorder, post-traumatic stress disorder, schizoaffective disorder, schizophrenia, social anxiety disorder, specific phobia, substance use disorder, and other. For each diagnosis endorsed, participants indicated whether this had been a problem for them in the past 12 months. Participants reported treatment in an emergency room and admissions to a hospital for at least one night for mental, emotional, behavioral, or psychological problems. Participants reported for both lifetime and past 3 months. Participants also reported the number of times they had seen a mental health doctor in an office or outpatient clinic (including telehealth) in the past 3 months, on how many of the past 90 days they had been bothered by mental, emotional, behavioral, or psychological problems and on how many of the past 90 days these problems had kept them from meeting their responsibilities or made them feel like they could not go on (Dennis et al., 2002; Miller & Delboca, 1994).
Mental and Emotional Health: Psychiatric Medication Use	Participants were asked if they had ever been prescribed medication by a physician or medical practitioner to help them with a mental health condition (lifetime use). If they said yes, they were asked which medication they had ever been prescribed with the options antidepressants, anti-anxiety medication, anti-psychotics, mood stabilizers, stimulants, painkillers, medications for sleep and other (to be specified). Participants were then asked i they were still taking the medicines they indicated. If participants were still taking the medication as medically indicated. At follow-up visits, participants were asked if they were still using any medication to help with a mental health condition, and if yes, what type of medication. For each medication endorsed, participants reported what proportion of the time they used the medication as medically indicated (Dennis et al., 2002; Miller & Delboca, 1994).
Social Support Questionnaire (SSQ)	Participants were asked to list the initials of up to 5 family members, up to 5 friends, and up to 3 other important people in their life who they felt close to. For each person, they listed their initials, relationship, alcohol use pattern, drug use pattern, days per month they had

	contact with this person over the past 3 months (including contact via phone/text), how much they value their relationship on a scale of 1 ( <i>not at all</i> ) to 10 ( <i>a great deal</i> ) and how helpful they are in their recovery efforts on a scale of 1 ( <i>not at all helpful</i> ) to 10 ( <i>a great deal</i> ) (Zywiak et al., 2009).
12-step/MHO Attendance History	At baseline, participants were asked about lifetime attendance to help with their AOD problem at 12 different MHOs, with an "other" option specified by participant (Kelly et al., 2011): 1) Alcoholics Anonymous (AA); 2) Narcotics Anonymous (NA); 3) Marijuana Anonymous (MA); 4) Cocaine Anonymous (CA); 5) Crystal Methamphetamine Anonymous (CMA); 6) SMART Recovery; 7) LifeRing Secular Recovery; 8) Moderation Management; 9) Celebrate Recovery; 10) Women for Sobriety; and 11) Secular Organization for Sobriety (S.O.S.).; 12) Dual Diagnosis Anonymous (DDA); and 13) Other. Other options were examined for possible inclusion in existing categories, and recategorized as appropriate. At follow-ups, participants reported attendance for the past 3-months. For each MHO attended, participants reported a) Whether they attended regularly (at least once per week), b) Number of meetings in the past 3 months, and c) Whether they had ever attended a meeting online.
Online Resources and Social Network Sites	For each MHO that a participant had attended online (as noted in "12-step/MHO Attendance History"), participants reported how many meetings they had attended online in the past 3 months, how they accessed these meetings (video, audio only, telephone, etc.), and how helpful they felt the online meetings were on a scale of 1 to 10. Participants also reported whether they used any online or mobile technologies to support their AOD problem resolution or recovery in their lifetime (baseline) and in the past 3 months. Potential online and mobile technologies included recovery-focused social network sites (e.g., InTheRooms.com), general social network sites (e.g., Facebook), and mobile smartphone applications. For each online or mobile technology endorsed, participants indicated how many of the past 90 days they had used the technology for recovery and how helpful they found it on a scale of 1 to 10. Participants were also given the opportunity to provide any other information or comments on their use of online or mobile recovery resources.
SMART Involvement	Questions about SMART involvement were asked for participants who had attended SMART Recovery. Participants were asked how long they have been attending SMART Recovery, how they heard about SMART Recovery, whether they consider themselves to be a current member of SMART Recovery ( <i>yes/no</i> ), how many times they have attended SMART recovery in their lifetime ( <i>numerical value</i> ) and if another member of SMART Recovery served as a personal mentor or guide to them in the past 3 months ( <i>yes/no</i> ). The participants were asked questions about their participation in SMART meetings in the past 3 months to gauge the frequency of the use of SMART meetings, tools, website, and web- application 'Overcoming Addictions.' Participants were also asked four questions about their level of engagement in SMART meetings.
Recovery/Abstinence time	Participants were asked to report in years and months how long they had been either 1) Sober (not using any alcohol/drugs) or 2) Drinking/using drugs without problems.
Multidimensional Mutual-Help Activity Scale (MM-HAS)	Questions from the MM-HAS were asked for participants who had attended meetings of any of the following MHOs: Alcoholics Anonymous, Narcotics Anonymous, Marijuana Anonymous, Cocaine Anonymous, Crystal Methamphetamine Anonymous, and Dual Diagnosis Anonymous. For each organization, participants were asked if they currently considered themselves to be a part of the MHO, their activities as part of the MHO in the past 3 months (sponsor, contact with sponsor outside a meeting, contact with other members outside a meeting, read 12 step literature outside of a meeting, shared or talked during meetings, helped with setting up/running a meeting), and the number of steps out of the 12 step program that they completed while participating in the MHO in the past 3 months. Participants were then asked to rate the helpfulness, enjoyability, and safety of the

	MHO from a scale of 1 ( <i>not at all helpful, do not enjoy at all,</i> or <i>not at all safe</i> ) to 10 ( <i>extremely helpful, enjoy a great deal,</i> or <i>completely safe</i> ) (Kelly et al., 2013; Kelly et al. 2011).
Recovery support services and formal treatment programs (RSSTX)	The questionnaire assessed history of participation in nine psychosocial treatment and recovery support services: 1) Sober living environment; 2) Recovery high school; 3) College recovery program/community 4) Recovery community center (RCC); 5) Faithbased recovery services (e.g., a recovery group provided by a church, synagogue, mosquetc.); 6) State or local recovery community organization (RCO); 7) Outpatient addiction treatment; 8) Alcohol/drug detoxification services; 9) Inpatient or residential treatment. they responded yes to any treatment service (7, 8 or 9), they reported the number of time they used the service (i.e., number of treatment episodes) in their lifetime (baseline) and past 3 months (baseline and follow-up). (Dennis et al., 2002; Miller & Delboca, 1994).
Year End Summary (YES)	At baseline, 12-month follow-up, and 24-month follow up, participants were asked if th felt like they were better off now than they were 12 months ago in terms of their alcohol and drug problems (worse off, same, better off). Participants were then asked to elabora on the reason for that answer. Participants were asked if their substance use had changed stayed the same in the past 12 months (changed for the better, changed for the worse, stathe same). If participants reported 'stayed the same', they were asked what factors they thought were most responsible for their substance use staying the same.
Timeline Follow Back (TLFB)	Participants provided specific dates for alcohol use, substance use, MHO attendance, inpatient and outpatient addiction treatment, inpatient and outpatient mental health treatment, and incarceration for the past 3 months (baseline, 3-, 6-, 9-, and 12-month follow-ups) or 6 months (18- and 24-month follow-ups) (Miller & Delboca, 1994). For alcohol use, participants were asked to report the number of standard drinks consumed or each drinking day. For MHO attendance and outpatient treatment for addiction and men health, participants were asked to report whether services were in-person or online. Dur in-person study visits, a printed calendar was used to facilitate the TLFB. For remote vis study staff prompted participants with potentially memorable dates within the timeframe (e.g., holidays).
Go/No-Go Cognitive Measure*	The Inquisit Go/No-Go Cognitive Measure is a computerized task used to assess impulsivity. The Inquisit script implemented the Go/No-Go Task as described in Fillmor al. (2006). Participants were asked to press the spacebar when they see a green rectangle (go) but refrain from pressing the spacebar when they see a blue rectangle $(no-go)$ . The b and green rectangles could be vertical or horizontal. The vertical rectangle had a high probability (4:1) of being green $(go)$ and the horizontal rectangle had a high probability ( of being blue $(no-go)$ . Participants were given information about the orientation of the rectangle shortly before the color of the rectangle was revealed. Participant response time and error rates were recorded. For remote visits, a web-based version of the Go/No-Go T was tested, but due to the effect of internet speed on results, this measure was not include
Breathalyzer*	Breathalyzer tests were used to establish a baseline level of substance use for participant the first assessment and to ensure that data was not collected from participants who were impaired due to alcohol use. Breathalyzer tests were performed at baseline and all follow time points prior to starting each assessment. If a participant's BAC was above .02, stud staff did not conduct the study visit; instead, study staff either waited with the participant until their BAC dropped to .02 or lower or attempted to re-schedule the participant's vis a participant's BAC was above the legal limit (.08), and the participant had driven to the assessment, study staff asked to hold the participant's car keys while waiting for their B to drop below the legal limit. If the participant insisted on holding their car keys and/or driving, or if the participant did not stay with study staff until their BAC dropped below study staff called security as a safety precaution. Study staff also offered to arrange and for a cab to transport the participant home. If a participant had driven to the appointmen

For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

Urine Drug Screen*Urine drug screens were used to estate self-reported estimates of alcohol and unable to perform urine drug screensSaliva TestSelf-administered saliva tests were in biochemical verification during remore assessment to confirm willingness to would be mailed to, and whether the During the assessment, participants complete staff guidance. If participants complete of the test to REDCap. If the participant complete of the test to REDCap or, if unable to perform the staff guidance.	
Saliva Test Self-administered saliva tests were in biochemical verification during remo assessment to confirm willingness to would be mailed to, and whether the During the assessment, participants v staff guidance. If participants complet test results to the research coordinate REDCap. If the participant complete of the test to REDCap or, if unable to	sh baseline substance use at baseline and to verify ther drug use. For remote visits, study staff were
inconsistencies in saliva test results ( test use was discontinued in May 202	lemented in March 2021 as an alternative method of visits. Participants were contacted prior to their articipate in the saliva test, what address the test sit would be conducted over Zoom or on the phone. re able to self-administer the saliva test with study d the assessment over Zoom, participants showed the who screenshotted the test and uploaded it to he assessment over the phone, they uploaded images pload images, self-reported the results. Due to results, partial results, and false negatives), saliva

## Table 2 (self-administered measures)

Measure	Description
Demographics Background	Participants reported the following: gender, race, ethnicity (whether participants were Hispanic/Latino), where they were living for the majority of the past 3 months (with fam or other relatives, with group of friend(s) or non-family members, alone in own dwelling homeless, hospital rehabilitation facility or nursing home, jail, prison or other corrections facility, other), current marital status (single, married, living with someone as if married, relationship, engaged to be married, legally separated, divorced, widowed), sexual orientation, left or right handed, highest level of schooling completed, highest level of schooling completed by either parent, whether they held a job in the past 3 months, (if ye nature of employment (odd jobs, part time, full time), (if no) reason for unemployment, major source of financial support, total annual household income, type of health insurance and financial well-being of their family. Numerical values were collected for the followin in the past 3 months: unplanned absences from work/school, times disciplined on the job school, times your job/school has been in jeopardy, times you were suspended or fired fr work/school (Dennis et al., 2002; Miller & Delboca, 1994).
school, times your job/school has been in jeopard work/school (Dennis et al., 2002; Miller & DelboCriminal Justice InvolvementThe questionnaire used adapted items about crime (Miller & Delboca, 1994). Participants reported of probation only, on parole only, on probation and outstanding warrant, case pending, other). At base had ever been arrested (yes/no). If yes, they report times for DUI/DWI in their lifetime, and how may At follow-up visits, participants reported whether months (yes/no). If yes, they reported how many DUI/DWI in the past 3 months, and how many ti n At baseline, participants reported how many ti in the past 3 months. At follow-up visits, particip the past 3 months.	<ul> <li>work/school (Dennis et al., 2002; Miller &amp; Delboca, 1994).</li> <li>The questionnaire used adapted items about criminal justice involvement from the Form (Miller &amp; Delboca, 1994). Participants reported on their current legal status (none, on probation only, on parole only, on probation and parole, awaiting charge, trial or sentence outstanding warrant, case pending, other). At baseline, participants reported whether the had ever been arrested (yes/no). If yes, they reported how many times overall, how many times for DUI/DWI in their lifetime, and how many times for other reasons in their lifeti At follow-up visits, participants reported how many times overall, how many times for DUI/DWI in the past 3 months (yes/no). If yes, they reported how many times for other reasons in the past 3 month at baseline, participants reported whether they had ever stayed in jail or prison overnigh longer (yes/no). If yes, they reported how many times in their lifetime and how many times the past 3 months. At follow-up visits, participants only reported the number of times the past 3 months.</li> </ul>

Religious Background and Behaviors (RBBS)	At baseline, the questionnaire assessed if the participant considered themselves to be par a religious group (No/none, Baptist, Buddhist, Catholic, Evangelical, Hindu, Jewish, Lutheran, Methodist, Mormon, Muslim, Presbyterian, Other Protestant, Shinto, Native American Church, Traditional Native American, Christian, Some other group). For all timepoints participants were asked which of the following describes them at this time: atheist, agnostic, unsure, spiritual, religious. Participants were asked how often they participated in religious activities in the past 3 months on a 7-point Likert scale ( <i>never</i> , <i>rarely, once a month, twice a month, once a week, twice a week, almost daily, more than</i> <i>once a day</i> ) and, at baseline, how often they participated in certain religious activities in their lifetime on a 3 point-Likert scale ( <i>never, yes, in the past but not now, yes, and I stil</i> (Connors et al., 1996).
Religious and Spiritual Intensity	The questionnaire included four items assessing participants' religiosity and spirituality. Participants reported the extent to which they considered themselves religious/spiritual of Likert scale from <i>not religious/spiritual at all</i> (1) to <i>very religious/spiritual</i> (4). Participareported the extent to which their religious/spiritual practices and beliefs help them with resolving an alcohol/drug problem on a scale from <i>do not help at all</i> (1) to <i>make all the difference</i> (5) (Idler et al., 2003).
Twelve Promises Scale (TPS)	This questionnaire assessed participants' current psychosocial state and attitudes toward drinking and using drugs. Participants rated how true each item was for them at the curre time on a scale of <i>never true</i> (1) to <i>true most of the time</i> (5) (Kelly & Greene, 2013).
Perceived Stress Scale (PSS-4)	This questionnaire assessed participants' level of stress over the last month. Participants rated each item on a scale from <i>never</i> (1) to <i>very often</i> (5) (Warttig et al., 2013).
Kessler 6 (K6)	This six-item scale assessed psychiatric symptoms (also referred to as psychological distress). On a scale from <i>all of the time</i> (1) to <i>none of the time</i> (5), participants are asked how often they felt: nervous, hopeless, restless or fidgety, so depressed that nothing could cheer you up, that everything was an effort, and worthless (Kessler et al., 2003).
Coping Strategies Scale (CSS)	Participants were asked to select how often they used a variety of coping strategies or thoughts in the past 3 months to help them not use alcohol or drugs. Participants rated ea item on a scale from <i>never</i> (1) to <i>frequently</i> (4) (Litt et al., 2003; Prochaska et al., 1988).
Alcohol and Drug Abstinence Self Efficacy (A-DSES-20)	Participants were asked about their feelings of confidence to not drink or use drugs in various situations in the past week. Participants rated their level of confidence for each scenario on a scale of <i>not at all confident</i> (1) to <i>extremely</i> (5) (Diclemente et al., 1994).
Penn Alcohol and Drug Craving (PADCS-5)	This questionnaire assessed the frequency and strength of cravings to use alcohol and oth drugs during the past week. Participants reported how often they thought about drinking/using drugs, how strong the craving was at its most severe, how much time they have spent thinking about drinking/using drugs, how difficult it would have been to resist drinking/using drugs, and then rated their overall alcohol/drug craving with options rang from <i>never thought about drinking/using drugs nearly all of the time and had the urge to drink/use drugs nearly all of the time</i> (Flannery et al., 1999).
Commitment to Sobriety Scale (CSS-5)	In this questionnaire, participants were asked 5 questions about their commitment to not using alcohol/drugs. Participants rated the extent to which they agreed with these statem on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6) (Kelly & Greene, 2014).
Drinking Goal	In this questionnaire, participants chose one goal that was the most true to them currentl from the 5 options: 1) Total abstinence; never use again; 2) Total abstinence; but realize slip is possible; 3) Occasional use when urges strongly felt; 4) Temporary abstinence; or Controlled use.

Short Inventory of Problems (SIP-2R)	This questionnaire assessed how often participants had experienced various problems during the past 3 months because of their drinking/drug. Participants indicated how often they had experienced each problem on a scale of <i>never</i> to <i>daily or almost daily</i> . Participants were also asked to indicate whether they had had an accident while drinking or intoxicated in the past 3 months (Miller et al., 1995).
Questions about Recovery	This questionnaire assessed recovery identity, definition, and what participants believe are the factors helping them resolve their problem with alcohol/drugs at baseline, 12-month follow-up, and 24-month follow-up. Participants selected a statement that best applied to them from whether they consider themselves to be <i>in recovery</i> , <i>seeking recovery</i> or <i>not in or seeking recovery</i> . If participants chose that they were 'in recovery', they were asked to provide the date they use to mark the beginning of their recovery. Participants were asked to provide their definition of recovery in one sentence (free response) and to select one of three statements that best fit their definition of recovery: 1) Abstinence from all drugs/alcohol; 2) Abstinence from only those drugs/alcohol with which they had a problem; or 3) Non-problematic/moderate use of drugs/alcohol, including those with which they had a problem. Participants were then asked to list the top 3 things that have helped or are helping them to resolve their problem with alcohol/drugs.
Brief Assessment of Recovery Capital (BARC-10)	The BARC-10 (Vilsaint et al., 2017) is a 10-item, abridged version of the Addiction Recovery Capital Scale (Groshkova et al., 2013). The BARC-10 measures personal (e.g., "I take full responsibility for my actions"), social (e.g., "I get lots of support from friends"), physical (e.g., "I have enough energy to complete the tasks I set for myself"), and environmental resources (e.g., "My living space has helped to drive my recovery journey") used to initiate and sustain recovery. Participants rated their agreement with each statement on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6).
Behavioral Addictions	The questionnaire used items adapted from Laudet et al. (2015) to assess whether individuals ever had a problem with one or more other behaviors apart from AOD use in their lifetime (baseline) and currently, including 1) Eating disorder; 2) Sex/love addiction; 3 Gambling; 4) Video gaming addiction; 5) Compulsive shopping; 6) Internet addiction (for issues not assessed by other choices); 7) Compulsive exercise; 8) Internet pornography addiction; 9) Self-harm/injury and 10) Other (specified). "Other" options were examined for possible inclusion in existing categories, and recategorized as appropriate. Participants were asked if any reported behavioral addictions had been a problem for them in the past 3 month and if so, how many days out of 90. If reporting more than one, participants indicated which behavior had been the most problematic.
Medical Marijuana Use	Participants were asked if they had ever been recommended to use marijuana for medical reasons. If yes was indicated, participants were asked how many days out of the past 90 marijuana was used for medical reasons and to list up to three medical reasons for using marijuana.
Medication Attitudes	This questionnaire assessed participant attitudes toward medication for an alcohol problem, opioid problem, any kind of alcohol/drug problem, and emotional problem. Participants rated their agreement with the use of medication for these problems on a scale of <i>strongly disagree</i> (1) to <i>strongly agree</i> (6).
Impulsive behavior (SUPPS-S)	This questionnaire assessed impulsivity. Participants rated their agreement with 20 items describing situations or feelings related to impulsivity on a scale of <i>agree strongly</i> (1) to <i>disagree strongly</i> (4) (Coskunpinar et al., 2013).
	This measure of quality of life was used to assess satisfaction related to physical health

Quality of Life (EQ5D3L)	This measure of quality of life was used to assess physical and mental health states. Participants rated their current mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Participants also rated their current overall physical and mental health states using a visual analogue scale with options between 0 ( <i>worst</i> ) and 100 ( <i>best</i> ) (Devlin & Brooks, 2017).
Quality of Life (EUROHIS-QOL)	This measure of quality of life is a widely used eight-item measure of quality of life, adapted from the World Health Organization Quality of Life – Brief Version (WHOQOL-BREF) (Schmidt et al., 2006). Participants rated each item on a 5-point Likert scale from 1 ( <i>very poor, very dissatisfied,</i> or <i>not at all</i> ) to 5 ( <i>very good, very satisfied,</i> or <i>completely</i> ) (da Rocha et al., 2012).
Pittsburgh Sleep Quality Index (PSQI)	This questionnaire assessed quality of sleep. Participants reported how many hours of sleep they got on average per night over the past month. Participants then rated their quality of sleep on a scale from <i>very good</i> (1) to <i>very bad</i> (4) (Buysse et al., 1989).
Pain Visual Analogue Scale (VAS)	This measure assessed physical pain. Participants rated the current severity of their pain using a visual analogue scale with options between 0 ( <i>no pain</i> ) to 100 ( <i>very severe pain</i> ) (Wewers & Lowe, 1990).
International Physical Activity Questionnaire (IPAQ)	This questionnaire asks participants about their level of physical activity over the past seven days. Participants indicate how many days in the past 7 days they have done: vigorous physical activity, moderate physical activity, and walking. Participants then indicate how much time per day they usually spent on each activity in hours and minutes. Participants are also asked how many hours they usually spent sitting on weekdays over the past 7 days (Hagstromer et al., 2006).
Meals	Participants reported how many meals on average they have eaten per day during the past 3 months.
Self-esteem, Happiness, and Satisfaction with Life	Three single-item measures were used to assess self-esteem (Robins et al., 2001), happiness, and satisfaction with life (Diener et al., 1985). For self-esteem, participants indicated their agreement with the statement "I have high self-esteem" on a scale from 1 ( <i>not very true of</i> me) to 10 ( <i>very true of</i> me). For happiness, participants rated how happy they were with their life in general on a scale of 1 ( <i>completely unhappy</i> ) to 10 ( <i>completely happy</i> ). For satisfaction with life, participants indicated their agreement with the statement "I am satisfied with my life" on a scale of <i>strongly disagree</i> (1) to <i>strongly agree</i> (7).
Abstinence Self- Efficacy Single Item	Participants rated how confident they were that they could remain abstinent or drink/use drugs without problem in the next 3 months on a scale from <i>not at all confident</i> (1) to <i>very confident</i> (10).
Daily Spiritual Experiences Scale (DSES)	This questionnaire assesses spiritual and/or religious experiences. The questionnaire includes items with the word "God" used but includes instructions for participants that if "God" is not a comfortable word that they should substitute it for one that calls to mind the divine and holy for them. Participants read 15 items describing spiritual and/or religious experiences that a person may have and rate how often they have this experience from <i>many times a day</i> (1) to <i>never or almost never</i> (6). The last item asks participants how close they feel to God from <i>not close</i> (1) to <i>as close as possible</i> (4) (Underwood & Teresi, 2002)

## References

1 2

3

4

5 6

7

8

9

10

11

12

13 14

15

16

- Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res, 28(2), 193-213. https://doi.org/10.1016/0165-1781(89)90047-4
- Connors, G. J., Tonigan, J. S., & Miller, W. R. (1996). A Measure of Religious Background and Behavior for Use in Behavior Change Research. Psychology of Addictive Behaviors, 10(2), 90-96.
- Coskunpinar, A., Dir, A. L., & Cyders, M. A. (2013). Multidimensionality in impulsivity and alcohol use: a meta-analysis using the UPPS model of impulsivity. Alcohol Clin Exp Res, 37(9), 1441-1450. https://doi.org/10.1111/acer.12131
- da Rocha, N. S., Power, M. J., Bushnell, D. M., & Fleck, M. P. (2012). The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health, 15(3), 449-457. https://doi.org/10.1016/j.jval.2011.11.035
- Dennis, M. L., Titus, J., White, M., Unsicker, J., & Hodkgins, D. (2002). Global Appraisal of Individual Needs (GAIN): Administration Guide for the GAIN and Related Measures. In. Bloomington, IL: Chestnut Health Systems.
- 18 Devlin, N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future [Review]. Applied 19 Health Economics and Health Policy, 15(2), 127-137. https://doi.org/10.1007/s40258-017-0310-5 20
- Diclemente, C. C., Carbonari, J. P., Montgomery, R. P. G., & Hughes, S. O. (1994). The Alcohol Abstinence 21 22 Self-Efficacy Scale [Article]. Journal of Studies on Alcohol, 55(2), 141-148. 23 https://doi.org/10.15288/jsa.1994.55.141 24
- Diener, E., Emmons, R. A., Larsen, R. J., & Griffin, S. (1985). The Satisfaction With Life Scale [Article]. 25 Journal of Personality Assessment, 49(1), 71-75. https://doi.org/10.1207/s15327752jpa4901\_13
- 26 Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction 27 Questionnaire - A New Measure [Article]. *Psychopharmacology Bulletin*, 29(2), 321-326. < Go to 28 29 ISI>://WOS:A1993MC72000028
- 30 Fillmore, M. T., Rush, C. R., & Hays, L. (2006). Acute effects of cocaine in two models of inhibitory control: 31 implications of non-linear dose effects [Article]. Addiction, 101(9), 1323-1332. 32 https://doi.org/10.1111/j.1360-0443.2006.01522.x 33
- Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999). Psychometric properties of the Penn Alcohol 34 Craving Scale [Article]. Alcoholism-Clinical and Experimental Research, 23(8), 1289-1295. 35 https://doi.org/10.1111/j.1530-0277.1999.tb04349.x 36
- 37 Groshkova, T., Best, D., & White, W. (2013). The Assessment of Recovery Capital: Properties and 38 psychometrics of a measure of addiction recovery strengths [Article]. Drug and Alcohol Review, 32(2), 39 187-194. https://doi.org/10.1111/j.1465-3362.2012.00489.x 40
- Hagstromer, M., Oja, P., & Sjostrom, M. (2006). The International Physical Activity Questionnaire (IPAQ): a 41 study of concurrent and construct validity [Article]. Public Health Nutrition, 9(6), 755-762. 42 https://doi.org/10.1079/phn2005898 43
- Idler, E. L., Musick, M. A., Ellison, C. G., George, L. K., Krause, N., Ory, M. G., Pargament, K. I., Powell, L. 44 45 H., Underwood, L. G., & Williams, D. R. (2003). Measuring multiple dimensions of religion and 46 spirituality or health research - Conceptual background and findings from the 1998 General Social 47 Survey [Article; Proceedings Paper]. Research on Aging, 25(4), 327-365. 48 https://doi.org/10.1177/0164027503025004001 49
- Kelly, J. F., & Greene, M. C. (2013). The Twelve Promises of Alcoholics Anonymous: Psychometric measure 50 validation and mediational testing as a 12-step specific mechanism of behavior change [Article]. Drug 51 52 and Alcohol Dependence, 133(2), 633-640. https://doi.org/10.1016/j.drugalcdep.2013.08.006
- 53 Kelly, J. F., & Greene, M. C. (2014). Beyond motivation: Initial validation of the commitment to sobriety scale 54 [Article]. Journal of Substance Abuse Treatment, 46(2), 257-263. 55 https://doi.org/10.1016/j.jsat.2013.06.010 56
- Kelly, J. F., Stout, R. L., & Slaymaker, V. (2013). Emerging adults' treatment outcomes in relation to 12-step 57 mutual-help attendance and active involvement [Article]. Drug and Alcohol Dependence, 129(1-2), 151-58 157. <u>https://doi.org/10.1016/j.drugalcdep.2012.10.005</u> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 59 60

Page 25 of 48

12

## BMJ Open

<ul> <li>Kelly, J. F., Urbanoski, K. A., Hoeppner, B. B., &amp; Slaymaker, V. (2011). Facilitating comprehensive assessment of 12-step experiences: A Multidimensional Measure of Mutual-Help Activity. <i>Alcoholism Treatment Quarterly</i>, <i>29</i>(3), 181-203. «Go to ISI&gt;://MEDLINE:22081741</li> <li>Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gforerr, J. C., Hiripi, E., Howes, M. J., Normand, S. L. T., Manderscheid, R. W., Walters, F. E., &amp; Zaslavsky, A. M. (2003). Screening for serious mental illness: in the general population [<i>Article]</i>. <i>Archives of General Psychiatry</i>, <i>60</i>(2), 184-189. https://doi.org/10.1001/archpsyc.60.2.184</li> <li>Laudet, A. B., Harris, K., Kimball, T., Winters, K. C., &amp; Moberg, D. P. (2015). Characteristics of Students Participating in Collegiate Recovery Programs: A National Survey [Article]. Journal of Substance Abuse Treatment, <i>51</i>, 38-46. https://doi.org/10.1037/002-006x.71.1.118</li> <li>Miller, W. R., &amp; Delboca, F. K. (1994). Measurement of Drinking Behavior Using the Form-90 Family of Instruments [Article]. Journal of Studies on Alcohol, 112-118. https://doi.org/10.1058/siles.109412.112</li> <li>Miller, W. R., Tonigan, J. S., &amp; Longabaugh, R. (1995). The Drinker Inventory of Consequences (DrInC): An instrument for assessing adverse consequences of alcohol abuse. Test manual. In M. E. Mattson &amp; L. A. Marshall (Eds.), <i>Project MATCH Monograph Series</i> (Vol. 4). National Institute on Alcohol Abuse and Alcoholism.</li> <li>National Institutes of Health, &amp; U.S. Food and Drug Administration. (2013). Population Assessment of Tobacco and Health (PATH) Study: Final Adult Baseline (Wave 1) Questionnaire. In Bethesda, MD: National Institutes of Health, &amp; U.S. Food and Drug Administration. (2013). Population Assessment of Tobacco and Health (PATH) Study: Final Adult Baseline (Wave 1) Questionnaire. In Sethesda, MD: National Institutes of Health, &amp; U.S. Food and Drug Administration. (2013). Population Assessment of Tobacco and Health (PATH) Study: Final Adult Baseline (Wave 1) Questio</li></ul>	BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliogra Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.
<ul> <li>Vilsaint, C. L., Kelly, J. F., Bergman, B. G., Groshkova, T., Best, D., &amp; White, W. (2017). Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder [Article]. <i>Drug and Alcohol Dependence</i>, <i>177</i>, 71-76. <u>https://doi.org/10.1016/j.drugalcdep.2017.03.022</u></li> <li>Warttig, S. L., Forshaw, M. J., South, J., &amp; White, A. K. (2013). New, normative, English-sample data for the Short Form Perceived Stress Scale (PSS-4) [Article]. <i>Journal of Health Psychology</i>, <i>18</i>(12), 1617-1628. <u>https://doi.org/10.1177/1359105313508346</u></li> <li>Wewers, M. E., &amp; Lowe, N. K. (1990). A Critical Review of Visual Analog Scales in the Measurement of Clinical Phenomena [Review]. <i>Research in Nursing &amp; Health</i>, <i>13</i>(4), 227-236. <u>https://doi.org/10.1002/nur.4770130405</u> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml</li> </ul>	at Agence Bibliographique de

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4 5 6 7	Zywiak, W. H., Neighbors, C. J., Martin, R. A., Johnson, J. E., Eaton, C. A., & Rohsenow, D. J. (2009). The Important People Drug and Alcohol interview: Psychometric properties, predictive validity, and implications for treatment [Article]. <i>Journal of Substance Abuse Treatment</i> , 36(3), 321-330. <u>https://doi.org/10.1016/j.jsat.2008.08.001</u>
8 9 10 11 12 13 14	
15 16 17 18 19 20 21	
22 23 24 25 26 27 28	
29 30 31 32 33 34 35	
36 37 38 39 40 41 42	
43 44 45 46 47 48 49	
50 51 52 53 54 55 56	
57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

Protocol Title: Pathways to Change

Principal Investigator: John F. Kelly, Ph.D.

Site Principal Investigator:

Description of Subject Population: Adults with an alcohol use disorder making a new recovery attempt.

## About this consent form

Please read this form carefully. It tells you important information about a research study. A member of our research team will also talk to you about taking part in this research study. People who agree to take part in research studies are called "subjects." This term will be used throughout this consent form.

Partners HealthCare System is made up of Partners hospitals, health care providers, and researchers. In the rest of this consent form, we refer to the Partners system simply as "Partners."

If you decide to take part in this research study, you must sign this form to show that you want to take part. We will give you a signed copy of this form to keep.

# **Key Information**

Taking part in this research study is up to you. You can decide not to take part. If you decide to take part now, you can change your mind and drop out later. Your decision won't change the medical care you get within Partners now or in the future.

The following key information is to help you decide whether or not to take part in this research study. We have included more details about the research in the Detailed Information section that follows the key information.

Subject Identification

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Partners HealthCare System Research Consent Form	
Certificate of Confidentiality Template Version Date: January 2019	Subject Identification

## Why is this research study being done?

This research is being done to obtain greater knowledge about the pathways followed in new recovery attempts for individuals with an alcohol use disorder (AUD). We are asking you to take part in this research study because you identified yourself as someone with an AUD and is making a new attempt to change your alcohol use. About 348 people will take part in this research study. We expect to enroll all subjects within the greater Boston, Massachusetts area.

# How long will you take part in this research study?

If you enroll today, it will take you a total of 24 months (two years) to complete this research study. During this time, you will complete a baseline assessment, along with follow-up surveys every 3-, 6-, 9-, 12-, 18-, and 24-months.

# What will happen if you take part in this research study?

If you choose to enroll, you will be required to come to our downtown Boston office at the MGH Center for Addiction Medicine (within 3-minute walking distance of two major subway stops) to complete your assessments. You will complete your questionnaires via the Harvard Catalyst's Electronic Data Capture (REDCap; project-redcap.org) and with a research coordinator. You will be asked about basic demographic questions, substance use history, mutual-help organization attendance, psychiatric symptoms, psychosocial functioning, treatment service utilization, quality of life, and recovery motivation/support.

If you are a participant from the San Diego area, all of your study visits will take place remotely. The questionnaires will be asked over Zoom, Skype, or phone call and through an online link that is sent to your personal device.

As a supplement to this research study, we are conducting an optional qualitative interview for a portion of study participants. The aim of this qualitative interview is to investigate the motivations, expectations, and experiences of individuals who do and do not participate in Mutual Help Organizations (MHOs) such as Alcoholics Anonymous and SMART Recovery. Additionally, we hope to assess how helpful individuals believe MHOs are in their recovery attempt and how MHOs and other recovery resources might be improved and adapted to better fit the needs of individuals currently seeking recovery from an Alcohol Use Disorder.

MHO attendance is not required to participate in this qualitative interview. We plan to include individuals following a variety of recovery pathways.

Page 18 of 23

Partners HealthCare System
<b>Research Consent Form</b>

Certificate of Confidentiality Template Version Date: January 2019 Subject Identification

Study staff will reach out directly to a pre-determined number of interested individuals via email or phone call to offer them the opportunity to participate in this qualitative interview and schedule an interview time. The interview will be approximately 30-60 minutes in length and will be conducted via Zoom or over the phone and will be recorded. This is done purely for data summarization purposes and once the data are transcribed, the recordings will be deleted. Participants will be compensated an additional \$50 following completion of the interview.

You are not required to participate in the optional qualitative interview in order to participate in the Pathways to Change Study. You can still take part in the original research study whether or not you choose to participate in this additional qualitative interview. Signing this form does not guarantee that you will be able to participate in the qualitative interview.

Do you consent to participate in the qualitative interview if selected?

[]YES []NO Initial\_\_\_\_

You will receive text/email reminders about upcoming appointments through REDCap's automated email feature and integrated Twilio SMS and voice call services. Both REDCap and Twilio are secure services for these appointment reminders.

Text messages by mobile/cell phones are a common form of communication. The Recovery Health research study involves sending you text messages that are relevant to the research study. Texting over mobile/cell phones carries security risks because text messages to mobile/cell phones are not encrypted. This means that information you send or receive by text message could be intercepted or viewed by an unintended recipient, or by your mobile/cell phone provider or carrier.

Below are some important points about texting in this research study.

- Text messages are not encrypted, and therefore carry security risks. This research study and Partners Healthcare are not responsible for any interception of messages sent through unencrypted text message communications.
- You will be responsible for all fees charged by your carrier's service plan for text messaging. This research study and Partners Healthcare are not responsible for any increased charges, data usage against plan limits or changes to data fees from the research texts.
- Text messaging should not be used in case of an emergency. If you experience a medical emergency, call 911 or go to the nearest hospital emergency department.

Page 18 of 23

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

- Subject Identification
- You may decide to not receive text messages with staff associated with this research study at any time. You can do this in person at your upcoming visit, by calling 617-643-5927, or by emailing recoveryhealth@mgh.harvard.edu.
- Your agreement applies to this research study only. Agreeing to other texts from Partners Healthcare, for example appointment reminders, is a separate process. Opting out of other texts from Partners Healthcare is a separate process as well.
- It is your responsibility to update your mobile/cell phone number with this research study in the event of a change.

I have had the chance to ask questions about texting with staff associated with this research study. I have been informed of the risks and other information covered above and consent to the use of unencrypted text communications associated with this research study.

# What are the risks and possible discomforts from being in this research study?

The risk of participating in this study is expected to be very small because your privacy is protected by law. We may report medical information if you need medical help, if we feel you might be in danger of harming yourself or others, or if there is any suspicion of child abuse or elder abuse.

It is possible that you may experience some discomfort during scheduled assessments from the questionnaires, as they ask for some sensitive personal information. However, you are free not to participate in any aspect of the study that makes you uncomfortable.

# What are the possible benefits from being in this research study?

You will gain no direct benefit from participation in this study. However, this study has the potential to contribute valuable information about recovery pathways for individuals with alcohol use disorder, and may provide additional support for mutual-help organizations.

# What other treatments or procedures are available for your condition?

Page 18 of 23

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

This study does not provide any treatment to you. Rather, we will ask you about your experiences with various treatments that you have been receiving or have received. You do not have to take part in this study to be able to obtain mental health services.

Subject Identification

# If you have questions or concerns about this research study, whom can you call?

You can call us with your questions or concerns. Our telephone numbers are listed below. Ask questions as often as you want.

**Dr. John F. Kelly, Ph.D.,** is the person in charge of this research study. You can call him at 617-643-1980, Monday-Friday, 9am-5pm. You may leave a message at this number and he will return your call. You can also call research staff at 617-643-9850, Monday-Friday 9am-5pm with questions about this research study. If you have questions about the scheduling of appointments or study visits, call research staff at 617-643-9850.

If you want to speak with someone **not** directly involved in this research study, please contact the Partners Human Research Committee office. You can call them at 857-282-1900.

You can talk to them about:

- Your rights as a research subject
- Your concerns about the research
- A complaint about the research
- Any pressure to take part in, or to continue in the research study

Page 18 of 23

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

## **Detailed Information**

# How may we use and share your samples and health information for other research?

The samples and information we collect in this study may help advance other research. If you join this study, we may remove all information that identifies you (for example your name, medical record number, and date of birth) and use these de-identified samples and data in other research. It won't be possible to link the information or samples back to you. Information and/or samples may be shared with investigators at our hospitals, at other academic institutions or at for-profit, commercial entities. You will not be asked to provide additional informed consent for these uses.

## Will you get the results of this research study?

No. The research study we are doing is only a stepping stone in understanding recovery from alcohol use disorder. Therefore, no information about the results of this research study or the results of your individual participation in the research study will be given to you or your doctor. Tests done for the research using your samples will not be useful in directing your medical treatment. The results of the tests will not be placed in your medical record.

# Can you still get medical care within Partners if you don't take part in this research study, or if you stop taking part?

Yes. Your decision won't change the medical care you get within Partners now or in the future. There will be no penalty, and you won't lose any benefits you receive now or have a right to receive.

We will tell you if we learn new information that could make you change your mind about taking part in this research study.

## What should you do if you want to stop taking part in the study?

If you take part in this research study, and want to drop out, you should tell us. We will make sure that you stop the study safely. We will also talk to you about follow-up care, if needed.

Page 18 of 23

Partners HealthCare System Research Consent Form	
Certificate of Confidentiality Template	Subject Identification
Version Date: January 2019	

Also, it is possible that we will have to ask you to drop out of the study before you finish it. If this happens, we will tell you why. We will also help arrange other care for you, if needed.

# Will you be paid to take part in this research study?

You will be compensated up to \$455 for completing the questionnaires. That is \$15, \$25, \$30, \$35, \$40, \$45, and \$55 for the baseline, 3-, 6-, 9-, 12-, 18-, and 24-month assessments, respectively. Additionally, you will be compensated \$20 for each of the computer-based REDCap surveys you complete at each assessment. Finally, in order to help offset the cost of travel, you will be compensated \$10 per assessment for coming to our offices. In order to receive payment for this study, we will need your Social Security Number (SSN). We need to collect this information in order to comply with tax reporting obligations. This information is confidential and protected, and will be stored securely and redacted when no longer required.

	Computer-based	In-Person Study	Travel
	REDCap Surveys	Visits with Staff	Reimbursement
Baseline	\$20	\$15	\$10
3-Month Follow-Up	\$20	\$25	\$10
6-Month Follow-Up	\$20	\$30	\$10
9-Month Follow-Up	\$20	\$35	\$10
12-Month Follow-Up	\$20	\$40	\$10
18-Month Follow-Up	\$20	\$45	\$10
24-Month Follow-Up	\$20	\$55	\$10
Total:			Up to \$455

As a supplement to this research study, we are conducting an optional qualitative interview for a portion of study participants. Participants will be compensated an additional \$50 following completion of the qualitative interview.

# What will you have to pay for if you take part in this research study?

There are no costs to participate in this research. All questionnaires and surveys will be provided to you by study staff members.

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

# What happens if you are injured as a result of taking part in this research study?

We will offer you the care needed to treat any injury that directly results from taking part in this research study. We reserve the right to bill your insurance company or other third parties, if appropriate, for the care you get for the injury. We will try to have these costs paid for, but you may be responsible for some of them. For example, if the care is billed to your insurer, you will be responsible for payment of any deductibles and co-payments required by your insurer.

Injuries sometimes happen in research even when no one is at fault. There are no plans to pay you or give you other compensation for an injury, should one occur. However, you are not giving up any of your legal rights by signing this form.

If you think you have been injured or have experienced a medical problem as a result of taking part in this research study, tell the person in charge of this study as soon as possible. The researcher's name and phone number are listed in the beginning of this consent form.

# If you take part in this research study, how will we protect your privacy?

Federal law requires Partners to protect the privacy of health information and related information that identifies you. We refer to this information as "identifiable information."

## In this study, we may collect identifiable information about you from:

- Past, present, and future medical records
- Research procedures, including research office visits, tests, interviews, and questionnaires

## Who may see, use, and share your identifiable information and why:

- Partners researchers and staff involved in this study
- The sponsor(s) of the study, and people or groups it hires to help perform this research or to audit the research
- Other researchers and medical centers that are part of this study
- The Partners ethics board or an ethics board outside Partners that oversees the research
- A group that oversees the data (study information) and safety of this study

Page 18 of 23

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Partners HealthCare System Research Consent Form				
Certificate of Confidentiality Template Version Date: January 2019	Subject Identification			
<ul> <li>Non-research staff within Partners who ne such as for treatment, payment (billing), o quality of care or research)</li> </ul>	ed identifiable information to do their jobs, r hospital operations (such as assessing the			
• People or groups that we hire to do certain accreditors, insurers, and lawyers	work for us, such as data storage companies,			
<ul> <li>Federal agencies (such as the U.S. Department of Health and Human Services (DHHS) and agencies within DHHS like the Food and Drug Administration, the National Institutes of Health, and the Office for Human Research Protections), state agencies, and foreign government bodies that oversee, evaluate, and audit research, which may include inspection of your records.</li> </ul>				
• Public health and safety authorities, if we or others (such as to make required reports or elder abuse)	learn information that could mean harm to you s about communicable diseases or about child			
• Other researchers within or outside Partne	rs, for use in other research as allowed by law.			
Certificate of Confidentiality				
A federal Certificate of Confidentiality (Certificat special protection for information and specimens unless you give permission (such as in this form) are not allowed to share your identifiable information court order or subpoena.	te) has been issued for this research to add that may identify you. With a Certificate, and except as described above, the researchers tion or identifiable specimens, including for a			
Certain information from the research will be put covered by the Certificate. This includes records hospitals and clinics, and information that treating you. Please ask your study doctor if you have any included in your medical record. Other researche specimens are expected to comply with the privac does not stop you from voluntarily releasing infor this study.	into your medical record and will not be of medical tests or procedures done at the g health care providers may need to care for y questions about what information will be rs receiving your identifiable information or cy protections of the Certificate. The Certificate mation about yourself or your participation in			
Even with these measures to protect your privacy outside Partners, we cannot control all the ways the that it will remain completely private.	, once your identifiable information is shared nat others use or share it and cannot promise			
Because research is an ongoing process, we cannot destroy or stop using or sharing your identifiable your identifiable information does not expire.	ot give you an exact date when we will either information. Your permission to use and share			
Page 18	of 23			
For peer review only - http://bmjopen.k	omj.com/site/about/guidelines.xhtml			

Subject Identification

## Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

The results of this research may be published in a medical book or journal, or used to teach others. However, your name or other identifiable information **will not** be used for these purposes without your specific permission.

## Your Privacy Rights

You have the right **not** to sign this form that allows us to use and share your identifiable information for research; however, if you don't sign it, you can't take part in this research study.

You have the right to withdraw your permission for us to use or share your identifiable information for this research study. If you want to withdraw your permission, you must notify the person in charge of this research study in writing. Once permission is withdrawn, you cannot continue to take part in the study.

If you withdraw your permission, we will not be able to take back information that has already been used or shared with others, and such information may continue to be used for certain purposes, such as to comply with the law or maintain the reliability of the study.

You have the right to see and get a copy of your identifiable information that is used or shared for treatment or for payment. To ask for this information, please contact the person in charge of this research study. You may only get such information after the research is finished.

# **Informed Consent and Authorization**

## Statement of Person Giving Informed Consent and Authorization

- I have read this consent form.
- This research study has been explained to me, including risks and possible benefits (if any), other possible treatments or procedures, and other important things about the study.
- I have had the opportunity to ask questions.
- I understand the information given to me.
- I have had the chance to ask questions about texting with staff associated with this research study. I have been informed of the risks and other information covered above and consent to the use of unencrypted text communications associated with this research study.

#### 

Certificate of Confidentiality Template Version Date: January 2019		Subject Identification
Signature of Subject (choose one)	):	
I give my consent to take part in this rese information to be used and shared as dese	earch study and agree to al cribed above.	low my identifiable
Subject	Date	Time (optional)
Subject	Date	
Subject Signature of Study Doctor or Per	Date	Time (optional)
Subject Signature of Study Doctor or Per Statement of Study Doctor or Person (	Date Date Son Obtaining Conse Obtaining Consent	Time (optional)
Subject Signature of Study Doctor or Per Statement of Study Doctor or Person ( I have explained the research to th I have answered all questions abo	Date Date Date Dotaining Conset be study subject. Dut this research study to the	Time (optional)
Subject Signature of Study Doctor or Per Statement of Study Doctor or Person ( I have explained the research to th I have answered all questions abo Study Doctor or Person Obtaining Conse	Date         Date         Date         Date         Domain of the study subject.         but this research study to the study to the study subject.         mt       Date	Time (optional) ent: he best of my ability. Time (optional)
Subject Subject Signature of Study Doctor or Per Statement of Study Doctor or Person ( I have explained the research to th I have answered all questions abo Study Doctor or Person Obtaining Consee Consent Form Version Date: 06/04/20	Date Date Date Dotaining Conset Dotaining Consent he study subject. but this research study to th nt Date D21	Time (optional) ent: he best of my ability. Time (optional)

Page 38 of 48

BMJ Open

Date:       Research ball? conducting the screen:         Thank you for your interest in our research ordinator at the Recovery Research conditator at the Recovery Research for the Massachusetts General Hospital. Is this a screen in the Massachusetts General Hospital. Is this a screen in the Massachusetts General Hospital. Is this a screen in this study, you a screes of questions and not the study and do a short phote screen to see if you are eligible to participate in this study, you as a screes of questions any not apply to you, but please answer them to the best of your are blighbe to participate in this study. You can be screen in this study. You can be screen in this study. You were found ineligible. I will call you a screes of participate in this study. You were found ineligible to participate in this study. You were found ineligible. I will were the screen in the best of your are blighbe to participate in the study. If you are found ineligible. I will were the screen in the study.       Yes       Yes         If FYSJ Okay great! First, may I ask how you heard about the study?       If Witter       Imagescreen inclusion. Imagescreen inclastreen inclusion. Imagescreen inclusion. Ima				BM
Date:       Arrowstanding         Provide the standy of the st	1			Jo D
Dute:       Image: Staff conducting the screen:         Imak you for your interest in our research       Image: Staff conducting the screen:         Imak you for your interest in our research       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting the screen:         Image: Staff conducting the screen:       Image: Staff conducting:	2			ben
Research Staff conducting the screen:         Thank you for your interest in our research         study. My name is [RC NAME] and 1 am a         research conditator at the Recovery. Research         Institute within the Department of Psychiatry at         10 codd time for your interest hospital. Is this a         11 (FNO) What time would be good for me to give you more information about the study?         12 (IF NO) What time would be good for me to give you more information about the study.         13 appreciate your time. Have a great day.         14 (FYFS) I am going to ask you a series of questions to determine if you have been answer them to the best of your ability.         14 the end of the sercen, I will tell you if you are endiple to participate in lengible. To protect the integrity of the study?         16 (FYFS) I am going to ask you a series of round ineligible. I would meligible. In order to protect the integrity of the study?         16 of the sercen, I will tell you if you are cligible to participate or ling you have been to the best of your ability.         17 Writter         18 recearch day great. First, may I ask how you hard of Mouth         19 result.         10 representer the study?         11 FYES] Okay great. First, may I ask how you hard about the study?         11 FYES] Okay great. First, may I ask how you hard about the study?         11 FWest and about the study?         12 FIFYEER         13 Fifted wout the study? <td>3</td> <td>Date:</td> <td></td> <td>- T</td>	3	Date:		- T
Thank you for your interest in our research       Image: Situdy, My mane is [RC NAME] and I am a         research coordinator at the Recovery Research       Image: Situdy, My mane is [RC NAME] and I am a         institute within the Department of Psychiath is this a       Image: Situdy, My mane is [RC NAME] and I am a         good time for you to talk about the study?       Image: Situdy, My mane is [RC NAME] and I am a         in the Department of Psychiath is this a       Image: Situdy, My mane is [RC NAME] and I am a         in the Department of Psychiath is thight and the astudy and the astudy and the study and the study and eligible is the situdy are eligible to participate or if you are leigible to participate or if you are been for the serie or jor about the study?       Date: [MM/DD/YYYY]       Image: Situdy, My mane is [MC NAME] and I am a         are eligible to participate or if you are been form are eligible to participate or if you are been for the study?       Image: Situdy, My mane is [MC NAME]       Image: Situdy, My mane is [MC NAME]         At the end of the screen, I will tell you if you are eligible to participate or if you are been for the study?       Image: Situdy, My mane is [MC NAME]       Image: Situdy, My mane is [MC NAME]         Image: Situdy and the study?       Image: Situdy, My mane is an astudy is good are situdy in the study?       Image: Situdy, My mane is an astudy?       Image: Situdy, My mane is an astudy?         Image: Situdy is an astudy?       Image: Situdy, My mane is an astudy?       Image: Situdy, My manee is an astudy?       Image: Situdy, My manee is an a	5	Research Staff conducting the screen:		p
1       Study. My name is IRC NAME] and I an a research coordinator at the Recovery Research coordinator at the Recovery Research characteristic within the Department of Psychiatry at the Masshoutts General Hospital. Is this a give you more information about the study?       If Yes         1       IFNO] What time would be good for me to give you more information about the study and do a short phone screen to see if you are eligible?       Date: [MM//DD/YYYY]       Date: [MM//DD/YYYY]         1       appreciate your time. Have a great day.       IF YES] I am going to ask you a scries of questions to determine if you are eligible to quarticipate or if you have been found ineligible. In order to protect the integrity of the study?       Date: [Yes]       No         1       appreciate your affilty.       No       The study. Some of these questions to other screen, found ineligible. In order to protect the integrity on the velocific reason why you were found ineligible to aparticipate or if you have been for the study?       Yes       The with the study?         1       IF YES] Okay great! First, may I ask how you heard data the study?       If Witter       RI Website       Facebook         1       IF YES] Okay great! First, may I ask how you heard about the study?       Image: SMART Maceting       Image: SMART Maceting       Image: SMART Maceting         1       IF YES] Okay great! First, may I ask how you heard about the study?       Image: SMART Maceting       Image: SMART Maceting       Image: SMART Maceting       Image: SMART Maceting         1       IF	6	Thank you for your interest in our research		db
g       rescarch coordinator at the Recovery Research       □ Yes         institute within the Department of Psychiatry at       □ No         if the Massachusetts General Hospital Is this a       □ No         if the Massachusetts General Hospital Is this a       □ No         if the Massachusetts General Hospital Is this a       □ No         if the Massachusetts General Hospital Is this a       □ No         if the Massachusetts General Hospital Is this at       □ No         if the Massachusetts General Hospital Is this at       □ No         if the Massachusetts General Hospital Is this at       □ No         if the Massachusetts General Hospital Is this at       □ No         if the Statest your time. Have a great day.       □ Date: [MM/DD/YYYY]       □ Date: [MM/DD/YYY]         if the ind of the streen, I will tell you if you are cligible to       □ Participate in this study.       □ Yes         if the end of the screen, I will tell you if you are cligible to       □ Twitter       □ Facebook         if the study?       □ Twitter       □ Racebook       □ RSVP for Health         if the study?       □ Twitter       □ RSVP for Health       □ Mouth         if the study?       □ Twitter       □ RSVP for Health       □ Mouth         if the study?       □ Other       □ Meet for thealth       □ Meet Gink <tr< td=""><td>7</td><td>study. My name is [RC NAME] and I am a</td><td></td><td>lish</td></tr<>	7	study. My name is [RC NAME] and I am a		lish
Institute within the Department of Psychiatry at the Massabuestic General Hespital. Is this a good time for you to talk about the study?       Image: Constraint of the Study and do a short phone screen to see if you are eligible?         I appreciate your time. Have a great day.       Image: Constraint of the Study and do a short phone screen to see if you are eligible?       Date: [MM/DD/YYYY]         I appreciate your time. Have a great day.       Image: Constraint of the Study.       Image: Constraint of the Study.         I appreciate your time. Have a great day.       Image: Constraint of the Study.       Image: Constraint of the Study.         I the cond of the screen, I will tell you are bigible to participate or if you have been found incligible. In order to protect the integrity on fort the study?       Yes       Yes         Knowing this, do you agree to proceed to screen for the study?       Image: Constraint of the Study.       Image: Constraint of the Study.       Image: Constraint of the Study.         I [IF YES] Okay great! First, may I ask how you heard about the study?       Image: Constraint of the Study.       Image: Constraint of the Study.       Image: Constraint of the Study.         I [IF YES] Okay great! First, may I ask how you heard about the study?       Image: Constraint of the Study.       Image: Constraint of the Study.         I [IF OTHER] What was the other source from which you heard about this study?       Image: Constraint of the Study.       Image: Constraint of the Study.         I [IF FLYER] Where did you get the flyer from?       Image:	8	research coordinator at the Recovery Research		ed
10       Inc Massachasets Octoral Hospital, is this a good fine for you to tak shout the study?       If P NO] What time would be good for me to give you more information about the study and do a short phone screen to see if you are ligible?       Date: [MM/DD/YYYY]       Date: [MM/DD/YYYY]         11       appreciate your time. Have a great day, great in this study.       If P YES] I am going to ask you a series of questions to determine if you are cligible to participate in this study. Some of these questions to determine if you are cligible to graticipate.       Date: [MM/DD/YYYY]       The study?         23       At the end of the screen, I will tell you if you are cligible to participate.       P Yes       To und incligible, I will undifyou the specific reason why you were found incligible to participate.         24       At the end of the screen, I will tell you if you the specific reason why you were found incligible to participate.       No       If Weshite         25       Knowing this, do you agree to proceed to screen for the study?       I witter       Facebook       R RI Weshite         26       IF YES] Okay great! First, may I ask how you head about the study?       I west Fad Clinic       Matts       Metro         26       IF OTHER! What was the other source from which was the other source from which was the other source from which was the study?       If PLYER! Where did you get the flyer from?       If New Fingland (MA, NH, RI, etc.)       California         26       IF PLYER! Where did you get the flyer from?       If New Fingland (MA, N	9	Institute within the Department of Psychiatry at		as
IP NOU       Use Not and Lot you to taik about the study and you are to prove the the study and you are to gligble?       IP NOU       IP N	10	the Massachusetts General Hospital. Is this a		Ŗ ġ
IF YOJ what mine would be good to fine 'o' give you more information about the study and to a short phone screen to see if you are tiggible?       Date: [MM//DD/YYYY]         Image:	11	UE NOT What time would be good for me to		
is you not much more than a construction account for study and do a short phone serier to use if you are the study. If appreciate your time. Have a great day.       Date: [MM//DD/YYYY]       If appreciate your time. Have a great day.         If IF YES] I am going to ask you a scries of questions to determine if you are eligible to participate in this study. Some of these questions may not apply to you, but please answer them to the best of your ability.       If the end of the sereen, I will tell you if you are eligible to participate or if you have been found ineligible. I will unoffundated to the specific to participate.       Yes       If apply the series of the study. If you are found ineligible to great the specific to participate.         If the study?       If YES] Okay great! First, may I ask how you bear day under the study?       If the other source from while you heard about the study?       If the other source from while you heard about the study?         If IF YES] Okay great! First, may I ask how you bear day under the study?       If HYES] Okay great! First, may I ask how you we wear found in the study?       If the other source from while you heard about the study?         If IF OTHER] What was the other source from which you heard about this study?       If PLYER] Where did you get the flyer from?       If New England (MA, NH, RL, etc.)         If IF IFLYER] Where did you get the flyer from?       If New England (MA, NH, RL, etc.)       If Other	12	give you more information about the study and		6/bi
Image: Second	14	do a short phone screen to see if you are	Date: [MM/DD/YYYY]	h nja
I appreciate your time. Have a great day.       If YES] I am going to ask you a series of         I [IF YES] I am going to ask you a series of       uestions to determine if you are eligible to         participate in this study. Some of these       uestions may not apply to you, but please         are eligible to participate or if you have been       Image: Some of these         fourth indigible. In order to protect the integrity       No         of the study. If you are found ineligible to       Pres         participate.       Pres         Knowing this, do you agree to proceed to screen       Twitter         for the study?       Twitter         standard       Facebook         mark       RRI Website         Flyer       SMART Meeting         standard       SMART Meeting         word of Mouth       Craigislit         Metro       Metro         Metro       Mark         Metro       Other         IF YES] Okay great! First, may I ask how you       SMART Meeting         heard about the study?       Other         West End Clinic       Mark         Metro       Metro         metro       Other         IF YES] Okay great! First, may I ask how you       SMART Meeting         heard about the study?	15	eligible?		/ cc
12       Lappreciate your time. Have a great day.       IP         17       IP YES] I am going to ask you a series of questions to determine if you are eligible to participate in this study. Some of these questions may not apply to you, but please answer them to the best of your ability.       IP         24       At the end of the screen, I will tell you if you are eligible to participate or if you have been for the study, if you are found ineligible. In order to protect the integrity of reaction and ineligible to participate.       Yes         26       reacond ineligible. In order to protect the study.       INO         27       found ineligible to participate or if you have been for the study, if you are found ineligible to participate.       No         27       cond ineligible to participate.       No         28       Knowing this, do you agree to proceed to screen for the study?       If Witter         29       RRI Website       RRI Website         29       RRI Website       Word of Mouth         29       RRI Website       Word of Mouth         20       IF YES] Okay great! First, may I ask how you       SARAT Meeting         20       Metro       MBTA         20       West End Clinic       ARMS         21       IF YES] What was the other source from which you heard about the study?       New England (MA, NH, RI, etc.)         25       Where are you located?	16		t the second	n-2
If YES] 1 am going to ask you a series of questions to determine if you are eligible to participate in this study. Some of these questions may not apply to you, but please answer them to the best of your ability.       If these questions may not apply to you, but please answer them to the best of your ability.         24       At the end of the screen, 1 will tell you if you are eligible to participate or if you have been found ineligible. In order to protect the integrity ou nofortnately not be able to tell you the specific or reason why you were found ineligible to participate.       Yes         26       Twitter       If Website         27       Facebook       At RRI Website         28       RNOWing this, do you agree to proceed to screen found inclusion       RRI Website         26       RRI Website       Flyer         28       RSVP for Health       Word of Mouth         29       SMART Meeting       SMART Meeting         29       MBTA       West End Clinic         20       MBTA       West End Clinic         21       MRS       Did not specify         25       If FLYER] What was the other source from which you heard about this study?       New England (MA, NH, RL etc.)         26       Where are you located?       New England (MA, NH, RL etc.)	17	I appreciate your time. Have a great day.	l l l l l l l l l l l l l l l l l l l	riat
10       questions to determine if you are eligible to participate in this study. Some of these questions may not apply to you, but pleace answer them to the best of your ability.       Image: Constraint of the study of the study if you are found ineligible. In order to protect the integrity of the study, if you are found ineligible to a participate.       Image: Constraint of the study. If you are found ineligible to a participate.         23       Knowing this, do you agree to proceed to screen for the study?       Image: Constraint of the study?       Image: Constraint of the study?         24       IF YES] Okay great? First, may I ask how you heard about the study?       Image: Constraint of the study?       Image: Constraint of the study?         25       IF YES] Okay great? First, may I ask how you heard about the study?       Image: Constraint of the study?       Image: Constraint of the study?         26       IF YES] Okay great? First, may I ask how you heard about the study?       Image: Constraint of the study?       Image: Constraint of the study?         27       IF OTHER] What was the other source from which you heard about this study?       Image: Constraint of the study?       Image: Constraint of the study?         28       IF FLYER] Where did you get the flyer from?       Image: Constraint of the study?       Image: Constraint of the study?         29       IF Constraint of the study?       Image: Constraint of the study?       Image: Constraint of the study?         28       Image: Constraint of the study?       Image: Constrain	18	[IF YES] I am going to ask you a series of		
21 participate in this study. Some of these   22 questions may not apply to you, but please   23 answer them to the best of your ability.   24 At the end of the screen, I will tell you if you   25 are eligible to participate or if you have been   26 for de study, if you are found ineligible, I will   27 of the study, if you are found ineligible, I will   28 nowing this, do you agree to proceed to screen   30 Knowing this, do you agree to proceed to screen   40 If YES] Okay great! First, may I ask how you   41 Flyer   42 IF YES] Okay great! First, may I ask how you   44 Metro   45 MBTA   46 West End Clinic   47 Did not specify   48 Did not specify   44 Metro   45 Metro   46 MBTA   47 Other	19	questions to determine if you are eligible to		689 ncli
2       questions may not apply to you, but please answer them to the best of your ability.       Image: Constraint of the screen, I will tell you if you are eligible to participate or if you have been found ineligible. In order to protect the integrity of the study, if you are found ineligible, I will unfortunately not be able to tell you the specific reason why you were found ineligible to participate.       Yes       Image: Constraint of the screen found ineligible, I will unfortunately not be able to tell you the specific reason why you were found ineligible to participate.       Image: Constraint of the screen found ineligible, I will unfortunately not be able to proceed to screen for the study?       Image: Constraint of the screen for the screen for the screen for the study?       Image: Constraint of the screen for the screen for the screen for the study?       Image: Constraint of the screen for the screen for the screen for the study?       Image: Constraint of the screen for the screen for the screen	20	participate in this study. Some of these 🔪 📃		di đ
answer them to the best of your ability.       At the end of the screen, I will tell you if you are eligible to participate or if you have been found ineligible. I will unfortunately not be able to tell you the specific reason why you were found ineligible to participate.       Yes       Best of the study, if you are found ineligible to participate.         3       Knowing this, do you agree to proceed to screen for the study?       Twitter       No         4       Facebook       RII Website       Flyer         8       Craigslist       Graigslist       Metro         9       Word of Mouth       Graigslist       Graigslist         9       At the study?       Craigslist       Metro         9       At and about the study?       Other       Metro         1       FYES] Okay great! First, may I ask how you       SMART Meeting       Graigslist         9       ARMS       Did not specify       Other         9       Other       Other       Other         9       Other       Other       Other	21	questions may not apply to you, but please		na i
At the end of the screen, 1 will tell you if you are eligible to participate or if you have been found ineligible. In order to protect the integrity of the study, if you are found ineligible, 1 will unfortunately not be able to tell you the specific reason why you were found ineligible to participate.       Yes       Image: Constraint of the study?         33       Knowing this, do you agree to proceed to screen for the study?       Twitter       Image: Constraint of the study?       Image: Constraint of the study?         34       Image: Constraint of the study?         35       Image: Constraint of the study?         36       Image: Constraint of the study?         37       Image: Constraint of the study?         38       Image: Constraint of the study?         39       Image: Constraint of the study?       Im	22	answer them to the best of your ability.		ior Fe
25       At the end of the screen, I will tell you if you are eligible to participate or if you have been found ineligible. In order to protect the integrity or feast of the study, if you are found ineligible to aparticipate.       Image: Screen integrity of the study is the specific or reason why you were found ineligible to aparticipate.       Image: Screen integrity of the study is the specific or the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study?       Image: Screen integrity of the study is the study is the study?       Image: Screen integrity of the study is the study is the study?       Image: Screen integrity of the study is the study is the study?       Image: Screen integrity is the study is the study is the study?       Image: Screen integrity is the study is the study?       Image: Screen integrity is the study is the study?       Image: Screen integrity is the study is the study is the study?       Image: Screen integrity is the study is	24			
26       are eligible to participate or if you have been       If yet are study:       If yet are you located?         27       found ineligible. I norder to protect the integrity:       No       If yet are you located?         28       are eligible to participate or if you are found ineligible. I will       If yet are you located?       If yet are you located?         29       are eligible. In order to protect the integrity:       No       If yet are you located?       If yet are you located?         29       are integrity.       If Yets       No       If yet are you located?       If yet are you located?         20       is the you are found ineligible. I will you the specific reason why you were found ineligible to participate.       If yet are you located?       If yet are you located	25	At the end of the screen, I will tell you if you		ary Isei
27       No       a rate         28       of the study, if you are found ineligible, in will unfortunately not be able to tell you the specific reason why you were found ineligible to participate.       a rate         38       Knowing this, do you agree to proceed to screen for the study?       Twitter         36       If or the study?       Facebook         37       RRI Website       Flyer         38       RSVP for Health       Word of Mouth         39       SMART Meeting       a single state         40       RSVP for Health       Word of Mouth         41       Word of Mouth       and single state         42       Metro       SMART Meeting         43       ARMS       Orgen state         44       Did not specify       Did not specify         45       Did not specify       Other         46       Did not specify       Other         47       Metro       SMARS         48       Did not specify       Other         49       Other       Metro         40       No the study?       State         41       West End Clinic       Other         51       IF FLYER] What was the other source from       Metro         52       Wh	26	are eligible to participate or if you have been	$\Box$ Yes	elat
28       On the study, if you are found inergion, if with         29       unfortunately not be able to tell you the specific         21       reason why you were found inergible to         22       participate.         23       Knowing this, do you agree to proceed to screen         4       for the study?         35       Pacebook         36       RRI Website         37       RRI Website         38       RRI Website         39       SMART Meeting         40       Word of Mouth         41       Word of Mouth         42       [IF YES] Okay great! First, may I ask how you         44       Metro         44       West End Clinic         45       Did not specify         46       Other         47       West End Clinic         48       Did not specify         49       Other         50       IF FLYER] Where did you get the flyer from?         51       [IF FLYER] Where did you get the flyer from?         52       New England (MA, NH, RI, etc.)         54       Other	27	of the study if you are found ineligible. I will		
20       information why you were found ineligible to         31       participate.         32       Knowing this, do you agree to proceed to screen         4       for the study?         35	28	unfortunately not be able to tell you the specific		
a labor in regione to a participate.       a definition of the study?         in articipate.       in articipate.         in art	29	reason why you were found ineligible to		Sup
33       Knowing this, do you agree to proceed to screen       Twitter         34       for the study?       Facebook         35       RRI Website       Facebook         36       RRI Website       File         37       RRI Website       File         38       RRI Website       File         39       RRI Website       File         40       SMART Meeting       Word of Mouth         41       Wetro       MBTA         44       Metro       MBTA         45       Did not specify       Softer         46       Did not specify       Softer         47       Weest End Clinic       Other         48       Did not specify       Softer         49       Other       Other         41       FILPER] Where did you get the flyer from?       Softer         43       Other       Other         44       Other       Other	31	participate.		oad
33       Knowing this, do you agree to proceed to screen for the study?       Image: Constraint of the study?         36       Facebook       RRI Website         37       Facebook       RRI Website         38       RRI Website       Flyer         39       SMART Meeting       SMART Meeting         41       Word of Mouth       Other         42       IF YES] Okay great! First, may I ask how you heard about the study?       SMART Meeting       Smill art tee for the study?         44       Wetro       MBTA       MBTA       Other         45       Did not specify       Other       Other         46       Did not specify       Other       Other         57       Where are you located?       New England (MA, NH, RI, etc.)       California         56       Where are you located?       Other       Other	32	F		
34       for the study?       Import         35       Import       Facebook         36       RRI Website       Facebook         37       RRI Website       Flyer         38       RRI Website       Flyer         39       RSVP for Health       Word of Mouth         41       Word of Mouth       Word of Mouth         42       [IF YES] Okay great! First, may I ask how you       SMART Meeting         44       Metro       Metro         45       Metro       MBTA         46       West End Clinic       mologges         47       Other       Other         51       [IF FLYER] What was the other source from       Other         53       [IF FLYER] Where did you get the flyer from?	33	Knowing this, do you agree to proceed to screen		at A d
35       Image: Twitter       Twitter         36       Facebook       A         37       RRI Website       Facebook         39       RRI Website       Flyer         40       RSVP for Health       Word of Mouth         41       Word of Mouth       SMART Meeting         42       IF YES] Okay great! First, may I ask how you       Craigslist         43       heard about the study?       Craigslist         44       Metro       MBTA         45       ARMS       Other         46       Other       Other	34	for the study?		
36 Facebook   37 RRI Website   38 RRI Website   39 RRVP for Health   40 Word of Mouth   41 Word of Mouth   42 IIF YES] Okay great! First, may I ask how you   43 heard about the study?   44 Metro   45 Metro   46 West End Clinic   47 Did not specify   48 Did not specify   49 Other   1 [IF OTHER] What was the other source from which you heard about this study?   54 New England (MA, NH, RI, etc.)   55 Where are you located?	35		□ Twitter	
37 RRI Website   38 Flyer   40 RSVP for Health   41 Word of Mouth   42 Word of Mouth   43 Craigslist   44 Metro   45 Metro   46 West End Clinic   47 Did not specify   50 Other	36		🗆 Facebook	
39 Flyer   41 RSVP for Health   42 [IF YES] Okay great! First, may I ask how you   43 SMART Meeting   44 Vord of Mouth   44 Metro   45 Metro   46 MBTA   47 Vest End Clinic   48 Did not specify   50 Other      51 [IF OTHER] What was the other source from which you heard about this study?   52 Where are you located?	37		□ RRI Website	
40       RSVP for Health       g         41       [IF YES] Okay great! First, may I ask how you       SMART Meeting       si,         42       [IF YES] Okay great! First, may I ask how you       SMART Meeting       si,         44       Craigslist       Metro       mathematical about the study?       mathematical about the study? <t< td=""><td>39</td><td></td><td>🗆 Flyer</td><td>aini</td></t<>	39		🗆 Flyer	aini
41       [IF YES] Okay great! First, may I ask how you       SMART Meeting       Image: SMART Meeting         43       heard about the study?       Craigslist       Image: SMART Meeting         44       Metro       Image: SMART Meeting       Image: SMART Meeting         45       Metro       Image: SMART Meeting       Image: SMART Meeting         46       Metro       Image: SMART Meeting       Image: SMART Meeting         47       Metro       Image: SMART Meeting       Image: Smart Meeting         48       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting         49       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting         49       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting         49       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting         49       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting         50       Image: Smart Meeting         51       [IF FLYER] Where did you get the flyer from?       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting       Image: Smart Meeting	40		□ RSVP for Health	
42       [IF YES] Okay great! First, may I ask how you       SMART Meeting       Sinital State of the study?         43       heard about the study?       Craigslist       Sinital State of the study?         44       Metro       MBTA       State of the study?         45       MBTA       West End Clinic       State of the study?         48       ARMS       Did not specify       State of the study?         49       Other       Other       State of the study?         50       Other       State of the study?       State of the study?         51       [IF OTHER] What was the other source from which you heard about this study?       State of the study?       State of the study?         53       [IF FLYER] Where did you get the flyer from?       Image: State of the study?       State of the study?         54       Where are you located?       Image: State of the study?       State of the study?         55       Where are you located?       Image: State of the study?       State of the study?         55       Image: State of the study?       Image: State of the study?       State of the study?         56       Where are you located?       Image: State of the study?       Image: State of the study?         57       Image: State of the study?       Image: State of the study?       Image:	41		□ Word of Mouth	an 🚽
43       heard about the study?       Craigslist       Image: Craigslist         44       Metro       MBTA       Image: Craigslist       Image: Craigslist         45       MBTA       MBTA       Image: Craigslist	42	[IF YES] Okay great! First, may I ask how you	□ SMART Meeting	
44       Image: Metro       Image: MetroImage: Metro       Image: MetroImage: MetroImage	43	heard about the study?	□ Craigslist	mi d
<ul> <li>MBTA</li> <li>West End Clinic</li> <li>ARMS</li> <li>Did not specify</li> <li>Did not specify</li> <li>Other</li> <li>IF OTHER] What was the other source from</li> <li>which you heard about this study?</li> <li>IF FLYER] Where did you get the flyer from?</li> <li>Mew England (MA, NH, RI, etc.)</li> <li>Khere are you located?</li> <li>California</li> <li>Other</li> </ul>	44		□ Metro	art J
47     West End Clinic     50       48     ARMS     Did not specify       49     Other       50     Other       51     [IF OTHER] What was the other source from       52     which you heard about this study?       53     [IF FLYER] Where did you get the flyer from?       55     New England (MA, NH, RI, etc.)       56     Other	45 46		□ MBTA	ane
48       ARMS       G         49       Did not specify       9         50       Other       9         51       [IF OTHER] What was the other source from which you heard about this study?       9         53       [IF FLYER] Where did you get the flyer from?       9         54       IF FLYER] Where did you get the flyer from?       9         55       Where are you located?       10         56       Where are you located?       10         57       0       Other	47		□ West End Clinic	
49       Did not specify       0         50       Other       0         51       [IF OTHER] What was the other source from       0         52       which you heard about this study?	48		□ ARMS	20
50     Other       51     [IF OTHER] What was the other source from which you heard about this study?       53     [IF FLYER] Where did you get the flyer from?       54     New England (MA, NH, RI, etc.)       55     California       57     Other	49		□ Did not specify	
51       [IF OTHER] What was the other source from         52       which you heard about this study?         53       [IF FLYER] Where did you get the flyer from?         54	50		□ Other	
52     which you heard about this study?       53     [IF FLYER] Where did you get the flyer from?       54	51	[IF OTHER] What was the other source from		lge
53       [IF FLYER] Where did you get the flyer from?	52	which you heard about this study?		e
55     State     State     New England (MA, NH, RI, etc.)       56     Where are you located?     California       57     Other	53 54	[IF FLYER] Where did you get the flyer from?		8
56     Where are you located?     California       57     Other	55		□ New England (MA, NH, RI, etc.)	blio
57 <u>Other</u>	56	Where are you located?	California	gra
	57	-	$\Box$ Other	phi
[IF OTHER] If located outside of New England or California, NOT ELIGIBLE to participate [Do not stop screen, complete]	58	[IF OTHER] If located outside of New England o	r California, NOT ELIGIBLE to participate [Do not stop screen, complete	que
60 <u>screen in its entirety]</u> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	59 60	screen in its entirety] For peer review only - h	http://bmjopen.bmj.com/site/about/guidelines.xhtml	de

			BM.
1			op J
2 3			en
4	Great! Let me tell you a little bit about our study so you can decide if this is something		first
5	vou'd like to participate in.		pu
5 7			olis
8	The study is funded by the National Institutes of		hed
9	Health to learn more about the different		as
10	pathways, resources, and services that individuals may use to overcome an alcohol	Pro	đ
11 12	problem. We hope this study will help advance	otec	136
13	treatment and recovery support service options.	te de la companya de	il di
14		by by	Jop
15 16	If you decide to take part in the study, your	Yes, remains interested	en-
10 17	Boston office over the course of 2 years. During		202:
18	each visit, you would complete a series of	ht.	2-06
19	questionnaires, computerized tasks, and		689
20 21	biochemical verification of abstinence, which	udi	0
22	includes a urine sample and breathalyzer test. In	ng fr	n 3
23	remotely (e.g., over the phone or zoom), study		ebi
24 25	procedures are similar; however, you would	Ses	uar
25 26	complete a self-administered saliva test that is		y 20
27	mailed to you in advance. Each visit will take		123. 19m
28 20	far?	t t t	Pnt U
29 20	[IF NO LONGER INTERESTED] Thank you ver	v much for your time, we understand that this study is not for everyone and $\frac{3}{4}$	ב ת
20		,	통 리
31	appreciate your interest.	and	nioade
31 32	appreciate your interest. STOP SCREEN	and dat	nloaded fr
31 32 33 34	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I	and data mi	nioaded from Imerieur (ARF
31 32 33 34 35	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you	and data mining	nloaded from http Merieur (ARFS)
31 32 33 34 35 36	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible.	and data mining, A	nloaded from http://bi
31 32 33 34 35 36 37 38	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history including your cleabel use and	Al tra	nloaded from http://bmjo
31 32 33 34 35 36 37 38 37 38	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time.	and data mining, Al trainin	nioaded from http://bmjopen. merieur (ABES)
31 32 33 34 35 36 37 38 39 40	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel	and data mining, Al training, a	nioaded from http://bmjopen.bmj merieur (ABES)
31 32 33 34 35 36 37 38 39 40 41 41	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does	and data mining, Al training, and	nloaded from http://bmjopen.bmj.co
31 32 33 34 35 36 37 38 39 40 41 42 43	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?	Al training, and simi	nioaded from http://bmjopen.bmj.com/ c merieur (ABES)
31 32 33 34 35 36 37 38 37 38 39 40 41 42 43 44	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay? I will record your answers in writing but only	<ul> <li>Pres</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on J merieur (ARES)
31 32 33 35 36 37 38 37 40 41 42 43 44 45 44	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay? I will record your answers in writing, but only collect detailed contact information if you	<ul> <li>Al training, and similar tech</li> <li>Yes</li> <li>No</li> </ul>	nioaded from http://bmjopen.bmj.com/ on June unerieur (ABES)
31 32 33 34 35 36 37 38 37 38 40 41 42 43 44 45 46 47	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay? I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an in-	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13,
31 32 33 34 35 36 37 38 37 38 37 38 37 38 37 40 41 42 43 44 45 46 47 48	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay? I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an in- person visit. As a reminder, collected information if you	<ul> <li>Yes</li> <li>No</li> </ul>	nioaded from http://bmjopen.bmj.com/ on June 13, 202 unerieur (ABES)
31 32 33 35 36 37 38 30 41 42 44 45 46 48 40 47 48 40	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of</li> </ul>	<ul> <li>□ Yes</li> <li>□ No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at
31         32         33         34         35         36         37         38         40         41         42         43         44         45         44         45         47         48         50         51	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate</li> </ul>	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Ag unerieur (ABES)
31         32         34         35         36         37         38         307	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay</li> </ul>	<ul> <li>and data mining, Al training, and similar technologies.</li> <li>☐ Yes</li> <li>☐ No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agenc unerieur (ABES)
33       34       35       37         33       34       35       37       38         34       35       37       38       37         35       37       38       39       41       42         44       45       45       47       48       49         55       53       55       55       55       55	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay to begin?</li> </ul>	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bi unerieur (ARES)
33       34       4       4       4       4       4       4       4       35       5	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay to begin?</li> </ul>	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Biblio
333       334       333       337       333       3	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay to begin?</li> <li>[IF NO] Thank you very much for your time, we us STOP SCREEN</li> </ul>	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliogra, unerieur (ARES)
333333333333333333333333333333333333	<ul> <li>appreciate your interest.</li> <li>STOP SCREEN</li> <li>[IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay?</li> <li>I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an inperson visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay to begin?</li> <li>[IF NO] Thank you very much for your time, we us STOP SCREEN</li> </ul>	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographic
31 31 32 33 34 35 36 37 38 39 40 41 42 43 33 44 45 50 51 52 33 44 44 55 55 55 55 55 55 55 55 55 55 55	appreciate your interest. STOP SCREEN [IF REMAINS INTERESTED] Great. Before I can enroll you in this study, I need to ask you some questions to make sure you are eligible. These questions are about your health and medical history, including your alcohol use, and should take about 10 minutes of your time. Some of the questions may make you feel uncomfortable. You may stop at any time. Does that sound okay? I will record your answers in writing, but only collect detailed contact information if you qualify for the study and want to schedule an in- person visit. As a reminder, collected information is completely confidential and protected. There is always risk of loss of confidentiality but we will take appropriate responsible steps to ensure confidentiality. Okay to begin? [IF NO] Thank you very much for your time, we u STOP SCREEN	<ul> <li>Yes</li> <li>No</li> </ul>	nloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique ( Interieur (ARES)

BMJ Open

Page 40 of 48

1 2	
3	How old are you?
5	Research Staff Use: Is the participant older than   Image: Yes     8?   Image: No
7	STOP SCREEN. If under 18, NOT ELIGIBLE to participate.
9 10 11 12	IF INELIGIBLE] Thank you, [es_name]. Unfortunately, you are not eligible to participate in our study. You may be eligible to participate in future research studies. If you are interested in participating in future research studies, we can take your contact of information and reach out to you with future study opportunities.
13 14	o travel to Boston to complete study visits? $\Box$ No
15 16 17	IF NO OR FROM CALIFORNIA] Are you villing to conduct all visits remotely (e.g. over home or Zoom)?
18	IF NO] If unwilling to travel to Boston for the research study and unwilling to conduct visits remotely, NOT ELIGIBLE to
19 20	participate. [Do not stop screen, complete screen in its entirety]
21	s there any reason that you would not be living $\Box$ Yes
22 23	n the Boston area within the next 2 years? $\square$ No $\boxed{2}$
24	IF YES] Would you be willing to conduct
25	visits remotely if you were no longer in the
26	Boston area?
27 28	E NOI If nontiving at the in Destan for the next 2 many and is not willing to some dust visits normataky. NOT ELICIDI USE
20 29	articipate [Do not stop screen, complete screen in its entirety]
30	
31	Are you willing to give us the contact
32 22	nformation for two of your friends or family
33 34	nembers, so that we can reach out to them, in
35	ease we lost contact with you?
36	$\nabla$ and for this information because plating $\Box$ Yes
37	We ask for this information because obtaining $\Box$ No
38	tudy. The last study visit will take place 2 years
39 10	rom the time of your baseline visit. We want to
40 41	nake sure we can reach you to complete your
12	inal visit at that time.
43 44	IF NO] If they aren't willing to provide collateral contacts NOT ELIGIBLE to participate. [Do not stop screen, complete screen]
+5 46	
47	Are you willing to provide your SSN in order to
18	eceive reimbursement?
19	S.
50 51	If asked for more information: If payments to $\Box$ Ves. Lem willing to provide my SSN to receive the study payment.
52	you are \$600 or greater in a calendar year, $\square$ No Lam not willing to provide my SSN however. I still wish to
53	Partners will report this to the Internal Revenue   participate in this study. I understand that I will not receive payments
54	Service (IRS) and you will receive a 1099-MISC for being in this study unless I provide my SSN.
55	his tax related murpose.
56	this study.
57	f vou do not provide vour SSN, we cannot issue
59 59	you a payment for participation. You may still
50	hoose to participate in this saude and viewinely - http://bmjopen.bmj.com/site/about/guidelines.xhtml
	reimbursement).

1				
∠ 3⊺		T		
1				
5				
5	[IF NO] If unwilling to provide SSN and decline t	to nartic	inate in f	he study NOT FLIGIBLE to participate [Do not stop screen
2	complete screen in its entirety]	to purifici	ipute in t	ie study, iter Eligibel to participate [Do not stop seleen,
, ,	I I I I I I I I I I I I I I I I I I I			
10	During assessments, are you willing to provide			Ţ
1	a urine sample and complete a breathalyzer test			ote
2	for biochemical verification? Or in the event			Ċte
3   <u>4</u>	that your visit takes place remotely, are you			d d
15	with study staff guidance? This test would be			V CC
6	mailed to your current address before the study			ру
7	visit and can be disposed of after use.			righ
8			Yes	,t T
9	Although you do not need to abstinent to		No	
21	participate in this study, we ask that participants			
22	not drink or use drugs before coming in for their			lg f
23	assessment or before completing their remote			or L
24	indicates that you are under the influence of			S E ns es
25 26	alcohol when you come in for your assessment			reig
.0	or begin your remote assessment, we will need			ate
8	to re-schedule the visit.			d to
29				e i s
30	[IF NO] If unwilling to participate in biochemical	verifica	tion, NO	T ELIGIBLE to participate [Do not stop screen, complete
51 22	screen in its entirety]			
33	Do you have a stable home address and contact		Vac	
84	information?		No	<u> i k</u>
35			110	. juric
36 27	[IF NO] If participant does not have a stable home	e addres	s and/or o	contact information, NOT ELIGIBLE to participate[Do not
37 38	stop screen, complete screen in its entirety]			
39				
10	Have you consumed alcohol in the past 3		Yes	, gi
1	months?		No	
וא וא				
14	[IF NO] II participant has not consumed alconol I.	n past 3	months,	
15	serven in its entirety]			r ter
16			Yes	<u> </u>
7	Do you think you have a problem with alcohol?		No	<u>o</u>
10 19		<u> </u>		<u> </u>
50	[IF NO] If participant does not think they have a p	oroblem	with alco	bhol, NOT ELIGIBLE to participant [Do not stop screen,
51	complete screen in its entirety]			
52		T (1	. 10	
53 :∧		In the j	past 12 n	nontns, nave you:
,4 55			Had tin	hes when you ended up drinking more, or longer, than you
56	[IF YES] I'm going to ask you a series of		More t	u:
57	questions about your alcohol use during the past		couldn <sup>3</sup>	t?
8	12 months.		Spent a	lot of time drinking? Or being sick or getting over other
99 50	For peer review only - k	ttp://bm	iastereff	Metem/site/about/quidelines.xhtml
טנ	. or peer review only it		Experie	enced craving — a strong need, or urge, to drink?

1			BMJ Op
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 22 22		<ul> <li>Found that drinking – or being sick from drinking – often interfered with taking care of your home or family? Or caused job troubles? Or school problems?</li> <li>Continued to drink even though it was causing trouble with your family or friends?</li> <li>Given up or cut back on activities that were important or interesting to you, or gave you pleasure, in order to drink?</li> <li>More than once gotten into situations while or after drinking that increased your chances of getting hurt (such as driving, swimming using machinery, walking in a dangerous area, or having unsafe so?)?</li> <li>Continued to drink even though it was making you feel depressed for anxious or adding to another health problem? Or after having had memory blackout?</li> <li>Had to drink much more than you once did to get the effect you want? Or found that your usual number of drinks had much less effect than before?</li> <li>Found that when the effects of alcohol were wearing off, you had withdrawal symptoms, such as trouble sleeping, shakiness, restlessness, nausea, sweating, a racing heart, or a seizure? Or sensed</li> </ul>	pen first published as 10.1136/bmjopen-2022-066898 on 3 Feb
24 25 26 27	Number of AUD criteria met:	things that were not there?     Image: Comparison of the second sec	ruary 2023. 1
28 29 30 31 32	AUD Severity:	<ul> <li>Does not meet criteria for AUD (0-1 symptoms)</li> <li>Mild (2-3 symptoms)</li> <li>Moderate (4-5 symptoms)</li> <li>Severe (6+ symptoms)</li> </ul>	Downloaded
33 34 35 36	[IF DO NOT MEET CRITERIA FOR AUD] Doe ELIGIBLE to participate. [Do not stop screen, cor	es not meet sufficient criteria for AUD diagnosis (0 or 1 AUD criterion), NO	from http://b
37 38 39	Meet sufficient criteria for AUD diagnosis (2+ AU	UD criteria = mild, moderate, or severe).	mjopen.
40 41 42 43 44	Are you currently making a new recovery attempt, that is, a serious effort to abstain from drinking or to drink without problems?	□ Yes □ No □ Yes	bmj.com/ on
45 46 47	(IF YES) When did you start this attempt?	Date: [MM/DD/YYYY]     tempt began:	June 13
48 49 50	Has the participant's new recovery attempt begun within the past 90 days?	□ Yes Ges Yes	2025 at
51 52 53 54	[IF NO, > 90 DAYS] If recovery attempt started r complete screen in its entirety]	more than 90 days ago, NOT ELIGIBLE to participate. [Do not stop screen,	Agence Bibl
55 56 57 58 59 60	(IF NO, NOT CURRENTLY MAKING A NEW RECOVERY ATTEMPT) Are you planning to make a new recovery attempt or serious effort to abstain from drinking or to drink without problems?view only - h	<ul> <li>Yes</li> <li>No</li> <li>http://bmjopen.bmj.com/site/about/guidelines.xhtml</li> </ul>	iographique de l

[IF NO] If not planning to make a new recovery its entirety]	attempt, NOT ELIGIBLE to participate. [Do not stop screen, complete screen in
(IF YES) When will you start?	Date: [MM/DD/YYYY] Days until new recovery attempt begins: (Must be less than 14 days away)
Is the participant's new recovery attempt beginning in the next 14 days?	□ Yes Cop
[IF NO] If not planning to make a new recovery a not stop screen, complete screen in its entirety]	attempt either at all OR within next 14 days, NOT ELIGIBLE to participate
Is alcohol the primary substance from which you are seeking recovery?	□ Yes for uses
(IF NO) What is the primary substance from which you are seeking recovery?	<ul> <li>Marijuana</li> <li>Cocaine (coke, crack, freebase)</li> <li>Heroin</li> <li>Methadone</li> <li>Suboxone/Subutex/Buprenorphine</li> <li>Other opioids (e.g. prescription opioids)</li> <li>Hallucinogens</li> <li>Synthetic Marijuana / Synthetic Drugs</li> <li>Amphetamine (uppers)</li> <li>Methamphetamine (crank, meth, crystal)</li> <li>Benzodiazepines (sedatives/tranquilizers)</li> <li>Barbiturates (downers)</li> <li>Inhalants</li> <li>Steroids</li> <li>Other substance (not specified above) [please specify:]</li> </ul>
[IF PRIMARY SUBSTANCE NOT ALCOHOL] ELIGIBLE to participate [Do not stop screen, co	] Report their primary substance. If alcohol is not primary substance, NOT mplete screen in its entirety]
Have you participated in any of the following mutual-help organizations in the past 30 days?	<ul> <li>Alcoholics Anonymous</li> <li>Narcotics Anonymous</li> <li>Other 12-Step Fellowship</li> <li>SMART Recovery</li> <li>Other mutual-help organization</li> <li>None of the above</li> <li>If other, please specify:</li> </ul>
Are you planning to participate in SMART Recovery during this recovery attempt or serious effort? For peer review only -	□ Yes □ No http://bmjopen.bmj.com/site/about/quidelines.xhtml
Page 44 of 48

1			RM.I One
3 4 5 6	(IF YES)In-person meetings onlyHow will you participate in SMART Recovery?In-person meetings and onlineOnline only		nr firet nublis
, 8 9 10 11	Are you planning to participate in Alcoholics Anonymous during this recovery attempt or serious effort?□Yes No	Prote	hod as 10 11
12 13 14 15 16	[IF NO PARTICIPATION IN SMART OR AA AND NO PLANNED PARTICIPATION] If participant has not participated SMART and/or AA in the past 30 days and does not plan to participate in SMART and/or AA, NOT ELIGIBLE to participat	)دteظظە∿َCob	k£/hminnen-2
17 18 19 20	RESEARCH STAFF USE: Does the participant□Yesmeet the eligibility criteria?□No	/right, includ	1868990-ccu
21 22 23 24 25 26 27	[IF NO] Thank you, [es_name]. Unfortunately, you are not eligible to participate in our study. In order to protect the integrity of the study, as mentioned before, I will not be able to tell you the specific reason why you were found ineligible to participate.	Enseigner	nn 3 Fehrijary 2023
28 29 30 31 32 33	However, you may be eligible to participate in future research studies. If you are interested in participating in future research studies, we can take your contact information and reach out to you with future study opportunities.	to text and data	Downloaded fro
34 35 36 37 38 39	[Ask question to all callers, including those who have been found ineligible]         Are you interested in participating in future         research studies? If so, we can take your contact         information and reach out to you with future         study opportunities.	BES) . mining, Al traini	m http://hmioper
40 41 42 43	(IF YES)         Collect contact information and note interest in screening log.         □       Primary Contact Number:         □       Email Address:	ng, and simila	nhmi com/ on
45 46 47 48	ELIGIBLE Great! It sounds like you are eligible to participate in our study! So now let me tell you a little bit more about the study.	r technologie	hine 13, 202
+9 50 51 52 53 54 55 56 57 58	If you decide take part in this study, the visits would include an initial assessment followed by 3-, 6-, 9-, 12-, 18-, and 24-month follow-up assessments. The questionnaires during visits will include questions regarding various topics such as your demographic information, substance use history, treatment service utilization and recovery support, among others.	s.	<del>¶ at Δαρασο Riblioαranhia</del> u
59 50	To compensate you for your time and effort, we would compensate you up to \$455. That is \$45,		며미

			BM
1			с ор
2			ben
3	\$55, \$60, \$65, \$70, \$75, and \$85 for the initial		: fir
5	visit and 3-,- 6-,- 9-,- 12-,- 18-,- and 24-month		stp
6	follow-up visits, respectively. The reason I say		dub
7	"up to \$455" is because we are unable to pay		lish
8	participants for the assessments they do not		led
9	come in to complete.		as
10			ੂ ਤੂ ਰੋ
11	take up to 10 business days to receive neuront		ete 113
12	after you complete your initial assessment per		cte
13	our MGH guidelines, but payment will likely be		d b
15	faster for subsequent payments. In order to		y c
16	receive payment for participating in this study		opy
17	vou will need to provide vour Social Security		rig 7
18	Number (SSN). This is necessary in order for us		ht,
19	to comply with tax reporting obligations. This		incl
20	information is confidential and protected, and		ludi 80
21	will be stored securely and redacted when no		ing
22	longer required.		for F
23			us Ed
25	Finally, please know that your honesty is the		nse nse es r
26	most important part of this study: research		ela 'ela
27	studies only work if participants tell us now they tryly think and feel. There are no "right"		ted
28	and "wrong" answers: never consider what you		t en d
29	think we might like to hear Always simply tell		tex Su
30	us how it is		t an
32			id d d
33	So, what do you think? Would you like to		ata r (A
34	participate in this study?		<u>n</u> . Ra
35			nin S T
36	[If NO]		
3/	Thank you very much for your time, we understan	d that this study is not for everyone and we appreciate your interest.	
38	STOP SCREEN		
40	[If YES]		ing n.b
41	In just a moment, I will collect your contact		an
42	for two people in your life, so we can reach out		d s
43	to them if we lose contact with you. We will		imi d
44	simply tell them that you are in a study tracking		lar J
45	health behaviors: they must confirm with us that		tec
46	they are willing to serve in this role.	□ Use SEND SECURE	hnc
47	<i>3 3 3 3 3 3 3 3 3 3</i>	Don't use SEND SECURE	5/0g
49	Before I ask you for your email address, I need	$\square$ N/A (no email)	) <del>25</del> Jies
50	to ask you about how you prefer to get emails		្ន
51	from us. There are two options: receiving them	Contact Number:	Age
52	using the "SEND SECURE" option, or	Email Address:	enci
53	receiving them without it. Let me explain:		e B
54			ibli
55 56	Email sent over the internet is not secure unless		ogr
57	technology This provides a secure connection		apt
58	both on the sender's and receiver's		ıiqt
59	communications while in transit Without	<i>, , , , , , , , , ,</i>	le c
60	encryption, it is possible for other individuals	ttp://bmjopen.bmj.com/site/about/guidelines.xhtml	e
L			

0 1 2 3 4	<ul> <li>(beyond the intended recipient of the email) to access and read the email and this could result in the unauthorized use or disclosure of your information, for which Partners HealthCare will not be held responsible. If you prefer to receive communications by unencrypted email despite these risks, your preference will apply to all emails sent to you from research staff in this study.</li> <li>If you would like to receive your emails encrypted, we will use the SEND SECURE</li> </ul>	Protected by co
6 7 8 9 0 1 2 3 4 5	<ul> <li>option. In order to read these emails, you will need to do two things:</li> <li>1. The first time you get a 'send secure' message, you need to register with Cisco Registered Envelope Service (CRES). This is done once and takes only a few minutes.</li> <li>2. To read future secure emails you need to enter the password you created.</li> </ul>	Ense pyright, including for uses
.6 .7 .8 .9 .0	If you would like to receive your emails unencrypted, we will not use the SEND SECURE option. What do you prefer?	related to text and
2 3 4 5 6 7 8 9	Who are the two people we can reach out to in case we are unable to contact you directly? These can be family members, friends, or partners. NOTE: Information for at least one contact person is required.	<ul> <li>Contact 1 Name:</li></ul>
1 2 3 4 5	(If eligible and interested in participating) Schedule assessment	Time: HH:MM Date: [MM/DD/YYYY] Scheduling Notes:
7 8 9 10 11 2 33 5 5 6	[IF ELIGIBLE AND SCHEDULED FOR AN AS [IF IN PERSON VISIT] Okay, we are all set then [schedule1]. I will send you an appointment confit [IF REMOTE VISIT] Okay, we are all set then. Y an appointment confirmation shortly. The first this which will be emailed to you. You'll need to sign time of your assessment.	SESSMENT] . Your assessment will take place in person at our office and is scheduled for rmation and directions to our office shortly. Your assessment will take place over the phone on [schedule1]. I will send you ng we'll be doing during your enrollment visit is going over our consent form, the form electronically, so we recommend having access to a computer at the additional questions or anything comes up, please don't besitate to reach out
7 8 9	by phone or email. (Confirm he/she has your cont study. It was great talking with you! CALL END. For peer review only - h	act information). Thank you again for your interest and participation in our

	Item		
	No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	2
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	4-
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of	6-
6		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	7-
I	-	selection of participants. Describe methods of follow-up	
		(b) For matched studies give matching criteria and number of exposed	
		and unexposed	
Variables	7	Clearly define all outcomes exposures predictors potential	9
, and to be	,	confounders and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest give sources of data and details of	9
measurement	Ũ	methods of assessment (measurement) Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6
Ouantitative variables	11	Explain how quantitative variables were handled in the analyses. If	7
<b>L</b>		applicable describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods including those used to control for	10
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	11
		(d) If applicable explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	10
Descrite		( <u>v</u> ) 2 control and construct analyses	10
Results Darticipanta	12*	(a) Deport numbers of individuals at each store of study as numbers	<b>N</b> 1/
1 articipalits	13'	a) report numbers of multiduals at each stage of study—eg numbers	1N/
		included in the study, completing follow up, and analyzed	
		(b) Give reasons for non perticipation at each stage	N
		(a) Consider use of a flow diagram	
Description 1.4	1 1 4	(c) Consider use of a flow diagram	N/
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	N/
		social) and information on exposures and potential confounders	
		(b) indicate number of participants with missing data for each variable	N/
		of interest	
		(c) Summarise follow-up time (eg, average and total amount)	N/
Outcome data	15*	Report numbers of outcome events or summary measures over time	N/
1. 1.	16	(a) Cive unadjusted estimates and if applicable confounder adjusted	I NL

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3
4
5
6
0
/
8
9
10
11
12
13
14
15
10
10
17
18
19
20
21
22
23
21
24
25
26
27
28
29
30
31
32
22
22
34
35
36
37
38
39
40
41
<u>4</u> 2
-⊤∠ //2
43 44
44
45
46
47
48
49
50
51
52
52 52
22
54
55
56
57
58
59

60

1 2

		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	N/A
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	N/A
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and	N/A
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	N/A
Limitations	19	Discuss limitations of the study, taking into account sources of	N/A
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	N/A
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	2
		study and, if applicable, for the original study on which the present	
		article is based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

# **BMJ Open**

#### An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

Journal:	BMJ Open	
Manuscript ID	bmjopen-2022-066898.R2	
Article Type:	Protocol	
Date Submitted by the Author:	17-Jan-2023	
Complete List of Authors:	Kelly, John; Harvard Medical School, Psychiatry; Massachusetts General Hospital, Psychiatry Levy, Samuel; Massachusetts General Hospital, Psychiatry Hoeppner, Bettina B; Harvard Medical School	
<b>Primary Subject Heading</b> :	Addiction	
Secondary Subject Heading:	Health services research, Evidence based practice	
Keywords:	Substance misuse < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH	



**BMJ** Open

An Investigation of SMART Recovery: protocol for a longitudinal cohort study of individuals making a new recovery attempt from alcohol use disorder

John F. Kelly<sup>1,2</sup>, Samuel Levy<sup>1</sup>, Bettina Hoeppner<sup>1,2</sup>

1. Massachusetts General Hospital, Psychiatry Department, Boston, Massachusetts; 2. Harvard Medical School, Department of Psychiatry, Boston, Massachusetts

Corresponding Author: John F. Kelly, PhD, MPH 151 Merrimac St, 6<sup>th</sup> Floor Boston, MA 02114 Email: jkelly11@mgh.harvard.edu Tel: 617-643-1980

Word Count: 3925

# ABSTRACT

## Introduction

Alcohol use disorder (AUD) remains one of the most pervasive of all psychiatric illnesses conferring a massive health and economic burden. In addition to professional treatments to address AUD, mutual-help organizations (MHOs) such as Alcoholics Anonymous (AA) and newer entities like Self-Management and Recovery Training (SMART Recovery) play increasingly important roles in many societies. While much is known about the positive effects of AA, very little is known about SMART. Hence, this study seeks to estimate real-world patterns of utilization and benefit from SMART Recovery as well as explore for whom (moderators) and how (mechanisms) SMART confers recovery benefits.

# Methods and analysis

Naturalistic, longitudinal, cohort study (N=368) of individuals with AUD recruited between February 2019-February 2022, initiating a new recovery attempt who self-select into one of four groups at study entry: 1. SMART Recovery; 2. AA; 3. SMART+AA; 4. Neither SMART nor AA; (stratified by DSM 5 severity markers), with assessments conducted at intake, and 3-, 6-, 9-, 12-, 18-, and 24-months. Primary outcomes are: Frequency of SMART and AA meetings attendance; Percent Days Abstinent (PDA) and percent days heavy drinking (PDHD). Secondary outcomes include: psychiatric distress; quality of life and functioning. Moderator variables include sex/gender; race/ethnicity; spirituality. Mediational variables include: social networks; coping skills; self-efficacy; impulsivity. Multivariable regression with propensity score matching will test for patterns of attendance and effects of participation over time on outcomes and test for mechanisms and moderators.

# Ethics and dissemination

This study is approved by the Mass General Brigham Institutional Review Board. Results will be published in peer-reviewed journals and presented conferences.

# **Registration and Funding**

This is a non-randomized, naturalistic, longitudinal, cohort study, and thus was not registered in advance. Results, therefore, should be considered exploratory. The study was funded by the US National Institute of Alcohol Abuse and Alcoholism (NIAAA; 5R01AA026288; K24AA022136).

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- The prospective naturalistic "real-world" nature of following individuals (N=368) with primary alcohol use disorder who are self-selecting into either SMART Recovery, Alcoholics Anonymous (AA), both SMART and AA, or neither, and comparing their addiction recovery outcomes over time is considered a strength of this study.
- Frequent follow-up assessments using psychometrically validated measures across a twoyear period will allow for examination of the dynamic topography of health-related behavior change and is considered a study strength.
- Multidimensional assessment of multiple clinical, public health, and public safety • outcomes will be conducted capturing a broad bandwidth of variables with relevance to a wide array of treatment and policy stakeholders and is considered a strength.
- Some limitations of the study are that research staff are not blinded to participants' selfselected recovery pathway and the use of self-report measures, despite psychometric validation, can yield social desirability and recall biases.
- Assessment data and study results rely on self-report and the majority of study assessments are conducted remotely (due to COVID-19 restrictions) without objective d is a m. validation using bioassay and is a limitation.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text

Alcohol and other drug use disorders confer a prodigious burden of disease, disability, and premature mortality in most middle- and high-income countries globally. To help alleviate this burden, most countries provide an array of professionally delivered addiction treatment services. Yet, despite these efforts, such services are often unable to meet both acute care and long-term relapse prevention needs of the millions or tens of millions affected annually. In response, most countries also possess an array of informal community-based peer recovery support services which can provide ongoing assistance for individuals suffering from these disorders [1]. The oldest and largest of these are the 12-step mutual-help organizations (MHOs), such as Alcoholics Anonymous (AA). Rigorous research evidence has now demonstrated that when AA is subjected to the same scientific standards as other addiction focused interventions it does as well on most outcomes measures, is better at sustaining abstinence and remission over time, and is highly cost effective [1].

A limitation of the current standard of care, however, borne out of a limitation in available empirical data, is the fact that referral oftentimes focuses solely on spiritually-oriented 12-step organizations, such as AA, which is the only empirically-supported MHO continuing care referral option. Not everyone chooses AA as a pathway to recovery for various reasons, and alternative MHO options - although much newer and smaller - are growing and may contain many of the same positive therapeutic elements and dynamics possessed by AA [2, 3]. These therapeutic pathways include adaptive social network changes, increases in social abstinence self-efficacy, and reducing negative affect. Indeed, some preliminary evidence suggests such organizations may confer similar benefits for those who self-select into them [4].

The largest and possibly most well-known of these newer alternative MHOs is Self-Management and Recovery Training (SMART) Recovery. There are approximately 1,200 SMART groups nationwide and another 1,000 internationally. SMART also has a strong online support presence including online meetings, forums, and chat rooms. Unlike AA, SMART is founded upon cognitive-behavioral principles and practices and is led by trained facilitators. It focuses on enhancing and maintaining motivation to abstain or (more recently) reduce use to non-problematic levels, coping with urges, problem solving, and lifestyle balance [5]. It also advocates for appropriate use of professional psychosocial and pharmacological treatments. A compelling aspect of SMART as an MHO is, because it is itself based on empirically-derived CBT principles, it provides a philosophically compatible recovery resource that is aligned with cognitive-behavioral treatment principles, which make up a large majority of national and international evidence-based treatments [6]. Consequently, SMART is appealing to many individuals with SUD [5], yet due to the lack of empirical evidence supporting its effectiveness, clinicians remain less likely to discuss or refer patients to SMART [7, 8]. This has hindered its growth and prevented many the opportunity to learn about and try SMART.

Compared to the dozens of high-quality studies examining 12-step MHOs [9-12], there have been just a handful of studies on SMART. We conducted a systematic review of this research [13] and found that only 12 studies exist (4 of which are unpublished dissertations) that have focused on SMART Recovery and used any kind of formal measurement. Most of these (8 out of the 12) are cross-sectional with mixed results and suffer from considerable biases as they possess substantial methodological limitations making it difficult to draw firm conclusions [14-16]. For instance, these studies have rarely assessed mental health status or its severity, despite the high rates of comorbidity between AUD and mental health. Two recent high-quality studies

#### **BMJ** Open

examining SMART Recovery, however, have been conducted, one in a criminal justice context, the other examining its effect on heavy alcohol use in an RCT.

The criminal justice study was a large quasi-experimental study of criminal offenders in Australia [17]. It compared a group of individuals participating in SMART Recovery and/or a criminal justice intervention (called "Getting SMART") designed to link offenders with SMART meetings following prison release, to a group of control participants who did not interact with any SMART materials or attended meetings, but who were matched on various other relevant characteristics through the use of propensity scores. The study found that participation in Getting SMART by itself, and Getting SMART + SMART Recovery meeting attendance, was associated with a reduced overall rate of reconviction with rates of reconviction reduced by 19 and 22%, respectively. For violent reconvictions, rates were reduced by 30% for Getting SMART participation and 42% for Getting SMART + SMART Recovery. While an important and promising set of results in their own right, unfortunately, the authors did not examine or report any alcohol/drug use outcomes [17].

There has been only one small, randomized trial evaluating SMART Recovery, which randomized people to (a) "Overcoming Addictions" (OA) - a SMART Recovery web application, (b) SMART Recovery meeting attendance, or (c) OA + SMART Recovery meeting attendance combined. The study found participants from all groups benefitted equally with respect to alcohol outcomes [18]. This finding underlines the promise of SMART Recovery to provide recovery support. Unfortunately, however, this trial did not include a control group, who did not have any exposure to SMART materials. Given, however, that all groups participated in SMART, it is not clear if observed benefits were simply naturally occurring improvements in alcohol outcomes, or really a function of SMART participation. Another limitation is that it only enrolled subjects with heavy drinking problems and excluded participants with more severe forms of AUD, who more typically enroll in formal treatment and are thus in need of referral options for continuing care.

A more recent study examined participation among individuals with alcohol use disorder recruited from various online and community venues with varying lengths of sobriety who self-selected into one of four different types of MHOs: Alcoholics Anonymous, LifeRing Secular Organization, SMART Recovery, and Women for Sobriety[4]. This study found that SMART Recovery participants had as good alcohol outcomes at 6- and 12-month follow-ups as those attending other MHOs. Again, however, the study did not include a control group with no MHO involvement.

These results provide some preliminary information about real-world benefits related to SMART Recovery participation. There is very little, if any, information regarding how involved they become or the mechanisms of behavior change through which SMART may help individuals attain AUD remission and recovery (e.g., via social changes, coping skills, recovery motivation, abstinence self-efficacy; reduced impulsivity). SMART has the potential to be a secular MHO alternative to 12-step MHOs for those preferring the secular and cognitivebehavioral foundation of SMART, yet in order to increase clinical confidence and referrals, more systematic research is needed. This study will be one of the first rigorous, real-world, evaluations of SMART providing objective estimates of recovery benefit (e.g., abstinence, AUD remission, quality of life, psychosocial functioning), and will explore the mechanisms (e.g., social network changes, self-efficacy, decreased impulsivity) and moderators (e.g., sex, race/ethnicity, addiction severity, psychiatric co-morbidity) of behavior change to determine how SMART Recovery may help its affiliates achieve and maintain remission from addiction and who seems to benefit most. To this end this study has the following specific aims: 1. Characterize and describe professional and non-professional recovery support service participation choices, migrations, and pathways using group trajectory analyses over a two-year period for individuals (N=368) starting a new AUD recovery attempt. More specifically in this regard, we will investigate the real-world effectiveness of SMART Recovery by comparing outcomes of AUD individuals making a new recovery attempt (N=368) pursuing either a SMART Recovery pathway (online or face-to-face; N=184) or a non-SMART recovery pathway (N=184). Because, according to SMART Recovery's annual survey data, roughly half of SMART participants also attend AA, we will use a stratified design to enroll persons with AUD making naturally occurring continuing care choices vis-à-vis participation in MHOs in a balanced fashion and follow them prospectively across a 24-month period. Of note, self-selection of treatment/recovery pathway options has been shown to potentially enhance outcomes. This will be explored in this study as well. This stratified design will allow us to compare the outcomes of persons choosing to participate in SMART Recovery vs. not (balanced by AUD severity), while accounting for simultaneous choices regarding AA or neither AA or SMART MHO participation. 2: Explore moderators and mechanisms of behavior change. Exploration of factors that may help uncover who (i.e., moderators) and why (i.e., mechanisms) SMART affiliates benefit from participation will be investigated. Moderators will include sex and gender, addiction severity, psychiatric distress; and mechanisms will include social network changes, recovery motivation, cognitive-behavioral coping, abstinence self-efficacy, and impulsivity.

## **METHODS AND ANALYSIS**

#### Study overview

This study is a naturalistic, prospective, longitudinal cohort study of 368 individuals making a new recovery attempt from AUD with seven assessments over a 24-month follow-up period. Following the baseline assessment, research staff will conduct additional follow-up assessments at 3, 6, 9, 12, 18, and 24 months after study enrollment. Assessments include both self-reports by participants using online surveys, and staff-administered assessments, conducted via phone and/or Zoom. Baseline visits were conducted from February 2019 to February 2022. Follow-up visits are ongoing and will continue until approximately February 2024. All study procedures are approved by the Institutional Review Board of Mass General Brigham (approval number: 2017P002029). Written consent was received from all participants following an explanation of the study, including confidentiality and freedom of choice to participate.

#### Sample size determination

The primary outcome variables are percent days abstinence (PDA) and percent days heavy drinking (PDHD; NIAAA-defined). Secondary outcomes include quality of life and psychosocial functioning. To estimate a plausible effect size to be expected in PDA as a function of mutual help organization (MHO) utilization, we examined the PDA outcomes in Project MATCH [19] for persons utilizing AA vs. not. Effects were surprisingly consistent across time, with patients with any AA utilization reporting a higher average number of PDA than patients with no AA involvement (d=0.45, 0.39, 0.38, 0.42, and 0.39 at 3-, 6-, 9-, 12- and 15-month follow-up respectively). Thus, conservatively, we are powering this study to detect an effect size of d=0.35. Using SAS proc power we determined that n=130 per group are necessary to detect d=0.35, leading to a combined sample size of n=260 (equally balanced, due to stratification, in

#### **BMJ** Open

terms of AA utilization and addiction severity). With a conservatively estimated retention rate of 75%, we would need to enroll n=347 to retain n=260. Given our stratified design (i.e., 2 [SMART vs. not] x 2 [12-step vs. not] x 3 [mild vs. moderate vs. severe AUD] design = 12 stratification cells), we proposed to enroll a final sample size of n=348 (i.e., n=29 per cell). In addition, 20 further participants were enrolled to increase representation of individuals attending SMART Recovery and to account for participants who withdrew, were terminated from the study, were found ineligible, or were otherwise no longer participating (e.g., death unrelated to the study).

Using this design, we will be equally well powered to test the main effect of 12-step participation. In terms of conducting pair-wise comparisons between the four possible combinations of using SMART Recovery and/or 12-Step, this sample size would enable us to detect pairwise differences of medium effect size (d=0.50). Improvements over our conservatively estimated retention rate would increase power (e.g., could detect d=0.46 with 85% retention).

#### Recruitment

Participants were recruited through SMART Recovery meetings, inpatient and outpatient treatment programs, and a variety of commercial recruitment sources during the recruitment period (January 2019 to January 2022).

Flyers and postcards for the study were distributed around buildings of Massachusetts General Hospital, particular around inpatient and outpatient SUD clinics. SMART facilitators were asked to advertise the study at SMART meetings and were provided with recruitment postcards and flyers. The study was also advertised on the SMART San Diego website. Additional recruitment methods included ResearchMatch, PeRC, TrialFacts, Rally for Recruitment, the Metro Newspaper, radio advertisements, MBTA advertisement, Facebook, Craigslist, and Reddit. For radio, MBTA, Facebook, and Craigslist advertisements, this study was advertised along with another ongoing R01 study of individuals making a new recovery attempt from AUD with similar eligibility criteria. Monthly meetings were also held with regional SMART Recovery MHO group facilitators to provide them with updates and inquire if there was anything we could provide to help facilitate study recruitment from online SMART resources or SMART meetings.

Interested individuals called the study-specific phone line, emailed the study-specific email address, or filled out an online screening form. Individuals were then able to participate in a brief 10–15-minute phone screen, during which eligibility criteria were confirmed (see Supplementary materials for a copy of Eligibility Screen). If the individual was eligible to participate, the baseline visit was scheduled and contact information for two locator contacts who can assist research staff in locating participants was collected.

**Consent Process:** Participants completed the consent process with a trained study staff member and were encouraged to ask questions about any aspect of the study. Through this process, participants were informed about the nature and extent of the study duration and procedures including the types of assessments administered, the risks and benefits of participation, as well as the financial renumeration schedule and protocol, and given telephone and email contact information in order to contact study staff at any time during the course of the study (see Consent Form in Supplementary Materials section for more details).

#### Eligibility

-----

Participants were required to be 18 years or older, living in the New England or San Diego metropolitan area, and willing to travel to Boston, Massachusetts, to complete study visits (for New England residents) or to complete study visits remotely (due to COVID-19 and for the San Diego participants). The geographical catchment area eligibility criteria were expanded to include people from the San Diego area in December 2020 to increase the number of SMART participants in the study. Since all visits were conducted remotely beginning in March 2020 due to the COVID-19 pandemic, participants from the New England area would also be considered eligible even if they could not travel to the Boston office for assessments in the foreseeable future.

Participants could be using other drugs but had to report alcohol as their primary substance of concern; they were also required to have a self-perceived alcohol problem, to meet current criteria for DSM 5 alcohol use disorder (AUD) using semi-structured interview; to have consumed alcohol in the past 90 days and report currently engaged in a new recovery attempt defined as "a serious effort to abstain from drinking or to drink without problems in the past 90 days or planning to make one in the next 14 days."

Additionally, participants were required to provide locator contact information for two close friends/family members in case we were unable to contact the participant directly; provide their social security number for reimbursement or be willing to not receive reimbursement; provide a urine sample and breathalyzer (for in-person visits) or remote saliva test (for remote visits) for biochemical verification; and provide a stable home address and contact information. These initial bioassay requirements were not required following the start of COVID-19 lock-downs which began in March 2020.

#### Methods

All assessments were initially conducted (prior to COVID) with a study research coordinator in person at our downtown Boston offices at the MGH Recovery Research Institute. Each assessment consisted of staff-administered and self-administered surveys, which were completed via REDCap (a secure, web-based application designed to support data capture for research studies), a computerized task to assess impulsivity (Go/No-Go task), and biochemical verification tests of abstinence (breathalyzer, urine) for all participants at all time points. For in person visits, the baseline and follow-up assessments lasted for approximately 3 hours. At the end of the first visit and every follow-up visit, the next follow-up was scheduled.

Due to the COVID-19 pandemic, all assessments were transitioned to be conducted remotely beginning in March 2020. During remote visits, the computerized task and urine and breath biochemical verifications of abstinence were not completed. A web-based version of the computerized task was tested, but the effects of internet speed on results made data unreliable. In lieu of the urine and breathalyzer tests, saliva tests were implemented for remote visits from March 2021 to May 2021 but were discontinued due to documented inconsistent results. Relative to in-person assessments, remote assessments were shorter with assessments lasting approximately 1.5 hours (for baseline) or 45 minutes (for follow-ups) on the phone and approximately 1 hour for participants to complete surveys individually.

All participants (in-person and remote) agreed to provide their phone numbers and email information and that of two locator contacts so that they may be contacted for follow-up assessment reminders. Research staff contacted and confirmed the contact information of the locator contacts as needed if research staff loses touch with the participant. Participants indicated their preferred method of contact (phone call, email, or text message) for receiving automated

#### **BMJ** Open

reminders throughout the project period. In keeping with a validated research follow-up protocol for maximizing retention in clinical addiction research, after the baseline assessment, research staff proactively reached out to participants for reminders and to check if there were any changes to their contact information. Check-ins occurred 1 month, 14 days, 7 days, and 24 hours before the next scheduled visit. These messages are automated and sent with Twilio, which is an approved REDCap module by Mass General Brigham. Participants are compensated \$45 for completing the baseline visit and \$55, \$60, \$65, \$70, \$75, and \$85 for completing the 3-, 6-, 9-, 12-, 18-, and 24-month follow-up visits, respectively. Payment for each timepoint is broken up into payment for the staff-administered surveys, self-administered surveys, and travel reimbursement. During remote visits due to COVID-19, all participants were still paid the travel reimbursement to maintain the same payment structure used for in-person assessments.

#### Measures

Staff-administered measures assess the following: substance use history including capture of primary outcomes (percent days of heavy drinking; percent days abstinent from alcohol/other drugs), AUD and SUD status and severity (including remission status), tobacco use, treatment utilization for physical health problems and alcohol/drug use problems, anti-craving and anti-relapse medications (alcohol and opioids), mental and emotional health diagnoses, hospitalizations, treatment history, and psychiatric medication use, social networks, 12-step/MHO attendance history, online resource utilization, SMART involvement, 12-step MHO involvement (MM-HAS), recovery/abstinence time, recovery support services and formal treatment program utilization, substance use change over the past year (YES), impulsivity (Go/No-go cognitive task), and biochemical verification of substance use (breathalyzer, urine drug screen).

Self-administered measures assess the following: demographics, criminal justice involvement, religiosity and spirituality (RBBS, religious and spiritual intensity, DSES), stress and psychiatric distress (PSS-4, K6), coping (CSS), self-efficacy (A-DSES-20, single item selfefficacy), alcohol/other drug craving (PADCS-5), commitment to sobriety (CSS-5), substance use consequences (SIP-2R), recovery status (questions about recovery, drinking goal), recovery capital (BARC-10), behavioral addictions, medical marijuana use, medication attitudes, impulsive behavior (SUPPS-S), quality of life and psychosocial functioning (TPS, Q-LES-Q, EQ5D3L, EUROHIS-QOL, self-esteem, happiness, and satisfaction with life), and physical health (PSQI, pain VAS, IPAQ, meals).

All measures were administered at each timepoint except for the Year End Summary (YES), SUD DART, and Questions about Recovery, which were administered at baseline, 12-months, and 24-months. Detailed descriptions of measures are available in Supplement 1.

#### **COVID-19** impact

The COVID-19 pandemic significantly affected the conduct of study assessments as all assessments were transitioned to fully remote visits beginning in March 2020. As previously noted, this shift to remote assessments meant that we were unable to conduct the Go/No-go cognitive measure, breathalyzer, or urine screen. Due to these changes, all substance use outcomes are self-reported. Self-administered saliva tests were used briefly as a replacement, but inconsistent results (e.g., false negatives, partial results, no results) made data collected from these tests unreliable and this strategy was stopped.

Additionally, recruitment was halted as the study team transitioned to remote assessments and many previous recruitment methods were no longer viable (e.g., recruitment from outpatient clinics, advertisements on Boston area trains). It was particularly challenging to recruit individuals attending SMART as meetings were halted, then moved to virtual-only. To address these challenges, we expanded the recruitment area to San Diego, where there is a large SMART Recovery MHO participation community. We also maintained contact with SMART facilitators throughout the recruitment period to encourage them to share the study with meeting attendees and solicit feedback on how to best improve recruitment of SMART participants.

To capture potential changes in recovery resource utilization due to the COVID-19 pandemic, we added a staff-administered measure related to use of online recovery resources and social network site use. In addition, a supplemental study focusing on the impact of COVID-19 was conducted, consisting of both quantitative measures and a qualitative interview with a sub-group (n=80) of study participants selected at random from the SMART, AA, SMART+AA, and neither cohorts (n=20 from each group).

# Limitations

The study employs a cohort based, naturalistic, non-randomised, design and research staff are not blinded to participants' self-selected recovery pathways. The use of self-report measures, despite having good psychometric properties and adequate validation, can still yield social desirability and memory recall biases.

# Patient and public involvement

No patient or public involvement.

# Data analysis plan

<u>Aim 1 Effectiveness</u>. We will use multiple linear regression analyses to determine whether our primary stratification factor of interest (predictor: SMART vs. no SMART) is associated with alcohol outcomes (primary dependent variables: PDA; PDHD) at 24-month (primary end-point), and 3-, 6-, 9-, 12- and 18-month (secondary) follow-ups, while controlling for other confounding variables (e.g., baseline variation in levels of the outcome variables) and by using propensity score matching methods that we have used successfully in prior work. We will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity. We will also test longitudinal models to investigate the dynamic relationship of these various recovery pathways over time (e.g., using hierarchical linear modeling as we have done previously [20]) controlling for baseline variation in the outcome variables.

<u>Aim 2a. Mechanisms and Moderators</u>. We will use mediational modeling, using the product-ofcoefficients approach [21, 22] to test how SMART Recovery confers benefit (or fails to do so). The independent variable will be stratification group (i.e., SMART vs. no SMART), and the outcome variables will be PDA (primary), PDHD, AUD remission, quality of life, and measures of psychosocial functioning. The mediators will be our theorized mechanisms of change (e.g., social network changes, recovery motivation, coping, self-efficacy, impulsivity), which we will quantify as change since baseline in these constructs as measured via REDCap administered scales prior to the outcome (e.g., change in craving observed from baseline to 3-month would be

used to predict 6-month ultimate outcomes). We will use multiple mediation to determine the relative impact of each mechanism, and moderated multiple mediation to identify differences in mechanisms across (moderator) subgroups (e.g., males vs. females, severe AUD addiction severity vs. moderate/mild), similar to our prior approach in delineating mechanisms of behavior change in AA [23-25].

<u>Aim 2b. Dose-response relationship of SMART Recovery</u>. Using only data from participants in the stratified SMART group, we will use linear regression (primary outcome: PDA) to test if the level of SMART involvement, as measured by the SMART Involvement Scale, is related to PDA at 24-month (primary endpoint) and other follow-up points over time. We will use basic model building practices to determine if such an effect persists after accounting for demographics, other important contextual variables, moderators, and baseline levels of the theorized mechanisms of change. In follow-up analyses, we will conduct this analysis separately for participants in the stratified AA vs. no AA groups, so as to test specifically if the effect exists both within and outside of the context of simultaneously seeking help via AA. Similarly, we will repeat analyses within strata of AUD severity.

<u>Multiple Testing</u>. We will use the false recovery rate adjustment [26] to control for multiple testing.

<u>Missing Data.</u> Some data will inevitably be missing. We will explore patterns of missingness to determine if missingness is occurring at random (MAR) (i.e., unrelated to the value of the missing observation) or likely to be missing not at random (MNAR). For each analysis, we will use a variety of recommended strategies to address the issue of missing data (e.g., multiple imputation, maximum likelihood estimation)[27]. Consistency in findings across missing data methods will enhance our confidence in the findings. Note that study participation will be completely separate from SMART participation; thus, participants should feel comfortable remaining in the study regardless of whether they continue in SMART or not. Assuming some attrition, we plan to conduct analyses examining predictors of attrition and control for these.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de

Enseignement Superieur

(ABES)

ata mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

# ETHICS AND DISSEMINATION

All study procedures are approved by the Institutional Review Board of Mass General Brigham (approval number: 2017P002029). Written consent was received from all participants following an explanation of the study, including confidentiality and freedom of choice to participate. Results will be published in relevant peer-reviewed scientific journals and presented at conferences.

to beet terien only

# **AUTHORS' CONTRIBUTIONS**

JK developed the idea and conceptualized the study design and led the writing of the manuscript. SL contributed to conducting the study and writing the manuscript. BH contributed to study design and development and statistical analysis as well as reviewing and editing final versions of the manuscript.

# **FUNDING STATEMENT**

This study is supported by NIAAA grant number 5R01AA026288 (Kelly, John F), the Massachusetts General Hospital Recovery Research Institute, and NIAAA grant number K24AA022136 (Kelly, John F).

# **COMPETING INTERESTS STATEMENT** ERES

None declared.

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de

Enseignement Superieur

(ABES

Protected by copyright, including for uses related to text

# REFERENCES

1. Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. *Cochrane Database Syst Rev.* 2020;3(3):Cd012880.

2. Kelly JF. Is Alcoholics Anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research. *Addiction*. 2017;112(6):929-36.

3. Kelly JF, Magill M, Stout RL. How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. *Addiction Research & Theory*. 2009;17(3):236-59.

4. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD. *J Subst Abuse Treat*. 2018;88:18-26.

5. Horvath AT, Yeterian JD. SMART Recovery: Self-empowering, science-based recovery support. *Journal of Groups in Addiction and Recovery*. 2013.

6. Roman PM, Johnson JA. National Treatment Center Study Summary Report: Private Treatment Centers. Athens, GA: Institute for Behavioral Research, University of Georgia; 2004.

7. Fenster J. Characteristics of clinicians likely to refer clients to 12-Step programs versus a diversity of post-treatment options. *Drug Alcohol Depend*. 2006;83(3):238-46.

8. Kelly JF, Stout R, Zywiak W, Schneider R. A 3-year study of addiction mutual-help group participation following intensive outpatient treatment. *Alcoholism: Clinical and Experimental Research* 2006;30(8):1381-92.

9. Emrick CD, Tonigan JS, Montgomery H, Little L. Alcoholics Anonymous: What is currently known? *Research on Alcoholics Anonymous: Opportunities and Alternatives* 1993:41-76.

10. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. *J Addict Dis*. 2009;28(2):145-57.

11. Kelly JF. Mutual-help for substance use disorders: History, effectiveness, knowledge gaps & research opportunities. *Clinical Psychology Review*. 2003;23(5):639-63.

12. Kelly JF, Yeterian JD. Empirical awakening: the new science on mutual help and implications for cost containment under health care reform. *Subst Abus*. 2012;33(2):85-91.

13. Beck AK, Forbes E, Baker AL, Kelly PJ, Deane FP, Shakeshaft A, et al. Systematic review of SMART Recovery: Outcomes, process variables, and implications for research. *Psychol Addict Behav.* 2017;31(1):1-20.

14. Atkins RG, Jr., Hawdon JE. Religiosity and participation in mutual-aid support groups for addiction. *J Subst Abuse Treat*. 2007;33(3):321-31.

15. Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: twelve-step and selfmanagement and recovery training. *The American journal of drug and alcohol abuse*. 2003;29(2):359-83.

16. MacGregor S, Herring R. The alcohol concern SMART Recovery pilot project final evaluation report. Middlesex University Drug and Alcohol Research Group; 2010.

17. Blatch C, O'Sullivan K, Delaney JJ, Doorn Gv, Sweller T. Evaluation of an Australian domestic abuse program for offending males. *Journal of Aggression, Conflict and Peace Research*. 2016;8(1):4-20.

18. Hester RK, Lenberg KL, Campbell W, Delaney HD. Overcoming Addictions, a Webbased application, and SMART Recovery, an online and in-person mutual help group for

problem drinkers, part 1: three-month outcomes of a randomized controlled trial. *J Med Internet Res.* 2013;15(7):e134.

 Project MATCH Research Group. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. *J Stud Alcohol.* 1997;58(1):7-29.

20. Kelly JF, Stout RL, Magill M, Tonigan JS, Pagano ME. Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change. *Alcohol Clin Exp Res.* 2011;35(3):454-63.

21. Sobell ME. Asymptotic confidence intervals for indirect effects in structural equations models. In: Leinhart S, editor. Sociological Methodology. San Francisco, CA: Jossey-Bass; 1982. p. 290–312.

22. Sobell ME. Some new results on indirect effects and their standard errors in covariance structure models. In: Tuma N, editor. Sociological Methodology. Washington, DC: American Sociological Association; 1986. p. 159–86.

23. Hoeppner BB, Hoeppner SS, Kelly JF. Do young people benefit from AA as much, and in the same ways, as adult aged 30+? A moderated multiple mediation analysis. *Drug Alcohol Depend*. 2014;143:181-8.

24. Kelly JF, Hoeppner B, Stout RL, Pagano M. Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis. *Addiction*. 2012;107(2):289-99.

25. Kelly JF, Hoeppner BB. Does Alcoholics Anonymous work differently for men and women? A moderated multiple-mediation analysis in a large clinical sample. *Drug Alcohol Depend*. 2013;130(1-3):186-93.

26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B* (*Methodological*). 1995;57(1):289-300.

27. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychol Methods*. 2002;7(2):147-77.

Page 16 of 46

BMJ Open

			BN
1			2
2			Ope
<u>г</u> З г			č
4			firs
5	Research Staff conducting the screen:		
6	Thank you for your interest in our research		ub
7	study. My name is [RC NAME] and I am a		Ish
8	research coordinator at the Recovery Research	⊔ Yes	ed
9	Institute within the Department of Psychiatry at	$\Box$ No	as
10	the Massachusetts General Hospital. Is this a		ਤੂ ਹੈ
11	good time for you to talk about the study?		
12	[IF NO] What time would be good for me to		361
13	give you more information about the study and		ju p
14	do a short phone screen to see if you are	Date: [MM/DD/YYYY]	y p
15	eligible?		cop P-
16			Ý Ż
1/	I appreciate your time. Have a great day.		ghi 23
10	[IF YES] I am going to ask you a series of		1, in
20	questions to determine if you are eligible to		
20	participate in this study. Some of these		idir
21	questions may not apply to you, but please		ng 13
23	answer them to the best of your ability.		° Fe
24			
25	At the end of the screen, I will tell you if you		nse Ps r
26	are eligible to participate or if you have been	□ Yes	elan 7
27	found ineligible. In order to protect the integrity	□ No	iter
28	of the study, if you are found ineligible, I will		
29	unfortunately not be able to tell you the specific		test
30	reason why you were found ineligible to		t a log
31	participate.		nd
32			da ur da
33	Knowing this, do you agree to proceed to screen		a r
34	for the study?		
35		□ Twitter	ing
30 27		□ Facebook	, A
32		□ RRI Website	특 클
30		□ Flyer	aini
40		□ RSVP for Health	ng
41		□ Word of Mouth	ar 📜
42	[IF YES] Okay great! First, may I ask how you	□ SMART Meeting	iq S
43	heard about the study?	Craigslist	sim 📍
44		$\square$ Metro	ilar
45		$\square$ MBTA	te
46		$\square$ West End Clinic	chr
47		$\Box  ADMS$	10k
48		$\Box  \text{ARIVIS}$	ği 202
49		$\Box  \text{Did not specify}$	8. 10 a
50			T A
51	[IF OTHER] what was the other source from		ge
52	which you heard about this study?		nge
53 54	[IF FLYER] Where did you get the flyer from?		ğ
54	· · ·	$\Box$ New England (MA NH DI etc.)	
56	Where are you located?	$\Box = \frac{\text{NGW Eligialiu (MA, NH, KI, Clc.)}}{\text{California}}$	ogr
57	Where are you located?	$\Box  \underline{Camorina}$	apl
58	IE OTHED If located anticide of New Prod	Colifornia NOT ELICIDI E to posticizato (De net stan server e 1 t	- pir
59	IF OTHER I TOCATED OUTSIDE OF NEW England of	complete to participate [Do not stop screen, complete	ue
60	<u>For peer review only - h</u>	ttp://bmjopen.bmj.com/site/about/guidelines.xhtml	de

			BM
1			J D
2			ben
5 1	Great! Let me tell you a little bit about our		
† 5	study, so you can decide if this is something		stp
5	you'd like to participate in.		an
7			ISN
3	I he study is funded by the National Institutes of		ed
)	nearly to learn more about the unificient		se
10	individuals may use to overcome an alcohol		
11 12	problem. We hope this study will help advance		130
13	treatment and recovery support service options.		
14			njo
15	If you decide to take part in the study, your	$\Box$ Yes, remains interested	22 pen
16	participation would include 7 visits to our	□ No longer interested	
17	Boston office over the course of 2 years. During		22-
10 10	each visit, you would complete a series of		- in 000
20	questionnaires, computerized tasks, and		268
21	includes a urine sample and broathaluzar tast		n on
22	the event that your visits will take place		- 3 F
23	remotely (e.g., over the phone or zoom), study		- epi
24	procedures are similar; however, you would		ruai Ens
25 26	complete a self-administered saliva test that is		, eig
20 27	mailed to you in advance. Each visit will take		nen
28	approximately 3 hours. How does that sound so		inen :
29	far?		
30	[IF NO LONGER INTERESTED] Thank you ver	y much for your time, we understand that this study is not for everyone and a	
31 22	STOP SCREEN		rieu
33	STOT SCILLIN		5 (A
34	[IF REMAINS INTERESTED] Great. Before I		3.83
35	can enroll you in this study, I need to ask you		S S S
36	some questions to make sure you are eligible.	, i i i i i i i i i i i i i i i i i i i	
37 28	These questions are about your health and		ĘĘ
39	medical history, including your alcohol use, and		
40	Some of the questions may make you feel	ng,	3 5
41	uncomfortable. You may stop at any time. Does	and	, <mark>1</mark>
42	that sound okay?		2
+3 1∧	-	$\Box$ Yes	
1 <del>-1</del> 15	I will record your answers in writing, but only		- Ju
46	collect detailed contact information if you		ne مہر
47	quality for the study and want to schedule an in-		<u>,</u> 3
18 10	person visit. As a reminder, collected		202
49 50	protected. There is always risk of loss of	Ň.	, o ai
51	confidentiality but we will take appropriate		- Ag
52	responsible steps to ensure confidentiality. Okav		Jen
53	to begin?		ce r
54	·		3101
55	[IF NO] Thank you very much for your time, we	understand that this study is not for everyone and we appreciate your interest.	Iog
50	STOP SCREEN		rapi
58	HE VESI		
59	[IF I E3] [ns name] could you please verify the spelling .		le a
		atto://pm/opon.bm/.com/sito/about/gu/dol/pos.yhtml	-

Page 18 of 46

1			
2			opper er
3 4	How old are you?		
5 5	Research Staff Use: Is the participant older than 18?		Yes Provide the Second Se
7 8	STOP SCREEN. If under 18, NOT ELIGIBLE to p	participa	e. e
9 10 11	[IF INELIGIBLE] Thank you, [es_name]. Unfortu participate in future research studies. If you are int information and reach out to you with future study	nately, y erested i	ou are not eligible to participate in our study. You may be eligible to participate in our study. You may be eligible to participating in future research studies, we can take your contact of the nities.
13	[IF FROM NEW ENGLAND] Are you willing		Yes <b>E</b>
14	to travel to Boston to complete study visits?		No by op
15 16	[IF NO OR FROM CALIFORNIA] Are you		Yes
17	willing to conduct all visits remotely (e.g. over		
18	IF NOI If unwilling to travel to Boston for the res	earch str	dy and unwilling to conduct visits remotely. NOT FLIGIBLE to
19	participate [Do not stop screen complete screen in	n its entir	rety]
20	paraelparel (20 hot stop serven, comprete serven h	i its cittai	
21 วา	Is there any reason that you would not be living		Yes
22 23	in the Boston area within the next 2 years?		No for the
24	[IF YES] Would you be willing to conduct		
25	visits remotely if you were no longer in the		
26	Boston area?		
27			
28	[IF NO] If participant will not be in Boston for the	next 2 y	ears and is not willing to conduct visits remotely, NOT ELIGIBLE
29 20	participate. [Do not stop screen, complete screen in	n its entii	ety]
31	A reason willing to give up the contest		aperid
32	information for two of your friends or family		d a cr
33	members so that we can reach out to them in		
34	case we lost contact with you?		
35 26	2		
30 37	We ask for this information because obtaining		res
38	complete data from you is very important to the		
39	study. The last study visit will take place 2 years		inir e
40	from the time of your baseline visit. We want to		, jū
41	make sure we can reach you to complete your		and
42 42			si s
43 44	[IF NO] If they aren't willing to provide collateral	contacts	NOT FLIGIBLE to participate [Do not stop screen complete screen]
45	in its entirety]	contacts	
46			chr chr
47	Are you willing to provide your SSN in order to		
48	receive reimbursement?		ygie Zozz
49 50			ў. э . а
50	(If asked for more information: If payments to		Yes, I am willing to provide my SSN to receive the study navment.
52	you are \$600 or greater in a calendar year,		No. I am not willing to provide my SSN: however, I still wish to
53	Farmers will report this to the Internal Revenue	_	participate in this study. I understand that I will not receive payments
54	income form and Partners will use your SSN for		for being in this study unless I provide my SSN.
55	this tax-related nurnose		No, I am not willing to provide my SSN and decline to participate in
56 57	πω ταπτετατία μπρόδε.		this study.
י 58	If you do not provide your SSN. we cannot issue		
59	you a payment for participation. You may still		ue e
60	choose to participate in this soudy and dewinely - h	ttp://bmj	ppen.bmj.com/site/about/guidelines.xhtml
	reimbursement).		

		BMJ
1 ว		Ope
2 3		n: T
4		Irst
5		bud
5 7	[IF NO] If unwilling to provide SSN and decline to participate in the study, NOT ELIGIBLE to participate [Do not stop screen,	SIIC
3	complete screen in its entirety]	led
9		as
10 11	During assessments, are you willing to provide	0.1
11 12	for biochemical verification? Or in the event	136
13	that your visit takes place remotely, are you	/bn
14	willing to provide a self-administered saliva test	lofi
15	with study staff guidance? This test would be	)en-
16 17	mailed to your current address before the study	202
17 18	visit and can be disposed of after use.	2-0
19	Although you do not need to abstiment to $\Box$ No.	899
20	participate in this study we ask that participants	98
21	not drink or use drugs before coming in for their	on a
22 23	assessment or before completing their remote	Fe
23 24	assessment. If the breathalyzer test or saliva test	Ē
25	indicates that you are under the influence of	ary ısei
26	alcohol when you come in for your assessment	ane 202
27 20	to re-schedule the visit	9me
20 29		₽ov
30	[IF NO] If unwilling to participate in biochemical verification, NOT ELIGIBLE to participate [Do not stop screen, complete	olu,
31	screen in its entirety]	ade
32 22		
34	Do you have a stable home address and contact	ABE
35		S
36	IF NOI If participant does not have a stable home address and/or contact information. NOT ELIGIBLE to participate[Do not	, .//p
37 38	stop screen, complete screen in its entirety]	mjo
39		per
40	Have you consumed alcohol in the past 3	ı.bn
41	months?	J.q
42 43	IE NOLE norticipant has not commend clockel in most 2 months NOT ELICIPLE to participate [Do not stop completed]	) M
13 44	screen in its entirety]	° n
45		Jun
46	Provide a la construction de la Yes	e 1
47 18	Do you think you have a problem with alcohol? $\Box$ No	3, Z
19	ies die state die st	025
50	[IF NO] If participant does not think they have a problem with alcohol, NOT ELIGIBLE to participant [Do not stop screen,	at 7
51	complete screen in its entirety]	\ge
52 53	In the past 12 months, have you:	nce
55 54	$\square$ Had times when you ended up drinking more or longer than you	Blo
55	intended?	<b>j</b> olio
56	[IF YES] I'm going to ask you a series of guestions shout your elected use during the past More than once wanted to cut down or stop drinking, or tried to, but	Jrap
57 50	12 months couldn't?	shiq
59	□ Spent a lot of time drinking? Or being sick or getting over other	ue
50	For peer review only - http://bmjoffere.ff9Ct8m/site/about/guidelines.xhtml	del

1 2				BMJ Ope
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 21 22 23			Found that drinking – or being sick from drinking – often interfere with taking care of your home or family? Or caused job troubles? school problems? Continued to drink even though it was causing trouble with your family or friends? Given up or cut back on activities that were important or interestin to you, or gave you pleasure, in order to drink? More than once gotten into situations while or after drinking that increased your chances of getting hurt (such as driving, swimming using machinery, walking in a dangerous area, or having unsafe se Continued to drink even though it was making you feel depressed anxious or adding to another health problem? Or after having had, memory blackout? Had to drink much more than you once did to get the effect you want? Or found that your usual number of drinks had much less ef than before? Found that when the effects of alcohol were wearing off, you had withdrawal symptoms, such as trouble sleeping, shakiness, restlessness, nausea, sweating, a racing heart, or a seizure? Or sente	penrfirst published as 10.1136/bmjopen-2022-066898 on 3 Feb 것 이 왜 Protecteokbycopyright,and no go
24 25 26 27	Number of AUD criteria met:	[Total 1	things that were not there?	ruary 2023. E Enseigneme Ises related t
29 30 31 32	AUD Severity:		Does not meet criteria for AUD (0-1 symptoms) Mild (2-3 symptoms) Moderate (4-5 symptoms) Severe (6+ symptoms)	bownloaded ht Superieur o text and da
33 34 35 36	[IF DO NOT MEET CRITERIA FOR AUD] Does ELIGIBLE to participate. [Do not stop screen, con	s not me nplete so	et sufficient criteria for AUD diagnosis (0 or 1 AUD criterion), NO creen in its entirety]	irom http://b (ABES) . ta r <del>hi</del> ning, <i>Α</i>
37 38 39	Meet sufficient criteria for AUD diagnosis (2+ AU	JD criter	ria = mild, moderate, or severe).	mjopen. Il trainin
40 41 42 43 44	Are you currently making a new recovery attempt, that is, a serious effort to abstain from drinking or to drink without problems?		Yes No	bmj.com/ on 1. and simila
45 46 47	(IF YES) When did you start this attempt?	Date: [ Days si	MM/DD/YYYY] ince new recovery attempt began:	r technol
48 49 50	Has the participant's new recovery attempt begun within the past 90 days?		Yes down	2025 at ogies.
51 52 53 54	[IF NO, > 90 DAYS] If recovery attempt started m complete screen in its entirety]	nore that	n 90 days ago, NOT ELIGIBLE to participate. [Do not stop screen,	Agence Bibl
55 56 57 58 59 60	(IF NO, NOT CURRENTLY MAKING A NEW RECOVERY ATTEMPT) Are you planning to make a new recovery attempt or serious effort to abstain from drinking or to drink without problems?view only - h	  ttp://bm	Yes No jopen.bmj.com/site/about/guidelines.xhtml	lographique de l

1 2 3 4			
55	[IF NO] If not planning to make a new recovery a its entirety]	ttempt, NOT ELIGIBLE to participate. [Do not stop screen, complete scree	n in trouble
3 9 10 11	(IF YES) When will you start?	Date: [MM/DD/YYYY] Days until new recovery attempt begins: (Must be less than 14 days away)	ned as iu.ii.
2  3  4  5	Is the participant's new recovery attempt beginning in the next 14 days?	<ul><li>Yes</li><li>No</li></ul>	cted by cop
7 8 9 20	[IF NO] If not planning to make a new recovery a not stop screen, complete screen in its entirety]	ttempt either at all OR within next 14 days, NOT ELIGIBLE to participate	נעבב-עשטאשס vrig∰, incluc
21 22 23 24	Is alcohol the primary substance from which you are seeking recovery?	□ Yes □ No	on 3 Februar Ens ling for uses
	(IF NO) What is the primary substance from which you are seeking recovery?	<ul> <li>Marijuana</li> <li>Cocaine (coke, crack, freebase)</li> <li>Heroin</li> <li>Methadone</li> <li>Suboxone/Subutex/Buprenorphine</li> <li>Other opioids (e.g. prescription opioids)</li> <li>Hallucinogens</li> <li>Synthetic Marijuana / Synthetic Drugs</li> <li>Amphetamine (uppers)</li> <li>Methamphetamine (crank, meth, crystal)</li> <li>Benzodiazepines (sedatives/tranquilizers)</li> <li>Barbiturates (downers)</li> <li>Inhalants</li> <li>Steroids</li> <li>Other substance (not specified above) [please specify:]</li> </ul>	ry 2023. Downloaded from http://pmjopen.brij.com eignement Superieur (ABES) . related to text and data mining, Al training, and sin
14 15 16	[IF PRIMARY SUBSTANCE NOT ALCOHOL] ELIGIBLE to participate [Do not stop screen, con	Report their primary substance. If alcohol is not primary substance, NOT plete screen in its entirety]	nilar techno
890123456	Have you participated in any of the following mutual-help organizations in the past 30 days?	<ul> <li>Alcoholics Anonymous</li> <li>Narcotics Anonymous</li> <li>Other 12-Step Fellowship</li> <li>SMART Recovery</li> <li>Other mutual-help organization</li> <li>None of the above</li> <li>If other, please specify:</li> </ul>	logies.
57 58 59 50	Are you planning to participate in SMART Recovery during this recovery attempt or serious effort? For peer review only - h	□ Yes □ No ttp://bmjopen.bmj.com/site/about/guidelines.xhtml	apnique de i

				BMJ
1 2				Op∈
2 3 4 5 6 7	(IF YES) How will you participate in SMART Recovery?		In-person meetings only In-person meetings and online Online only	en <mark>: first publis</mark>
7 8 9 10 11	Are you planning to participate in Alcoholics Anonymous during this recovery attempt or serious effort?		Yes No	med as 10.113
12 13 14 15 16-	[IF NO PARTICIPATION IN SMART OR AA A SMART and/or AA in the past 30 days and does n	ND NO iot plan	PLANNED PARTICIPATION] If participant has not participated in to participate in SMART and/or AA, NOT ELIGIBLE to participate	6/bmjopen-2
17 18 19 20	RESEARCH STAFF USE: Does the participant meet the eligibility criteria?		Yes right, includ	022-066898
21 22 23 24 25 26 27	[IF NO] Thank you, [es_name]. Unfortunately, you are not eligible to participate in our study. In order to protect the integrity of the study, as mentioned before, I will not be able to tell you the specific reason why you were found ineligible to participate.	000	Enseigner ling for uses related	on 3 February 2023
28 29 30 31 32 33	However, you may be eligible to participate in future research studies. If you are interested in participating in future research studies, we can take your contact information and reach out to you with future study opportunities.		to text and data	. Downloaded fro
34 35 36 37 38 39	[Ask question to all callers, including those who have been found ineligible] Are you interested in participating in future research studies? If so, we can take your contact information and reach out to you with future study opportunities.		Yes No Al trainir	m http://bmjopen
40 41 42 43 44	(IF YES) Collect contact information and note interest in screening log.		Primary Contact Number: and similar Simi	bmj.com/ on
45 46 47 48 40	ELIGIBLE Great! It sounds like you are eligible to participate	e in our s	study! So now let me tell you a little bit more about the study.	June 13, 202:
50 51 52 53 54 55 56 57	If you decide take part in this study, the visits would include an initial assessment followed by 3-, 6-, 9-, 12-, 18-, and 24-month follow-up assessments. The questionnaires during visits will include questions regarding various topics such as your demographic information, substance use history, treatment service utilization and recovery support, among others.		Yes No	at Agence Bibliograph
58 59 60	To compensate you for your time and effort, we would compensate you up to \$455. That is \$45,	ttp://bm	jopen.bmj.com/site/about/guidelines.xhtml	ique de i

			BM
1			op C
2			ben
3	\$55, \$60, \$65, \$70, \$75, and \$85 for the initial		111
4	visit and 3-,- 6-,- 9-,- 12-,- 18-,- and 24-month		stp
6	follow-up visits, respectively. The reason I say		ane
7	"up to \$455" is because we are unable to pay		ISI
8	participants for the assessments they do not		led
9	come in to complete.		as
10			Pr 10.
11	Reimbursement will be by check and it may		ote 113
12	after you complete your initial assessment per		cte
13	our MCH guidelines, but payment will likely be		d b
14	faster for subsequent payments. In order to		y c
16	receive navment for participating in this study		opy
17	vou will need to provide your Social Security		/rig
18	Number (SSN). This is necessary in order for us		1-06 ht,
19	to comply with tax reporting obligations. This		inc
20	information is confidential and protected, and		png 98 c
21	will be stored securely and redacted when no		ing
22	longer required.		for
25 24			us us
25	Finally, please know that your honesty is the		nse es i
26	most important part of this study: research		y zu rela
27	studies only work if participants tell us how		Ited
28	they truly think and feel. There are no "right"		
29	and "wrong" answers; never consider what you		tex
30	us how it is		t al
31	us now it is.		nd e
5∠ 33	So, what do you think? Would you like to		ur (/ data
34	participate in this study?		a m BE
35	Farnerhand in and story .		ini;S
36	[If NO]		Ģ.
37	Thank you very much for your time, we understand	d that this study is not for everyone and we appreciate your interest.	Alt
38	STOP SCREEN		op raiı
39	[If YES]		ing
40 1	In just a moment, I will collect your contact		j, a
41	information as well as the contact information		nd .co
43	for two people in your life, so we can reach out		sim
44	to them if we lose contact with you. We will		ilar
45	simply tell them that you are in a study tracking		tec
46	they are willing to serve in this role.	Use SEND SECURE	le 1 chn
47	they are winning to serve in this role.	Dop't use SEND SECURE	olo 3, 2
48	Refore Lask you for your email address. I need	$\square N/A (no email)$	gie
49 50	to ask you about how you prefer to get emails		s.
50 51	from us. There are two options: receiving them	Contact Number:	Ag
52	using the "SEND SECURE" option, or	Email Address:	Jen
53	receiving them without it. Let me explain:		ce
54			510
55	Email sent over the internet is not secure unless		<u> Joll</u>
56	both parties are using an encryption		Irap
57	technology. This provides a secure connection		onic
28 20	both on the sender's and receiver's		lue
60	communications while in transit. Without	ttp://bmjopen.bmj.com/site/about/guidelines.xhtml	de
	encryption, it is possible for other individuals	· · · · · ·	

1		
1 2 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	<ul> <li>(beyond the intended recipient of the email) to access and read the email and this could result in the unauthorized use or disclosure of your information, for which Partners HealthCare will not be held responsible. If you prefer to receive communications by unencrypted email despite these risks, your preference will apply to all emails sent to you from research staff in this study.</li> <li>If you would like to receive your emails encrypted, we will use the SEND SECURE option. In order to read these emails, you will need to do two things: <ol> <li>The first time you get a 'send secure' message, you need to register with Cisco Registered Envelope Service (CRES). This is done once and takes only a few minutes.</li> <li>To read future secure emails you need to enter the password you created.</li> </ol> </li> <li>If you would like to receive your emails unencrypted, we will not use the SEND SECURE option.</li> <li>What do you prefer?</li> <li>Who are the two people we can reach out to in case we are unable to contact you directly? These can be family members, friends, or partners.</li> </ul>	Protected by copyright, including for uses related to text and data mining.         Contact 1 Name:         Contact 1 Email:         Contact 1 Phone:         Contact 1 Relation:         Contact 1 Relation:         Contact 2 Name:         Contact 2 Email:
39 40 41	person is required.	Contact 2 Phone:
42 43 44 45 46	(If eligible and interested in participating) Schedule assessment	Time: HH:MM     Similar       Date: [MM/DD/YYYY]     Scheduling Notes:
47 48 49 50 51 52 53 54 55 56 57	[IF ELIGIBLE AND SCHEDULED FOR AN AS [IF IN PERSON VISIT] Okay, we are all set then. [schedule1]. I will send you an appointment confin [IF REMOTE VISIT] Okay, we are all set then. Y an appointment confirmation shortly. The first thin which will be emailed to you. You'll need to sign time of your assessment. Again, my name is [rcname], and if you have any	SESSMENT] Your assessment will take place in person at our office and is scheduled for mation and directions to our office shortly. our assessment will take place over the phone on [schedule1]. I will send you ng we'll be doing during your enrollment visit is going over our consent form, the form electronically, so we recommend having access to a computer at the additional questions or anything comes up, please don't hesitate to reach out
58 59 60	by phone or email. (Confirm he/she has your conta study. It was great talking with you! CALL END. For peer review only - h	act information). Thank you again for your interest and participation in our

# $Supplement \ 1-Measures$

# Table 1 (staff-administered measures)

Measure	Description
Substance Use History	Participants answered a series of questions about 15 substances/classes of substances (hereafter simply referred to as substances) from the Global Appraisal of Individual Needs (GAIN-I; (Dennis et al., 2002)): 1) Alcohol, 2) Marijuana, 3) Heroin, 4) Methadone, 5) Buprenorphine and its formulations (e.g., suboxone), 6) Other opioids (e.g., pharmaceutical opioids), 7) Cocaine, 8) Amphetamines (including MDMA), 9) Methamphetamine, 10) Benzodiazepines, 11) Barbiturates, 12) Hallucinogens, 13) Synthetic drugs (e.g., synthetic cannabinoid like "K2" and synthetic cathinones such as "bath salts"), 14) Inhalants, and 15) Steroids, as well as "Other" (specified by participant). At baseline, participants reported which of these substances they used 10 or more times in their life. Then for each substance endorsed, they provided information on the following from the Form-90 (Miller & Delboca, 1994): a) Age of first use; b) If they had ever used the substance regularly (i.e., at least once per week) (yes/no) and if so, the age of first regular use; c) Whether they had used the substance in the past three months (yes/no), and if so how many days out of the past 90 they used the substance and d) If they had not used the substance in the past 3 months, the date of their last use. For follow-ups, the questionnaire assessed if participants had used these substances in any capacity in the past 3 months, if they had used the substance. Participants then chose their primary substance ("drug of choice") and secondary substance from the substances they had used (lifetime use for baseline assessment, past 3 month use for follow-ups). Finally, participants were asked for how many of the past 90 days their use of alcohol/drugs interfered with their functioning, and how many out of the past 90 days they got drunk at all or high for most of the day.
Alcohol Use Disorder DART	Participants were asked this validated semi-structured interview to capture AUD status (AUD severity and withdrawal symptoms). Participants were first asked if they had consumed alcohol in the past 3 months. If the participant answered 'yes', the DART would pertain to the past 3 months. If the participant answered 'no', they would be asked if they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered 'no', they would be asked if they they consumed alcohol during the past 12 months, and the DART would pertain to the past 12 months. If the participant answered 'no' to both the questions, they would only be asked if they experienced strong urges or cravings to drink.
Substance Use Disorder DART	Participants were asked about the recreational drugs/medications they used in the past 12 months. They then ranked the substances in the order that they caused problems for them. The DART was administered for the top 3 substances that caused the most problems for participants.
NIH PhenX Toolkit	Participants reported on lifetime use of cigarettes, e-cigarettes, or another tobacco/nicotine product (specified by participant). For those who smoked cigarettes, they reported on the following: 1) Age of first regular use; 2) Of how many of the past 30 days they smoked cigarettes 3) Average number of cigarettes smoked per day in the past 30 days 4) Whether or not they had ever made a serious attempt to quit smoking. This was asked pertaining to 'lifetime' for the baseline visit and for the past 90 days in the follow-up visits. If participants had made a serious quit attempt either in their life (baseline) or in the past 90 days (follow-up), they reported how old they were when they most recently quit smoking, the number of quit attempts in the past 90 days, the longest length of time they had quit smoking for, as well as on psychosocial smoking cessation resources. If not currently still smoking, participants reported the age when they stopped smoking, as well as psychosocial smoking cessation resources used in their most recent quit attempt. Finally, regarding smoking cessation, all participants answered a single item with four multiple choice options

to gauge attitudes toward inclusion of smoking cessation in AOD treatment (e.g., "Services

	(National Cancer Institute, 2009; National Institutes of Health & U.S. Food and Drug Administration, 2013; Prorok et al., 2000).
Treatment for Injuries or Physical Health Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for health problems. At baseline, participants reported for both lifetime at past 3 months. At follow-up visits, participants were asked to report only on treatments i the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Treatment for Alcohol and Drug Use Problems	Participants reported treatment in an emergency room and admissions to a hospital for at least one night for alcohol or drug use problems. At baseline, participants reported for bolifetime and past 3 months. At follow-up visits, participants were asked to report only on treatments in the past 3 months (Dennis et al., 2002; Miller & Delboca, 1994).
Anti-craving and Anti- relapse Medications (Alcohol and Opioids)	At baseline, participants reported whether they had ever been prescribed a medication to prevent them from drinking alcohol or using opioids. At follow-up visits, participants we asked if they had been newly prescribed any medication to prevent them from drinking alcohol or using opioids in the past 3 months. If participants responded yes to either item participants reported lifetime (baseline), past 3 months (follow-up) and current (baseline and follow-up) use of specific medications from the Form-90, including both generic and brand names (Miller & Delboca, 1994). Participants were also asked to rate what proport of the time they used each medication as medically indicated.
Mental and Emotional Health: Diagnoses, Hospitalizations, Treatment History	Participants reported whether they had ever been told that they had a mental health condition by a doctor, nurse, or counselor, including agoraphobia, anorexia nervosa, biped disorder, bulimia nervosa, delusional disorder, dysthymic disorder, generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, personality disorder, post-traumatic stress disorder, schizoaffective disorder, schizophrer social anxiety disorder, specific phobia, substance use disorder, and other. For each diagnosis endorsed, participants indicated whether this had been a problem for them in th past 12 months. Participants reported treatment in an emergency room and admissions to a hospital for at least one night for mental, emotional, behavioral, or psychological problems. Participant reported for both lifetime and past 3 months. Participants also reported the number of tim they had seen a mental health doctor in an office or outpatient clinic (including telehealtl in the past 3 months, on how many of the past 90 days they had been bothered by mental emotional, behavioral, or psychological problems, and on how many of the past 90 days these problems had kept them from meeting their responsibilities or made them feel like they could not go on (Dennis et al., 2002; Miller & Delboca, 1994).
Mental and Emotional Health: Psychiatric Medication Use	Participants were asked if they had ever been prescribed medication by a physician or medical practitioner to help them with a mental health condition (lifetime use). If they say yes, they were asked which medication they had ever been prescribed with the options antidepressants, anti-anxiety medication, anti-psychotics, mood stabilizers, stimulants, painkillers, medications for sleep and other (to be specified). Participants were then asket they were still taking the medicines they indicated. If participants were still taking the medicate as medically indicated. At follow-up visits, participants were asked if they were still using any medication to help with a mental health condition, and if yes, what type of medication. For each medication endorsed, participants reported what proportion the time they used the medication as medically indicated (Dennis et al., 2002; Miller & Delboca, 1994).
Social Support Questionnaire (SSQ)	Participants were asked to list the initials of up to 5 family members, up to 5 friends, and to 3 other important people in their life who they felt close to. For each person, they liste their initials, relationship, alcohol use pattern, drug use pattern, days per month they had

	contact with this person over the past 3 months (including contact via phone/text), how much they value their relationship on a scale of 1 ( <i>not at all</i> ) to 10 ( <i>a great deal</i> ) and he helpful they are in their recovery efforts on a scale of 1 ( <i>not at all helpful</i> ) to 10 ( <i>a great deal</i> ) (Zywiak et al., 2009).
12-step/MHO Attendance History	At baseline, participants were asked about lifetime attendance to help with their AOD problem at 12 different MHOs, with an "other" option specified by participant (Kelly et 2011): 1) Alcoholics Anonymous (AA); 2) Narcotics Anonymous (NA); 3) Marijuana Anonymous (MA); 4) Cocaine Anonymous (CA); 5) Crystal Methamphetamine Anonymous (CMA); 6) SMART Recovery; 7) LifeRing Secular Recovery; 8) Moderati Management; 9) Celebrate Recovery; 10) Women for Sobriety; and 11) Secular Organization for Sobriety (S.O.S.).; 12) Dual Diagnosis Anonymous (DDA); and 13) O Other options were examined for possible inclusion in existing categories, and recategorized as appropriate. At follow-ups, participants reported attendance for the past months. For each MHO attended, participants reported a) Whether they attended regular (at least once per week), b) Number of meetings in the past 3 months, and c) Whether the had ever attended a meeting online.
Online Resources and Social Network Sites	For each MHO that a participant had attended online (as noted in "12-step/MHO Attendance History"), participants reported how many meetings they had attended online the past 3 months, how they accessed these meetings (video, audio only, telephone, etc.) and how helpful they felt the online meetings were on a scale of 1 to 10. Participants als reported whether they used any online or mobile technologies to support their AOD problem resolution or recovery in their lifetime (baseline) and in the past 3 months. Potential online and mobile technologies included recovery-focused social network sites (e.g., InTheRooms.com), general social network sites (e.g., Facebook), and mobile smartphone applications. For each online or mobile technology endorsed, participants indicated how many of the past 90 days they had used the technology for recovery and H helpful they found it on a scale of 1 to 10. Participants were also given the opportunity to provide any other information or comments on their use of online or mobile recovery resources.
SMART Involvement	Questions about SMART involvement were asked for participants who had attended SMART Recovery. Participants were asked how long they have been attending SMART Recovery, how they heard about SMART Recovery, whether they consider themselves to be a current member of SMART Recovery ( <i>yes/no</i> ), how many times they have attended SMART recovery in their lifetime ( <i>numerical value</i> ) and if another member of SMART Recovery served as a personal mentor or guide to them in the past 3 months ( <i>yes/no</i> ). The participants were asked questions about their participation in SMART meetings in the p. 3 months to gauge the frequency of the use of SMART meetings, tools, website, and we application 'Overcoming Addictions.' Participants were also asked four questions about their level of engagement in SMART meetings.
Recovery/Abstinence time	Participants were asked to report in years and months how long they had been either 1) Sober (not using any alcohol/drugs) or 2) Drinking/using drugs without problems.
Multidimensional Mutual-Help Activity Scale (MM-HAS)	Questions from the MM-HAS were asked for participants who had attended meetings of any of the following MHOs: Alcoholics Anonymous, Narcotics Anonymous, Marijuana Anonymous, Cocaine Anonymous, Crystal Methamphetamine Anonymous, and Dual Diagnosis Anonymous. For each organization, participants were asked if they currently considered themselves to be a part of the MHO, their activities as part of the MHO in the past 3 months (sponsor, contact with sponsor outside a meeting, contact with other members outside a meeting, read 12 step literature outside of a meeting, shared or talked during meetings, helped with setting up/running a meeting), and the number of steps out the 12 step program that they completed while participating in the MHO in the past 3 months. Participants were then asked to rate the helpfulness, enjoyability, and safety of

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	MHO from a scale of 1 ( <i>not at all helpful, do not enjoy at all,</i> or <i>not at all safe</i> ) to 10 ( <i>extremely helpful, enjoy a great deal,</i> or <i>completely safe</i> ) (Kelly et al., 2013; Kelly et al., 2011).
Recovery support services and formal treatment programs (RSSTX)	The questionnaire assessed history of participation in nine psychosocial treatment and recovery support services: 1) Sober living environment; 2) Recovery high school; 3) College recovery program/community 4) Recovery community center (RCC); 5) Faithbased recovery services (e.g., a recovery group provided by a church, synagogue, mosque, etc.); 6) State or local recovery community organization (RCO); 7) Outpatient addiction treatment; 8) Alcohol/drug detoxification services; 9) Inpatient or residential treatment. If they responded yes to any treatment service (7, 8 or 9), they reported the number of times they used the service (i.e., number of treatment episodes) in their lifetime (baseline) and th past 3 months (baseline and follow-up). (Dennis et al., 2002; Miller & Delboca, 1994).
Year End Summary (YES)	At baseline, 12-month follow-up, and 24-month follow up, participants were asked if they felt like they were better off now than they were 12 months ago in terms of their alcohol and drug problems (worse off, same, better off). Participants were then asked to elaborate on the reason for that answer. Participants were asked if their substance use had changed o stayed the same in the past 12 months (changed for the better, changed for the worse, staye the same). If participants reported 'stayed the same', they were asked what factors they thought were most responsible for their substance use staying the same.
Timeline Follow Back (TLFB)	Participants provided specific dates for alcohol use, substance use, MHO attendance, inpatient and outpatient addiction treatment, inpatient and outpatient mental health treatment, and incarceration for the past 3 months (baseline, 3-, 6-, 9-, and 12-month follow-ups) or 6 months (18- and 24-month follow-ups) (Miller & Delboca, 1994). For alcohol use, participants were asked to report the number of standard drinks consumed on each drinking day. For MHO attendance and outpatient treatment for addiction and mental health, participants were asked to report whether services were in-person or online. During in-person study visits, a printed calendar was used to facilitate the TLFB. For remote visits study staff prompted participants with potentially memorable dates within the timeframe (e.g., holidays).
Go/No-Go Cognitive Measure*	The Inquisit Go/No-Go Cognitive Measure is a computerized task used to assess impulsivity. The Inquisit script implemented the Go/No-Go Task as described in Fillmore e al. (2006). Participants were asked to press the spacebar when they see a green rectangle (go) but refrain from pressing the spacebar when they see a blue rectangle $(no-go)$ . The blu and green rectangles could be vertical or horizontal. The vertical rectangle had a high probability (4:1) of being green $(go)$ and the horizontal rectangle had a high probability (4: of being blue $(no-go)$ . Participants were given information about the orientation of the rectangle shortly before the color of the rectangle was revealed. Participant response times and error rates were recorded. For remote visits, a web-based version of the Go/No-Go Tas was tested, but due to the effect of internet speed on results, this measure was not included.
Breathalyzer*	Breathalyzer tests were used to establish a baseline level of substance use for participants the first assessment and to ensure that data was not collected from participants who were impaired due to alcohol use. Breathalyzer tests were performed at baseline and all follow- time points prior to starting each assessment. If a participant's BAC was above .02, study staff did not conduct the study visit; instead, study staff either waited with the participant until their BAC dropped to .02 or lower or attempted to re-schedule the participant's visit. a participant's BAC was above the legal limit (.08), and the participant had driven to their assessment, study staff asked to hold the participant's car keys while waiting for their BAC to drop below the legal limit. If the participant insisted on holding their car keys and/or driving, or if the participant did not stay with study staff until their BAC dropped below .0 study staff called security as a safety precaution. Study staff also offered to arrange and pa for a cab to transport the participant home. If a participant had driven to the appointment

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

τ
S
* -
Ta N
E B
C

	and decided to take a cab home, the participant could return to pick up their car keys during
	business hours when their BAC was below .08. For remote visits, study staff were unable to
	perform breathalyzer tests and instead asked participants to verify that they had not used
	alcohol or other drugs prior to the assessment via self-report
	aconor or other drugs prior to the assessment via sen-report.
Urine Drug Screen*	Urine drug screens were used to establish baseline substance use at baseline and to verify
C	self-reported estimates of alcohol and other drug use. For remote visits study staff were
	unable to perform urine drug screens
	unable to perform unne drug screens.
Saliva Test	Self-administered saliva tests were implemented in March 2021 as an alternative method of
	biochemical verification during remote visits. Participants were contacted prior to their
	assessment to confirm willingness to participate in the saliva test, what address the test
	would be mailed to and whether the visit would be conducted over Zoom or on the phone
	During the assessment, participants were able to self administer the soliva test with study
	staff guidenee. If participants completed the assessment over Zoom, participants showed the
	start guidance. If participants completed the assessment over Zoom, participants showed the
	test results to the research coordinator who screenshotted the test and uploaded it to
	REDCap. If the participant completed the assessment over the phone, they uploaded images
	of the test to REDCap or, if unable to upload images, self-reported the results. Due to
	inconsistencies in saliva test results (no results, partial results, and false negatives), saliva
	test use was discontinued in May 2021.
* = not administered d	uring remote visits
Table 2 (self-administed)	ered measures)
Maggura	Description

# able 2 (self-administered measures)

Description
Participants reported the following: gender, race, ethnicity (whether participants were
Hispanic/Latino), where they were living for the majority of the past 3 months (with family
or other relatives, with group of friend(s) or non-family members, alone in own dwelling,
homeless, hospital rehabilitation facility or nursing home, jail, prison or other correctional
facility, other), current marital status (single, married, living with someone as if married, in relationship, engaged to be married, legally separated, divorced, widowed), sexual
orientation, left or right handed, highest level of schooling completed, highest level of
schooling completed by either parent, whether they held a job in the past 3 months, (if yes) nature of employment (odd jobs, part time, full time), (if no) reason for unemployment,
major source of financial support, total annual household income, type of health insurance,
and financial well-being of their family. Numerical values were collected for the following
in the past 3 months: unplanned absences from work/school, times disciplined on the job/a
school, times your job/school has been in jeopardy, times you were suspended or fired from
work/school (Dennis et al., 2002; Miller & Delboca, 1994).
The questionnaire used adapted items about criminal justice involvement from the Form-90
(Miller & Delboca, 1994). Participants reported on their current legal status (none, on
probation only, on parole only, on probation and parole, awaiting charge, trial or sentence,
outstanding warrant, case pending, other). At baseline, participants reported whether they
had ever been arrested (yes/no). If yes, they reported now many times overall, now many times for DUU/DWU in their lifetime, and how many times for other reasons in their lifetime.
At follow up visits, participants reported whether they had been arrested in the past 3
months (yes/no). If yes, they reported how many times overall, how many times for
DUI/DWI in the past 3 months, and how many times for other reasons in the past 3 months
At baseline, participants reported whether they had ever staved in jail or prison overnight of
longer (yes/no). If yes, they reported how many times in their lifetime and how many times
in the past 3 months. At follow-up visits, participants only reported the number of times in
the past 3 months

Religious Background and Behaviors (RBBS)	At baseline, the questionnaire assessed if the participant considered themselves to be part of a religious group (No/none, Baptist, Buddhist, Catholic, Evangelical, Hindu, Jewish, Lutheran, Methodist, Mormon, Muslim, Presbyterian, Other Protestant, Shinto, Native American Church, Traditional Native American, Christian, Some other group). For all timepoints participants were asked which of the following describes them at this time: atheist, agnostic, unsure, spiritual, religious. Participants were asked how often they participated in religious activities in the past 3 months on a 7-point Likert scale ( <i>never</i> , <i>rarely, once a month, twice a month, once a week, twice a week, almost daily, more than</i> <i>once a day</i> ) and, at baseline, how often they participated in certain religious activities in their lifetime on a 3 point-Likert scale ( <i>never, yes, in the past but not now, yes, and I still do</i> ) (Connors et al., 1996).
Religious and Spiritual Intensity	The questionnaire included four items assessing participants' religiosity and spirituality. Participants reported the extent to which they considered themselves religious/spiritual on a Likert scale from <i>not religious/spiritual at all</i> (1) to <i>very religious/spiritual</i> (4). Participants reported the extent to which their religious/spiritual practices and beliefs help them with resolving an alcohol/drug problem on a scale from <i>do not help at all</i> (1) to <i>make all the difference</i> (5) (Idler et al., 2003).
Twelve Promises Scale (TPS)	This questionnaire assessed participants' current psychosocial state and attitudes towards drinking and using drugs. Participants rated how true each item was for them at the current time on a scale of <i>never true</i> (1) to <i>true most of the time</i> (5) (Kelly & Greene, 2013).
Perceived Stress Scale (PSS-4)	This questionnaire assessed participants' level of stress over the last month. Participants rated each item on a scale from <i>never</i> (1) to <i>very often</i> (5) (Warttig et al., 2013).
Kessler 6 (K6)	This six-item scale assessed psychiatric symptoms (also referred to as psychological distress). On a scale from <i>all of the time</i> (1) to <i>none of the time</i> (5), participants are asked how often they felt: nervous, hopeless, restless or fidgety, so depressed that nothing could cheer you up, that everything was an effort, and worthless (Kessler et al., 2003).
Coping Strategies Scale (CSS)	Participants were asked to select how often they used a variety of coping strategies or thoughts in the past 3 months to help them not use alcohol or drugs. Participants rated each item on a scale from <i>never</i> (1) to <i>frequently</i> (4) (Litt et al., 2003; Prochaska et al., 1988).
Alcohol and Drug Abstinence Self Efficacy (A-DSES-20)	Participants were asked about their feelings of confidence to not drink or use drugs in various situations in the past week. Participants rated their level of confidence for each scenario on a scale of <i>not at all confident</i> (1) to <i>extremely</i> (5) (Diclemente et al., 1994).
Penn Alcohol and Drug Craving (PADCS-5)	This questionnaire assessed the frequency and strength of cravings to use alcohol and other drugs during the past week. Participants reported how often they thought about drinking/using drugs, how strong the craving was at its most severe, how much time they have spent thinking about drinking/using drugs, how difficult it would have been to resist drinking/using drugs, and then rated their overall alcohol/drug craving with options ranging from <i>never thought about drinking/using drugs and never had the urge to drink/use drugs</i> to <i>thought about drinking/using drugs nearly all of the time and had the urge to drink/use drugs nearly all of the time</i> (Flannery et al., 1999).
Commitment to Sobriety Scale (CSS-5)	In this questionnaire, participants were asked 5 questions about their commitment to not using alcohol/drugs. Participants rated the extent to which they agreed with these statements on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6) (Kelly & Greene, 2014).
Drinking Goal	In this questionnaire, participants chose one goal that was the most true to them currently from the 5 options: 1) Total abstinence; never use again; 2) Total abstinence; but realize a slip is possible; 3) Occasional use when urges strongly felt; 4) Temporary abstinence; or 5) Controlled use
Snort Inventory of Problems (SIP-2R)	This questionnaire assessed how often participants had experienced various problems due the past 3 months because of their drinking/drug. Participants indicated how often they a experienced each problem on a scale of <i>never</i> to <i>daily or almost daily</i> . Participants were asked to indicate whether they had had an accident while drinking or intoxicated in the 3 months (Miller et al., 1995).
--	--
Questions about Recovery	This questionnaire assessed recovery identity, definition, and what participants believe a the factors helping them resolve their problem with alcohol/drugs at baseline, 12-month follow-up, and 24-month follow-up. Participants selected a statement that best applied to them from whether they consider themselves to be <i>in recovery</i> , <i>seeking recovery</i> or <i>not</i> <i>seeking recovery</i> . If participants chose that they were 'in recovery', they were asked to provide the date they use to mark the beginning of their recovery. Participants were asked provide their definition of recovery in one sentence (free response) and to select one of the statements that best fit their definition of recovery: 1) Abstinence from all drugs/alcohol Abstinence from only those drugs/alcohol with which they had a problem; or 3) Non- problematic/moderate use of drugs/alcohol, including those with which they had a probl Participants were then asked to list the top 3 things that have helped or are helping them resolve their problem with alcohol/drugs.
Brief Assessment of Recovery Capital (BARC-10)	The BARC-10 (Vilsaint et al., 2017) is a 10-item, abridged version of the Addiction Recovery Capital Scale (Groshkova et al., 2013). The BARC-10 measures personal (e.g take full responsibility for my actions"), social (e.g., "I get lots of support from friends" physical (e.g., "I have enough energy to complete the tasks I set for myself"), and environmental resources (e.g., "My living space has helped to drive my recovery journe used to initiate and sustain recovery. Participants rated their agreement with each statem on a scale from <i>strongly disagree</i> (1) to <i>strongly agree</i> (6).
Behavioral Addictions	The questionnaire used items adapted from Laudet et al. (2015) to assess whether individuals ever had a problem with one or more other behaviors apart from AOD use in their lifetime (baseline) and currently, including 1) Eating disorder; 2) Sex/love addiction Gambling; 4) Video gaming addiction; 5) Compulsive shopping; 6) Internet addiction (fi issues not assessed by other choices); 7) Compulsive exercise; 8) Internet pornography addiction; 9) Self-harm/injury and 10) Other (specified). "Other" options were examined possible inclusion in existing categories, and recategorized as appropriate. Participants v asked if any reported behavioral addictions had been a problem for them in the past 3 m and if so, how many days out of 90. If reporting more than one, participants indicated w behavior had been the most problematic.
Medical Marijuana Use	Participants were asked if they had ever been recommended to use marijuana for medica reasons. If yes was indicated, participants were asked how many days out of the past 90 marijuana was used for medical reasons and to list up to three medical reasons for using marijuana.
Medication Attitudes	This questionnaire assessed participant attitudes toward medication for an alcohol proble opioid problem, any kind of alcohol/drug problem, and emotional problem. Participants rated their agreement with the use of medication for these problems on a scale of <i>strong</i> <i>disagree</i> (1) to <i>strongly agree</i> (6).
Impulsive behavior (SUPPS-S)	This questionnaire assessed impulsivity. Participants rated their agreement with 20 item describing situations or feelings related to impulsivity on a scale of <i>agree strongly</i> (1) to <i>disagree strongly</i> (4) (Coskunpinar et al., 2013).
Quality of Life (Q-LES-	This measure of quality of life was used to assess satisfaction related to physical health,

	each item during the past week on a scale of <i>very poor</i> (1) to <i>very good</i> (5) (Endicott et a 1993).
Quality of Life (EQ5D3L)	This measure of quality of life was used to assess physical and mental health states. Participants rated their current mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Participants also rated their current overall physical and mental health states using a visual analogue scale with options between 0 ( <i>worst</i> ) and 100 ( <i>best</i> ) (Devli Brooks, 2017).
Quality of Life (EUROHIS-QOL)	This measure of quality of life is a widely used eight-item measure of quality of life, adapt from the World Health Organization Quality of Life – Brief Version (WHOQOL-BREF) (Schmidt et al., 2006). Participants rated each item on a 5-point Likert scale from 1 ( <i>very poor, very dissatisfied,</i> or <i>not at all</i> ) to 5 ( <i>very good, very satisfied,</i> or <i>completely</i> ) (da Ro et al., 2012).
Pittsburgh Sleep Quality Index (PSQI)	This questionnaire assessed quality of sleep. Participants reported how many hours of sle they got on average per night over the past month. Participants then rated their quality of sleep on a scale from <i>very good</i> (1) to <i>very bad</i> (4) (Buysse et al., 1989).
Pain Visual Analogue Scale (VAS)	This measure assessed physical pain. Participants rated the current severity of their pain using a visual analogue scale with options between 0 ( <i>no pain</i> ) to 100 ( <i>very severe pain</i> ) (Wewers & Lowe, 1990).
International Physical Activity Questionnaire (IPAQ)	This questionnaire asks participants about their level of physical activity over the past sev days. Participants indicate how many days in the past 7 days they have done: vigorous physical activity, moderate physical activity, and walking. Participants then indicate how much time per day they usually spent on each activity in hours and minutes. Participants also asked how many hours they usually spent sitting on weekdays over the past 7 days (Hagstromer et al., 2006).
Meals	Participants reported how many meals on average they have eaten per day during the pas- months.
Self-esteem, Happiness, and Satisfaction with Life	Three single-item measures were used to assess self-esteem (Robins et al., 2001), happing and satisfaction with life (Diener et al., 1985). For self-esteem, participants indicated their agreement with the statement "I have high self-esteem" on a scale from 1 ( <i>not very true of</i> me) to 10 ( <i>very true of</i> me). For happiness, participants rated how happy they were with their life in general on a scale of 1 ( <i>completely unhappy</i> ) to 10 ( <i>completely happy</i> ). For satisfaction with life, participants indicated their agreement with the statement "I am satisfied with my life" on a scale of <i>strongly disagree</i> (1) to <i>strongly agree</i> (7).
Abstinence Self- Efficacy Single Item	Participants rated how confident they were that they could remain abstinent or drink/use drugs without problem in the next 3 months on a scale from <i>not at all confident</i> (1) to <i>ver confident</i> (10).
Daily Spiritual Experiences Scale (DSES)	This questionnaire assesses spiritual and/or religious experiences. The questionnaire includes items with the word "God" used but includes instructions for participants that if "God" is not a comfortable word that they should substitute it for one that calls to mind the divine and holy for them. Participants read 15 items describing spiritual and/or religious experiences that a person may have and rate how often they have this experience from <i>matimes a day</i> (1) to <i>never or almost never</i> (6). The last item asks participants how close the feel to God from <i>not close</i> (1) to <i>as close as possible</i> (4) (Underwood & Teresi, 2002)

	₩
	5
	9
	ìen
	ĭ: ≢
	irs
	Ę
	Ъ
	lis
	he
	<u>о</u>
	Ñ
	<u>ē</u>
	1
	36/
	'n
	Ч.
	pe
	2
	202
	Ņ
	6
	389
	8
	g
	မ
	Fel
ш	br
nsu	lar
eig	~ N
ne	1 N N
Ĩ	ω
ent	0
õ	ĭ
Ē	F
eri	ad
Ē	Ð
_	<u>o</u>
ŝ	d frc
r (ABl	d from
r (ABES)	d from ht
r (ABES) .	d from http:
r (ABES) .	d from http://b
r (ABES) .	d from http://bmj
r (ABES) .	d from http://bmjop
r (ABES) .	d from http://bmjopen.
r (ABES) .	d from http://bmjopen.bn
r (ABES) .	d from http://bmjopen.bmj.u
r (ABES) .	d from http://bmjopen.bmj.coi
r (ABES) .	d from http://bmjopen.bmj.com/
r (ABES) .	d from http://bmjopen.bmj.com/ on
r (ABES) .	d from http://bmjopen.bmj.com/ on Ju
r (ABES) .	d from http://bmjopen.bmj.com/ on June
r (ABES) .	d from http://bmjopen.bmj.com/ on June 1.
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 202
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 .
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at .
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Ag
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agen
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bi
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibli
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliog
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliogra <sub>l</sub>
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographi
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographiqu
r (ABES) .	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Dage	33 of 46	BMJ Open
1	Refere	ences
2 3 4 5	Buysse	e, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. <i>Psychiatry Res</i> , 28(2), 193-213. https://doi.org/10.1016/0165-1781(89)90047-4
5 7	Conno	rs, G. J., Tonigan, J. S., & Miller, W. R. (1996). A Measure of Religious Background and Behavior for Use in Behavior Change Research. <i>Psychology of Addictive Behaviors</i> , 10(2), 90-96.
3 9 10	Cosku	npinar, A., Dir, A. L., & Cyders, M. A. (2013). Multidimensionality in impulsivity and alcohol use: a meta-analysis using the UPPS model of impulsivity. <i>Alcohol Clin Exp Res</i> , <i>37</i> (9), 1441-1450. https://doi.org/10.1111/acer.12131
12 13 14	da Roc	cha, N. S., Power, M. J., Bushnell, D. M., & Fleck, M. P. (2012). The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. <i>Value Health</i> , <i>15</i> (3), 449-457. https://doi.org/10.1016/j.jval.2011.11.035
5  6  7	Dennis	(GAIN): Administration Guide for the GAIN and Related Measures. In. Bloomington, IL: Chestnut Health Systems
18 19 20 21	Devlin Diclen	N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future [Review]. Applied Health Economics and Health Policy, 15(2), 127-137. <u>https://doi.org/10.1007/s40258-017-0310-5</u> nente, C. C., Carbonari, J. P., Montgomery, R. P. G., & Hughes, S. O. (1994). The Alcohol Abstinence
22 23 24	Diener	Self-Efficacy Scale [Article]. <i>Journal of Studies on Alcohol</i> , 55(2), 141-148. <u>https://doi.org/10.15288/jsa.1994.55.141</u> F. Emmons R. A. Larsen R. L. & Griffin S. (1985). The Satisfaction With Life Scale [Article]
25 26 27 28 29	Endico	<i>Journal of Personality Assessment</i> , 49(1), 71-75. <u>https://doi.org/10.1207/s15327752jpa4901_13</u> ott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire - A New Measure [Article]. <i>Psychopharmacology Bulletin</i> , 29(2), 321-326. <go to<br="">ISI&gt;://WOS:A1993MC72000028</go>
30 31 32	Fillmo	re, M. T., Rush, C. R., & Hays, L. (2006). Acute effects of cocaine in two models of inhibitory control: implications of non-linear dose effects [Article]. <i>Addiction</i> , <i>101</i> (9), 1323-1332. https://doi.org/10.1111/j.1360-0443.2006.01522.x
33 34 35 36	Flanne	Ary, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999). Psychometric properties of the Penn Alcohol Craving Scale [Article]. <i>Alcoholism-Clinical and Experimental Research</i> , 23(8), 1289-1295. https://doi.org/10.1111/j.1530-0277.1999.tb04349.x
37 38 39	Groshl	kova, T., Best, D., & White, W. (2013). The Assessment of Recovery Capital: Properties and psychometrics of a measure of addiction recovery strengths [Article]. <i>Drug and Alcohol Review</i> , 32(2), 187-194. https://doi.org/10.1111/j.1465-3362.2012.00489.x
40 41 42 43	Hagstr	omer, M., Oja, P., & Sjostrom, M. (2006). The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity [Article]. <i>Public Health Nutrition</i> , 9(6), 755-762. https://doi.org/10.1079/phn2005898
14 15 16 17 18	Idler, I	E. L., Musick, M. A., Ellison, C. G., George, L. K., Krause, N., Ory, M. G., Pargament, K. I., Powell, L. H., Underwood, L. G., & Williams, D. R. (2003). Measuring multiple dimensions of religion and spirituality or health research - Conceptual background and findings from the 1998 General Social Survey [Article; Proceedings Paper]. <i>Research on Aging</i> , 25(4), 327-365.
19 50	Kelly.	J. F., & Greene, M. C. (2013). The Twelve Promises of Alcoholics Anonymous: Psychometric measure

- Alcoholics Anonymous: Psychometric measure validation and mediational testing as a 12-step specific mechanism of behavior change [Article]. Drug 51 52 and Alcohol Dependence, 133(2), 633-640. https://doi.org/10.1016/j.drugalcdep.2013.08.006
- 53 Kelly, J. F., & Greene, M. C. (2014). Beyond motivation: Initial validation of the commitment to sobriety scale 54 [Article]. Journal of Substance Abuse Treatment, 46(2), 257-263. 55 https://doi.org/10.1016/j.jsat.2013.06.010 56
- Kelly, J. F., Stout, R. L., & Slaymaker, V. (2013). Emerging adults' treatment outcomes in relation to 12-step 57 mutual-help attendance and active involvement [Article]. Drug and Alcohol Dependence, 129(1-2), 151-58 157. https://doi.org/10.1016/j.drugalcdep.2012.10.005 59 60
  - For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
10	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
72 //2	
ΔΛ	
44 15	
45 AC	
40 47	
4/	
48	
49	
50	
51	
<b>FD</b>	

- Kelly, J. F., Urbanoski, K. A., Hoeppner, B. B., & Slaymaker, V. (2011). Facilitating comprehensive assessment of 12-step experiences: A Multidimensional Measure of Mutual-Help Activity. Alcoholism *Treatment Quarterly*, 29(3), 181-203. <Go to ISI>://MEDLINE:22081741
- Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S. L. T., Manderscheid, R. W., Walters, E. E., & Zaslavsky, A. M. (2003). Screening for serious mental illness in the general population [Article]. Archives of General Psychiatry, 60(2), 184-189. https://doi.org/10.1001/archpsyc.60.2.184
- Laudet, A. B., Harris, K., Kimball, T., Winters, K. C., & Moberg, D. P. (2015). Characteristics of Students Participating in Collegiate Recovery Programs: A National Survey [Article]. Journal of Substance Abuse Treatment, 51, 38-46. https://doi.org/10.1016/j.jsat.2014.11.004
- Litt, M. D., Kadden, R. M., Cooney, N. L., & Kabela, E. (2003). Coping skills and treatment outcomes in cognitive-behavioral and interactional group therapy for alcoholism [Article]. Journal of Consulting and Clinical Psychology, 71(1), 118-128. https://doi.org/10.1037/0022-006x.71.1.118
- Miller, W. R., & Delboca, F. K. (1994). Measurement of Drinking Behavior Using the Form-90 Family of Instruments [Article]. Journal of Studies on Alcohol, 112-118. https://doi.org/10.15288/jsas.1994.s12.112
- BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. Miller, W. R., Tonigan, J. S., & Longabaugh, R. (1995). The Drinker Inventory of Consequences (DrInC): An instrument for assessing adverse consequences of alcohol abuse. Test manual. In M. E. Mattson & L. A. Marshall (Eds.), Project MATCH Monograph Series (Vol. 4). National Institute on Alcohol Abuse and Alcoholism.
- National Cancer Institute. (2009). Tobacco Use Supplement to the Current Population Survey: Reports and publications using the TUS-CPS. http://riskfactor.cancer.gov/studies/tus-cps/publications.html
- National Institutes of Health, & U.S. Food and Drug Administration. (2013). Population Assessment of Tobacco and Health (PATH) Study: Final Adult Baseline (Wave 1) Questionnaire. In. Bethesda, MD: National Institutes of Health.
- Prochaska, J. O., Velicer, W. F., Diclemente, C. C., & Fava, J. (1988). Measuring Processes of Change -Applications to the Cessation of Smoking [Article]. Journal of Consulting and Clinical Psychology, 56(4), 520-528. https://doi.org/10.1037/0022-006x.56.4.520
- Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., Crawford, E. D., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., Hayes, R. B., Johnson, C. C., Mandel, J. S., Oberman, A., O'Brien, B., Oken, M. M., Rafla, S., Reding, D., Rutt, W., ... Team, P. P. (2000). Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial [Review]. Controlled Clinical Trials, 21(6), 273S-309S. https://doi.org/10.1016/s0197-2456(00)00098-2
- Robins, R. W., Hendin, H. M., & Trzesniewski, K. H. (2001). Measuring global self-esteem: Construct validation of a single-item measure and the Rosenberg self-esteem scale [Article]. Personality and Social Psychology Bulletin, 27(2), 151-161. https://doi.org/10.1177/0146167201272002
- Schmidt, S., Muhlan, H., & Power, M. (2006). The EUROHIS-OOL 8-item index: psychometric results of a cross-cultural field study [Article]. European Journal of Public Health, 16(4), 420-428. https://doi.org/10.1093/eurpub/cki155
- Underwood, L. G., & Teresi, J. A. (2002). The daily spiritual experience scale: Development, theoretical description, reliability, exploratory factor analysis, and preliminary construct validity using healthrelated data [Article]. Annals of Behavioral Medicine, 24(1), 22-33. https://doi.org/10.1207/s15324796abm2401 04
- Vilsaint, C. L., Kelly, J. F., Bergman, B. G., Groshkova, T., Best, D., & White, W. (2017). Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder [Article]. Drug and Alcohol Dependence, 177, 71-76. https://doi.org/10.1016/j.drugalcdep.2017.03.022 52
- 53 Warttig, S. L., Forshaw, M. J., South, J., & White, A. K. (2013). New, normative, English-sample data for the 54 Short Form Perceived Stress Scale (PSS-4) [Article]. Journal of Health Psychology, 18(12), 1617-1628. 55 https://doi.org/10.1177/1359105313508346 56
- Wewers, M. E., & Lowe, N. K. (1990). A Critical Review of Visual Analog Scales in the Measurement of 57 Clinical Phenomena [Review]. Research in Nursing & Health, 13(4), 227-236. 58 https://doi.org/10.1002/nur.4770130405 59
- 60

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### BMJ Open

1 2 3 4	Zywiak, W. H., Neighbors, C. J., Martin, R. A., Johnson, J. E., Eaton, C. A., & Rohsenow, D. J. (2009). The Important People Drug and Alcohol interview: Psychometric properties, predictive validity, and implications for treatment [Article]. <i>Journal of Substance Abuse Treatment</i> , <i>36</i> (3), 321-330. <u>https://doi.org/10.1016/j.jsat.2008.08.001</u>
5 6	
7 8	
9	
10	Prote
12 13	
14	l by c
16	оруг
17 18	ight,
19 20	
20	ding
22 23	for
24 25	
26	
27 28	
29 30	
31 32	and c
33	
34 35	
36 37	
38	
40	ing, s
41 42	and s
43 44	
45	n rec
46 47	
48 49	ogies ies
50	
52	
53 54	
55 56	
57	
58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 Certificate of Confidentiality Template Version Date: January 2019

Protocol Title: Pathways to Change

Principal Investigator: John F. Kelly, Ph.D.

Site Principal Investigator:

Description of Subject Population: Adults with an alcohol use disorder making a new recovery attempt.

#### About this consent form

Please read this form carefully. It tells you important information about a research study. A member of our research team will also talk to you about taking part in this research study. People who agree to take part in research studies are called "subjects." This term will be used throughout this consent form.

Partners HealthCare System is made up of Partners hospitals, health care providers, and researchers. In the rest of this consent form, we refer to the Partners system simply as "Partners."

If you decide to take part in this research study, you must sign this form to show that you want to take part. We will give you a signed copy of this form to keep.

## **Key Information**

Taking part in this research study is up to you. You can decide not to take part. If you decide to take part now, you can change your mind and drop out later. Your decision won't change the medical care you get within Partners now or in the future.

The following key information is to help you decide whether or not to take part in this research study. We have included more details about the research in the Detailed Information section that follows the key information.

Page 1 of 11

Partners HealthCare System Research Consent Form	
Certificate of Confidentiality Template Version Date: January 2019	Subject Identification

### Why is this research study being done?

This research is being done to obtain greater knowledge about the pathways followed in new recovery attempts for individuals with an alcohol use disorder (AUD). We are asking you to take part in this research study because you identified yourself as someone with an AUD and is making a new attempt to change your alcohol use. About 348 people will take part in this research study. We expect to enroll all subjects within the greater Boston, Massachusetts area.

## How long will you take part in this research study?

If you enroll today, it will take you a total of 24 months (two years) to complete this research study. During this time, you will complete a baseline assessment, along with follow-up surveys every 3-, 6-, 9-, 12-, 18-, and 24-months.

### What will happen if you take part in this research study?

If you choose to enroll, you will be required to come to our downtown Boston office at the MGH Center for Addiction Medicine (within 3-minute walking distance of two major subway stops) to complete your assessments. You will complete your questionnaires via the Harvard Catalyst's Electronic Data Capture (REDCap; project-redcap.org) and with a research coordinator. You will be asked about basic demographic questions, substance use history, mutual-help organization attendance, psychiatric symptoms, psychosocial functioning, treatment service utilization, quality of life, and recovery motivation/support.

If you are a participant from the San Diego area, all of your study visits will take place remotely. The questionnaires will be asked over Zoom, Skype, or phone call and through an online link that is sent to your personal device.

As a supplement to this research study, we are conducting an optional qualitative interview for a portion of study participants. The aim of this qualitative interview is to investigate the motivations, expectations, and experiences of individuals who do and do not participate in Mutual Help Organizations (MHOs) such as Alcoholics Anonymous and SMART Recovery. Additionally, we hope to assess how helpful individuals believe MHOs are in their recovery attempt and how MHOs and other recovery resources might be improved and adapted to better fit the needs of individuals currently seeking recovery from an Alcohol Use Disorder.

MHO attendance is not required to participate in this qualitative interview. We plan to include individuals following a variety of recovery pathways.

Page 2 of 11

5	8				
9	çonsent Form Title: Consent 2021.06.04 - CLEAN				
6	RB Protocol No: 2017P002029	or peer review only - ht <b>SpoʻrisorjBrotodontij.coNA</b> (site/about/guid	elines.xhtml		
	Consent Form Valid Date: 8/31/202	IRB Amendment No: CR4/AME57	Sponsor Amendment No: N/A		
	Consent Form Expiration Date: 8/3	I/2023 IRB Amendment Approval Date: 8/31/2021			

Certificate of Confidentiality Template Version Date: January 2019 Subject Identification

Study staff will reach out directly to a pre-determined number of interested individuals via email or phone call to offer them the opportunity to participate in this qualitative interview and schedule an interview time. The interview will be approximately 30-60 minutes in length and will be conducted via Zoom or over the phone and will be recorded. This is done purely for data summarization purposes and once the data are transcribed, the recordings will be deleted. Participants will be compensated an additional \$50 following completion of the interview.

You are not required to participate in the optional qualitative interview in order to participate in the Pathways to Change Study. You can still take part in the original research study whether or not you choose to participate in this additional qualitative interview. Signing this form does not guarantee that you will be able to participate in the qualitative interview.

Do you consent to participate in the qualitative interview if selected?

[]YES []NO Initial

You will receive text/email reminders about upcoming appointments through REDCap's automated email feature and integrated Twilio SMS and voice call services. Both REDCap and Twilio are secure services for these appointment reminders.

Text messages by mobile/cell phones are a common form of communication. The Recovery Health research study involves sending you text messages that are relevant to the research study. Texting over mobile/cell phones carries security risks because text messages to mobile/cell phones are not encrypted. This means that information you send or receive by text message could be intercepted or viewed by an unintended recipient, or by your mobile/cell phone provider or carrier.

Below are some important points about texting in this research study.

- Text messages are not encrypted, and therefore carry security risks. This research study and Partners Healthcare are not responsible for any interception of messages sent through unencrypted text message communications.
- You will be responsible for all fees charged by your carrier's service plan for text messaging. This research study and Partners Healthcare are not responsible for any increased charges, data usage against plan limits or changes to data fees from the research texts.
- Text messaging should not be used in case of an emergency. If you experience a medical emergency, call 911 or go to the nearest hospital emergency department.

Page 3 of 11

### Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019 Subject Identification

- You may decide to not receive text messages with staff associated with this research study at any time. You can do this in person at your upcoming visit, by calling 617-643-5927, or by emailing recoveryhealth@mgh.harvard.edu.
- Your agreement applies to this research study only. Agreeing to other texts from Partners Healthcare, for example appointment reminders, is a separate process. Opting out of other texts from Partners Healthcare is a separate process as well.
- It is your responsibility to update your mobile/cell phone number with this research study in the event of a change.

I have had the chance to ask questions about texting with staff associated with this research study. I have been informed of the risks and other information covered above and consent to the use of unencrypted text communications associated with this research study.

# What are the risks and possible discomforts from being in this research study?

The risk of participating in this study is expected to be very small because your privacy is protected by law. We may report medical information if you need medical help, if we feel you might be in danger of harming yourself or others, or if there is any suspicion of child abuse or elder abuse.

It is possible that you may experience some discomfort during scheduled assessments from the questionnaires, as they ask for some sensitive personal information. However, you are free not to participate in any aspect of the study that makes you uncomfortable.

## What are the possible benefits from being in this research study?

You will gain no direct benefit from participation in this study. However, this study has the potential to contribute valuable information about recovery pathways for individuals with alcohol use disorder, and may provide additional support for mutual-help organizations.

## What other treatments or procedures are available for your condition?

Page 4 of 11

 Sonsent Form Title: Consent 2021.06.04 - CLEAN

 IRB Protocol No: 2017P002029
 For peer review only - htspon/sonj@potodom/loc/Nra/site/about/guidelines.xhtml

 Consent Form Valid Date: 8/31/2021
 IRB Amendment No: CR4/AME57
 Sponsor Amendment No: N/A

 Consent Form Expiration Date: 8/31/2023
 IRB Amendment Approval Date: 8/31/2021

**Certificate of Confidentiality Template** Version Date: January 2019

This study does not provide any treatment to you. Rather, we will ask you about your experiences with various treatments that you have been receiving or have received. You do not have to take part in this study to be able to obtain mental health services.

#### If you have questions or concerns about this research study, whom can you call?

You can call us with your questions or concerns. Our telephone numbers are listed below. Ask questions as often as you want.

Dr. John F. Kelly, Ph.D., is the person in charge of this research study. You can call him at 617-643-1980, Monday-Friday, 9am-5pm. You may leave a message at this number and he will return your call. You can also call research staff at 617-643-9850, Monday-Friday 9am-5pm with questions about this research study. If you have questions about the scheduling of appointments or study visits, call research staff at 617-643-9850.

If you want to speak with someone **not** directly involved in this research study, please contact the Partners Human Research Committee office. You can call them at 857-282-1900.

You can talk to them about:

- Your rights as a research subject
- Your concerns about the research
- A complaint about the research
- Any pressure to take part in, or to continue in the research study

Consent Form Title: Consent 2021.06.04 - CLEAN For peer review only - htsponsoriprotocontracional state about/guidelines.xhtml IRB Protocol No: 2017P002029 Consent Form Valid Date: 8/31/2021 IRB Amendment No: CR4/AME57 Sponsor Amendment No: N/A Consent Form Expiration Date: 8/31/2023 IRB Amendment Approval Date: 8/31/2021

Page 5 of 11

#### Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

## **Detailed Information**

# How may we use and share your samples and health information for other research?

The samples and information we collect in this study may help advance other research. If you join this study, we may remove all information that identifies you (for example your name, medical record number, and date of birth) and use these de-identified samples and data in other research. It won't be possible to link the information or samples back to you. Information and/or samples may be shared with investigators at our hospitals, at other academic institutions or at for-profit, commercial entities. You will not be asked to provide additional informed consent for these uses.

### Will you get the results of this research study?

No. The research study we are doing is only a stepping stone in understanding recovery from alcohol use disorder. Therefore, no information about the results of this research study or the results of your individual participation in the research study will be given to you or your doctor. Tests done for the research using your samples will not be useful in directing your medical treatment. The results of the tests will not be placed in your medical record.

# Can you still get medical care within Partners if you don't take part in this research study, or if you stop taking part?

Yes. Your decision won't change the medical care you get within Partners now or in the future. There will be no penalty, and you won't lose any benefits you receive now or have a right to receive.

We will tell you if we learn new information that could make you change your mind about taking part in this research study.

#### What should you do if you want to stop taking part in the study?

If you take part in this research study, and want to drop out, you should tell us. We will make sure that you stop the study safely. We will also talk to you about follow-up care, if needed.

Page 6 of 11

5	8				
4	Sonsent Form Title: Consent 2021.06.04 - CLEAN				
6	RB Protocol No: 2017P002029	For peer review only -	htSponsorjBpotodom).coNA/site/about/guidelin	nes.xhtml	
	Consent Form Valid Date: 8/31/20	21	IRB Amendment No: CR4/AME57	Sponsor Amendment No: N/A	
	Consent Form Expiration Date: 8/	31/2023	IRB Amendment Approval Date: 8/31/2021		

Partners HealthCare System Research Consent Form	
Certificate of Confidentiality Template	Subject Identification
Version Date: January 2019	

Also, it is possible that we will have to ask you to drop out of the study before you finish it. If this happens, we will tell you why. We will also help arrange other care for you, if needed.

### Will you be paid to take part in this research study?

You will be compensated up to \$455 for completing the questionnaires. That is \$15, \$25, \$30, \$35, \$40, \$45, and \$55 for the baseline, 3-, 6-, 9-, 12-, 18-, and 24-month assessments, respectively. Additionally, you will be compensated \$20 for each of the computer-based REDCap surveys you complete at each assessment. Finally, in order to help offset the cost of travel, you will be compensated \$10 per assessment for coming to our offices. In order to receive payment for this study, we will need your Social Security Number (SSN). We need to collect this information in order to comply with tax reporting obligations. This information is confidential and protected, and will be stored securely and redacted when no longer required.

	Computer-based	In-Person Study	Travel
	REDCap Surveys	Visits with Staff	Reimbursement
Baseline	\$20	\$15	\$10
3-Month Follow-Up	\$20	\$25	\$10
6-Month Follow-Up	\$20	\$30	\$10
9-Month Follow-Up	\$20	\$35	\$10
12-Month Follow-Up	\$20	\$40	\$10
18-Month Follow-Up	\$20	\$45	\$10
24-Month Follow-Up	\$20	\$55	\$10
Total:			Up to \$455

As a supplement to this research study, we are conducting an optional qualitative interview for a portion of study participants. Participants will be compensated an additional \$50 following completion of the qualitative interview.

#### What will you have to pay for if you take part in this research study?

There are no costs to participate in this research. All questionnaires and surveys will be provided to you by study staff members.

Page 7 of 11

#### Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019

# What happens if you are injured as a result of taking part in this research study?

We will offer you the care needed to treat any injury that directly results from taking part in this research study. We reserve the right to bill your insurance company or other third parties, if appropriate, for the care you get for the injury. We will try to have these costs paid for, but you may be responsible for some of them. For example, if the care is billed to your insurer, you will be responsible for payment of any deductibles and co-payments required by your insurer.

Injuries sometimes happen in research even when no one is at fault. There are no plans to pay you or give you other compensation for an injury, should one occur. However, you are not giving up any of your legal rights by signing this form.

If you think you have been injured or have experienced a medical problem as a result of taking part in this research study, tell the person in charge of this study as soon as possible. The researcher's name and phone number are listed in the beginning of this consent form.

## If you take part in this research study, how will we protect your privacy?

Federal law requires Partners to protect the privacy of health information and related information that identifies you. We refer to this information as "identifiable information."

#### In this study, we may collect identifiable information about you from:

- Past, present, and future medical records
- Research procedures, including research office visits, tests, interviews, and questionnaires

#### Who may see, use, and share your identifiable information and why:

- Partners researchers and staff involved in this study
- The sponsor(s) of the study, and people or groups it hires to help perform this research or to audit the research
- Other researchers and medical centers that are part of this study
- The Partners ethics board or an ethics board outside Partners that oversees the research
- A group that oversees the data (study information) and safety of this study

Page 8 of 11

 Certificate of Confidentiality Template Version Date: January 2019

• Non-research staff within Partners who need identifiable information to do their jobs, such as for treatment, payment (billing), or hospital operations (such as assessing the quality of care or research)

Subject Identification

- People or groups that we hire to do certain work for us, such as data storage companies, accreditors, insurers, and lawyers
- Federal agencies (such as the U.S. Department of Health and Human Services (DHHS) and agencies within DHHS like the Food and Drug Administration, the National Institutes of Health, and the Office for Human Research Protections), state agencies, and foreign government bodies that oversee, evaluate, and audit research, which may include inspection of your records
- Public health and safety authorities, if we learn information that could mean harm to you or others (such as to make required reports about communicable diseases or about child or elder abuse)
- Other researchers within or outside Partners, for use in other research as allowed by law.

#### **Certificate of Confidentiality**

A federal Certificate of Confidentiality (Certificate) has been issued for this research to add special protection for information and specimens that may identify you. With a Certificate, unless you give permission (such as in this form) and except as described above, the researchers are not allowed to share your identifiable information or identifiable specimens, including for a court order or subpoena.

Certain information from the research will be put into your medical record and will not be covered by the Certificate. This includes records of medical tests or procedures done at the hospitals and clinics, and information that treating health care providers may need to care for you. Please ask your study doctor if you have any questions about what information will be included in your medical record. Other researchers receiving your identifiable information or specimens are expected to comply with the privacy protections of the Certificate. The Certificate does not stop you from voluntarily releasing information about yourself or your participation in this study.

Even with these measures to protect your privacy, once your identifiable information is shared outside Partners, we cannot control all the ways that others use or share it and cannot promise that it will remain completely private.

Because research is an ongoing process, we cannot give you an exact date when we will either destroy or stop using or sharing your identifiable information. Your permission to use and share your identifiable information does not expire.

Page 9 of 11

Sonsent Form Title: Consent 2021.06.04 - CLEAN			
RB Protocol No: 2017P002029 For peer review only	/ - ht <b>SpoʻńsonjBrozodom)l.c</b> o <b>NA</b> /site/about/gui	delines.xhtml	
Consent Form Valid Date: 8/31/2021	IRB Amendment No: CR4/AME57	Sponsor Amendment No: N/A	
Consent Form Expiration Date: 8/31/2023	IRB Amendment Approval Date: 8/31/202	1	

### Partners HealthCare System Research Consent Form

Certificate of Confidentiality Template Version Date: January 2019 Subject Identification

The results of this research may be published in a medical book or journal, or used to teach others. However, your name or other identifiable information **will not** be used for these purposes without your specific permission.

#### Your Privacy Rights

You have the right **not** to sign this form that allows us to use and share your identifiable information for research; however, if you don't sign it, you can't take part in this research study.

You have the right to withdraw your permission for us to use or share your identifiable information for this research study. If you want to withdraw your permission, you must notify the person in charge of this research study in writing. Once permission is withdrawn, you cannot continue to take part in the study.

If you withdraw your permission, we will not be able to take back information that has already been used or shared with others, and such information may continue to be used for certain purposes, such as to comply with the law or maintain the reliability of the study.

You have the right to see and get a copy of your identifiable information that is used or shared for treatment or for payment. To ask for this information, please contact the person in charge of this research study. You may only get such information after the research is finished.

## **Informed Consent and Authorization**

#### Statement of Person Giving Informed Consent and Authorization

- I have read this consent form.
- This research study has been explained to me, including risks and possible benefits (if any), other possible treatments or procedures, and other important things about the study.
- I have had the opportunity to ask questions.
- I understand the information given to me.
- I have had the chance to ask questions about texting with staff associated with this research study. I have been informed of the risks and other information covered above and consent to the use of unencrypted text communications associated with this research study.

Page 10 of 11

BMJ Open: first published as 10.1136/bmjopen-2022-066898 on 3 February 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

		Subject Identification
Version Date: January 2019		Subject Identification
Signature of Subject (choose one):		
I give my consent to take part in this research s information to be used and shared as described	tudy and agree to a above.	llow my identifiable
Subject	Date	Time (optional)
Signature of Study Doctor or Person (	Obtaining Conse	ent:
Statement of Study Doctor or Person Obtain	ling Consent	
<ul> <li>Statement of Study Doctor or Person Obtain</li> <li>I have explained the research to the stude</li> <li>I have answered all questions about this</li> </ul>	dy subject. s research study to t	he best of my ability.
<ul> <li>Statement of Study Doctor or Person Obtain</li> <li>I have explained the research to the stude</li> <li>I have answered all questions about this</li> <li>Study Doctor or Person Obtaining Consent</li> </ul>	dy subject. s research study to t	he best of my ability.
<ul> <li>Statement of Study Doctor or Person Obtain</li> <li>I have explained the research to the stude</li> <li>I have answered all questions about this</li> <li>Study Doctor or Person Obtaining Consent</li> <li>Consent Form Version Date: 06/04/2021</li> </ul>	dy subject. s research study to t	he best of my ability.